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Summary 
Human cytomegalovirus (HCMV) is the leading infectious cause of congenital 
malformation. In vitro propagation of HCMV strains that authentically represent clinical 
virus are required to facilitate effective research. However, this is problematic, since 
efficient replication of clinical HCMV strains in vitro is achieved only after mutations 
have been selected. The first gene to mutate is consistently RL13. RL13 encodes a virion 
envelope protein that suppresses release of infectious virus from cells. Despite mutation 
in cell culture it is conserved in clinical strains, indicating that it is important in vivo. 
However, it is unclear how RL13 inhibits virus in vitro, or what advantage it provides in 
vivo.   
RL13 expression did not affect genome replication or virion protein production, however 
it reduced the infectivity of released virions. Mass spectrometry revealed that RL13 
expression altered the composition of released virions, however there was no obvious 
reason for these changes to effect infectivity. During virus spread, RL13 promoted cell-
cell transfer of virus, reducing the ability of neutralising antibodies to inhibit virus spread 
in fibroblasts, however this effect was masked by UL128L expression in other cell types. 
Genetic analysis of RL13 from clinical strains revealed that RL13 sequences clustered 
into 9 distinct clades, with sequences from different clades retaining the ability to inhibit 
the release of infectious virus. A RL13 homologue from Rhesus CMV also restricted the 
release of infectious virus. This conservation of function suggests that the phenotype is 
not an artefact of in vitro culture conditions.  RL13 on the cell surface bound human IgG, 
however it did not inhibit antibody-dependent cellular cytotoxicity during infection.  
This thesis has delivered insights into the role of RL13 during infection, has 
demonstrated the importance of using more clinically relevant RL13+ HCMV strains and 
will aid future research using such HCMV strains.
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CHAPTER 1. INTRODUCTION 
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1.1 Human Cytomegalovirus (HCMV) 
Human Cytomegalovirus (HCMV), also known as Human Herpes virus 5 (HHV-5), infects 
people worldwide and is the leading infectious cause of congenital malformation. 
Infections are lifelong and although typically asymptomatic, HCMV infection poses a 
serious risk of disease in the immunocompromised or immunosuppressed. The 
management of complications caused by this virus is very costly and a burden on health 
care. As currently there is no licensed HCMV vaccine, the development of a successful 
vaccine is a high priority target (8). 
1.1.1 The Herpesvirus Family 
The family Herpesviridae under the order Herpesvirales includes a large collection of 
DNA viruses that infect a range of hosts that include fish, reptiles, birds as well as 
mammals (9). Herpes viruses are very successful pathogens as proved by their wide 
distribution in nature with most animal species playing host to at least one herpesvirus 
(10). Herpes viruses are defined based on their general structure (9, 10). The large linear 
double stranded DNA genome is encased in an icosahedral capsid which is coated by a 
proteinaceous layer termed the tegument. This entire structure is then further 
surrounded by the glycoprotein studded lipid bi-layer envelope. Members are assigned 
to subfamilies based on criteria such as growth kinetics, host range, tropism and genetic 
homology (11). The family Herpesviridae contains three subfamilies: the 
Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae (10). HCMV is a 
member of the subfamily Betaherpesvirinae and the genus Cytomegalovirus. 
Betaherpesvirinae generally are highly host specific, exhibit cell-associated methods of 
infection and have relatively long replication cycles (11). This subfamily currently 
includes five genera: Cytomegaloviruses, Muromegaloviruses, Roseoloviruses, 
Probosciviruses and a genus for unassigned (Figure 1). So far 20 different species of 
viruses have been assigned within these genera, with 8 occupying the Cytomegalovirus 
genus (4). 
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Figure 1 – Phylogenetic tree showing the evolution of the Betaherpesvirinae family 
(adapted from (4)). The concatenated amino acid sequences of the essential genes 
(U38, U39, U40, U41, U57, U60, U77, and U81) were used to create this phylogenetic 
neighbour-joining tree. The scale bar shown at the bottom displays nucleotide 
differences/nucleotide and the confidence values are shown as fractions. The 20 
betaherpesviruses are; HCMV, human cytomegalovirus; CCMV, chimpanzee 
cytomegalovirus; GMCMV, green monkey cytomegalovirus; RhCMV, rhesus 
cytomegalovirus; OMCMV, owl monkey cytomegalovirus; SMCMV, squirrel monkey 
cytomegalovirus; GPCMV, guinea pig cytomegalovirus; MSHV, Miniopterus 
schreibersii herpesvirus; TuHV, tupaiid herpesvirus 1; MCMV, murine 
cytomegalovirus; RCMVE, rat cytomegalovirus England; RCMV, rat cytomegalovirus; 
HHV6A, human herpesvirus 6A; HHV6B, human herpesvirus 6B; HHV7, human 
herpesvirus 7; and PCMV, porcine cytomegalovirus. 
Betaherpesvirinae 
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 1.1.2 Discovery and Isolation 
HCMV infection was first noted by Pathologist Dr. Ribbert. His case study, presented in a 
meeting of the Natural History Society of Prussian Rhineland and Westphalia in Germany 
1881, detailed enlarged ‘cytomegalic’ cells with intranuclear inclusions observed in 
kidney secretions from a stillborn presenting with interstitial nephritis and Lues-like 
symptoms (12, 13). Similar giant cells were described again in 1904 by Jesionek and 
Kiolemenoglou (14) prompting Dr Ribbert to reinterpret the cytomegalic cells as 
protozoa (15). von Glahn and Pappenheimer and co-workers were the first to suggest 
that the intranuclear inclusions were a result of virally infected cells (16), however this 
aetiology would not be confirmed until the electron microscopy analysis of cytomegalic 
pancreatic cells in 1953 which found 199-nm particles thought to be the virus 
responsible (17). The name “Cytomegalic inclusion disease (CID)” was suggested after 
noting the presentation of cytomegalic cells correlated with the clinical manifestations 
of congenital infection in both humans and other animals (18). 
Early attempts to isolate and propagate HCMV were frustrated by an inability to culture 
human cells routinely and the host-specificity of the virus. Successful isolation and 
propagation of the infectious agent was reported almost simultaneously by three 
independent research groups (19-21). During Margaret Smith’s early attempts to isolate 
virus from human salivary gland, she noted that the clinical agent was only able to be 
propagated in human tissues and not in murine cells indicating the host specificity of the 
virus (20, 22). Weller was responsible for the serological testing that identified the 
distinct strain differences within the viral species and propose the name 
cytomegalovirus (22, 23).  
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1.2 Clinical Importance and manifestations of HCMV 
infection 
1.2.1 Epidemiology 
HCMV is a ubiquitous pathogen with a worldwide distribution. For example, 
seroprevalence rates of adults of reproductive age in the United States are around 60%, 
and these rates increase with age to around 90% in adults over 80 years. HCMV 
seroprevalence is significantly influenced by socioeconomic status, age and geography 
old (24, 25).  Generally, people in developing countries are at more risk of contact during 
the early years of life, likely due to overcrowding, large families or unsanitary living 
conditions. However, this does mean that in more developed countries likely exposure 
to the virus increases with age, and so developed countries have a higher risk of primary 
infection during pregnancy (24, 26). Lower seroprevalence is seen in Western Europe 
and the United States, whilst the highest seroprevalence is seen in South American, 
African and Asian countries (27). Some studies show a tendency of higher infection rates 
in females than in males (24) however in most of these cases the differences are small. 
1.2.2 Transmission and Primary Infection 
 The main method of dissemination is through contact with bodily fluids containing the 
infectious agent from individuals with symptomatic or asymptomatic infection. This can 
be via saliva, breast milk, blood transfusion, solid-organ transplant, hematopoietic stem 
cell transplantation, placental transfer or sexual contact (5, 28, 29). A study found that 
HCMV was viable for as long as 6 hours if the surface it was applied to was wet (30). This 
demonstrates the necessity of good hygiene practices such as handwashing in limiting 
transmission of HCMV.  
Most frequently initial acquisition of HCMV (primary infection) occurs in mucosal tissues 
after direct contact with the infectious secretions of another seropositive individual. This 
primary acute infection typically lasts weeks to a few months and is characterised by 
persistently shedding virus from restricted cellular sites from within the host. HCMV 
persists for the lifetime of the host following primary infection and, in the immune-
competent individual, infection is generally asymptomatic and constantly under immune 
surveillance (5, 31). After primary infection there are two potential routes the infection 
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can follow, chronic infection characterised by dissemination of the virus to form 
restricted infection foci, lytic replication and low titre shedding (31) or latent infection 
characterised by epigenetic repression of the viral genome allowing for the maintenance 
of the viral genomes in the absence of virion production (32). Primary infection appears 
to be associated with more clinical problems than exogenous reinfection or endogenous 
reactivation (33, 34), however seropositive stem cell transplant recipients are also at 
great risk when receiving seronegative stem cells naïve to HCMV infection (35). 
1.2.3 Infection in the Immunocompetent Host 
Infection in the immunologically competent host can very occasionally result in mild 
febrile mononucleosis-like illness characterised by prolonged fever, fatigue and cervical 
lymphadenopathy. HCMV infection has also been reported to cause gastrointestinal 
disease or even pneumonia (36). Only rarely do more serious clinical complications 
involving specific organ systems occur (1). 
1.2.4 Congenital and Perinatal Infection 
 While transplacental transmission is rare with other herpes viruses, HCMV is the leading 
infectious cause of congenital malformation and the prognosis can include sensorineural 
hearing loss, mental retardation and loss of or compromised vision (1, 5, 34, 37). A small 
percentage of infected neonates develop severe systemic, life-threatening cytomegalic 
inclusion disease. These problems can occur due to primary infection, reactivation or 
reinfection with a different strain. The birth prevalence of congenital HCMV infections 
varies amongst populations from 0.2-2.2% of live births (25, 38). Although the medical 
complications that coincide with congenital HCMV infection can be severe, the majority 
of infected infants are asymptomatic at birth with only around 13.5% displaying 
symptoms immediately and a further 12.7% displaying symptoms on follow-up (38, 39). 
Mothers who experience primary infection during pregnancy are at higher risk from 
congenital infection than seropositive mothers undergoing reinfection or reactivation. A 
study found that of the children born to mothers experiencing primary HCMV infection 
during pregnancy, 32.3% suffered from congenital HCMV infection. This was significantly 
higher than the 1.4% of children with congenital HCMV born to mothers with 
reactivated HCMV infection (25). Children with congenital HCMV infection from a 
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mother experiencing primary infection during pregnancy are more likely to have at least 
one sequela and are likely to be more severely affected (40).  Although infection can 
occur during all trimesters, if primary infection to a seronegative mother occurs during 
the first trimester the risk and severity of disease are greatest (41). Transplacental 
transmission of HCMV is the most medically significant route of maternal transmission 
however, the most frequent method of transmission between mother and child is 
through breastfeeding. It is thought that around 69% of infants contract HCMV from 
breastfeeding by shedding seropositive mothers. In fact, virus is most prevalent in breast 
milk from day 9 to 3 months postpartum after which it declines (42). Clinical disease is 
more uncommon in cases where transmission to infants occurs after birth (1).  
1.2.5 Infection in at-risk groups 
HCMV is a clinically important opportunistic pathogen and lytic viral replication can 
cause serious medical complications for those who do not have a fully functioning 
immune system. These at-risk groups include neonates (covered in section 1.2.4), the 
immunocompromised and the immunosuppressed. What makes these populations at-
risk is their inability to respond effectively to primary infection or recurrent infection.  
Individuals in these groups include Acquired Immunodeficiency Syndrome (AIDS) 
patients, solid organ transplant (SOT) recipients, haematopoietic stem cell 
transplantation (HSCT) patients and other allograft recipients. Symptoms are similar to 
those that the immunocompetent experience but typically more severe and usually 
HCMV viraemia is seen. For unknown reasons, HCMV disease can vary between patient 
groups (43). The most common pathology observed in AIDS patients is retinitis, usually 
starting with one eye but eventually leading to both and can lead to complete loss of 
vision. The introduction of Highly Active Antiretroviral Therapy (HAART) has had a 
dramatic effect on the incidence of end organ disease caused by HCMV infection (44, 
45). New cases of HCMV retinitis have declined by roughly 80% following HAART and the 
survival rate of those already suffering with this end organ disease has increased by 93% 
(46). High levels of HCMV viraemia are common in HIV-infected individuals, and is 
strongly associated with progression to AIDS and mortality (44).  
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HCMV infection is often associated with allograft rejection as a result of the pro-
inflammatory environment resulting from persistent and chronic infection (47). 
However, the cause and effect relationship is considered controversial. One study found 
evidence of a bidirectional relationship between the two post-transplant complications. 
They found that the immunosuppressive effect of graft-versus-host disease and its 
therapy can induce HCMV infection, but also that patients experiencing active HCMV 
replication were at a greater risk of allograft rejection than those without active HCMV 
replication (48). Liver transplant patients are often diagnosed with HCMV hepatitis, 
whereas HCMV pneumonitis is a major complication for bone marrow transplant 
patients (43).  
HCMV infection has also been reported to cause serious complications in settings not 
traditionally known to have been a risk for HCMV disease. It is not known whether 
HCMV is a causative agent in these diseases or whether it is just an opportunistic 
bystander, but it has been suggested that HCMV can be associated with glioblastomas 
(49, 50), new-onset post-transplant diabetes (51), inflammatory bowel disease (52), 
atherosclerosis (53) and immunosenecence (54). 
1.2.6 Treatments and Vaccination 
As there is currently no licensed HCMV vaccine, an anti-HCMV vaccine that successfully 
treats and clears infection is still a highest priority target (8). However, five HCMV 
antivirals are currently available: Ganciclovir (GCV) and its orally administered prodrug 
Valganciclovir, Foscarnet (FOS), Cidofovir (CDV) and Fomivirsen (FMV) (55). However 
these therapies only provide disease management and have some substantial limitations 
(56). The commonly used HCMV antivirals can cause significant toxicity (57) and HCMV 
can become resistant through prolonged treatments (58).   
GCV was the first antiviral therapy approved for HCMV disease and remains the most 
commonly used (55). It is a synthetic analogue of 2′-deoxyguanosine which is 
phosphorylated by the viral protein kinase encoded by HCMV UL97, and subsequently 
converted into GCV triphosphate. Viral DNA synthesis catalysed by the HCMV DNA 
polymerase (HCMV UL54) is targeted by GCV triphosphate (59). It is rare for HCMV to 
develop resistance to GCV, however, when it does it is likely to be the result of a 
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mutation in the HCMV gene UL97 or UL54 (60). In fact, mutations in UL54 have also 
been reported to lead to HCMV resistance to FOS and CDV (55). 
The first live-attenuated vaccine to be trialled on humans was derived from the 
laboratory-adapted strain AD169. Shortly after vaccine candidates were based on the 
strain Towne (61). The live-attenuated Towne vaccine was trialled in seronegative renal 
transplant patients and although the HCMV pathologies seen in the treatment group 
were not as severe as the control, the vaccine did not protect patients from acquisition 
of the virus or development of acute infection (62). 
Recently a recombinant HCMV vaccine based on the envelope glycoprotein B has had 
significant success in clinical trials. This subunit vaccine was developed in the 1980s and 
is comprised of soluble gB in an oil-in-water adjuvant (MF59) (63). In phase 1 clinical 
trials the vaccine was found to be immunogenic and safe (64). The recipients of the 
vaccine reported to elicit potent anti-gB responses (65). In phase 2 clinical trials the 
vaccine proved to reduce the HCMV infection rate in young mothers by 50% (66) and in 
adolescents girls by 43% (67). In another study conducted in SOT patients, the gB 
subunit vaccine was found to not only reduce CMV disease but also to decrease the 
duration that patients required pre-emptive anti-CMV antivirals after transplant (68). It 
was presumed that the efficacy of the gB subunit vaccine was due to induction of a 
neutralising antibody response, however this has since been proved false (69, 70). 
 The T-cell target pp65 (ppUL83) and IE1 have also undergone evaluation as potential 
vectored or subunit vaccines (56). A bivalent plasmid DNA vaccine has also been 
evaluated in phase 2 clinical trials. This vaccine encoding HCMV pp65 and gB was 
reported to cause fewer cases of viraemia in seropositive HSCT patients compared to the 
control group (71). gB and pp65 have also been the focus in another type of vaccine that 
has reached phase 2 of clinical trials and delivers the HCMV antigens via an attenuated 
canarypox vector (72, 73). 
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1.3 Viral Particles 
1.3.1 Components of Infectious virions 
Like other Herpesvirus virions, mature HCMV virions are large and are reported to range 
from 150-200nm (45, 74) to 200-300 nm (1) in diameter. HCMV virions follow the same 
basic structure of four concentric layers found in all herpesviruses. These four layers 
consist of a double stranded genome core, an icosahedral capsid to protect the DNA, a 
thick proteinaceous layer and finally a membrane derived from the host cell studded 
with envelope glycoproteins (11, 75, 76). 
Nucleocapsid 
The nucleocapsid, otherwise known as the C capsid is a sturdy icosahedral lattice with 
T=16 symmetry measuring 100–110 nm in diameter. What differentiates the 
nucleocapsid from the other capsids (A and B, described in section 1.3.2.1) is the 
efficient packaging of the large double stranded HCMV genome inside (77). 
Many HCMV proteins structure the capsid making up 162 capsomeres (capsid subunits) 
and 320 hetero-trimeric triplexes. Capsomeres are either hexamers or pentamers of the 
UL86 encoding major capsid protein (MCP) located within either the 20 triangular faces 
or the 12 vertices respectively. The triplexes are composed of two copies of the UL85 
encoding minor capsid protein (mCP), and one copy of the mCP-binding protein (pUL46) 
(76-78). One vertex is specialised in that it is made of 12 copies of the portal protein 
(PORT, pUL104) forming a symmetrical portal complex enabling the viral DNA to pass 
through during encapsidation and viral DNA release (2, 79). The smallest protein UL48.5 
(SCP) is found tightly bound exterior faces of capsomeres. Six copies are attached to 
each hexon and it is essential for the production of infectious HCMV virions (2, 80).  
Tegument 
The tegument is an intricate layer of proteins that associate with the capsid and lie 
beneath the outer viral envelope. It is formed of 59 viral proteins and also contains 
cellular proteins, many of which are phosphorylated (75). However only 39 of the viral 
tegument proteins are incorporated into the virion at significant levels (74, 75). The 
tegument is thought to be amorphous and relatively unstructured in nature, however 
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some tegument proteins are bound to the capsid giving some structure (81). This 
proteinaceous layer is approximately 50 nm thick and predominated by pp150 (UL32), 
pp71 (UL82), pp65 (UL83) (2, 82). 
As tegument proteins are components of virions and are delivered to the host cell during 
initial infection, they can have significant impact on viral replication even before the viral 
genome has been transcribed. These important roles include delivery of preformed 
protein necessary for the commencement of infection, providing structural stability to 
nucleocapsids and regulating signalling required for final envelopment and egress of 
virions (7). They are also reported to contribute to immune evasion, regulation of 
cellular processes and the release of viral DNA from the capsid into the nucleus (83).  
Envelope 
HCMV virions, dense bodies and non-infectious enveloped particles are all enclosed in a 
lipid bilayer envelope derived from the host cell. The virion envelope is ~10 nm thick and 
like all herpesviruses is studded with an array of envelope glycoproteins (82). Five of 
these envelope glycoproteins (gB, gH, gL, gM and gN) are considered essential for 
replication, whilst loss of gO (UL74) results in moderately defective viral growth (84). 
During infection these glycoproteins accumulate on the plasma and internal membranes 
of infected cells and are targets of neutralising antibodies (85). 
Virion envelope proteins can be potential targets for neutralising antibodies but could 
also be involved in modulating the host cell response to infection or could aid in 
attachment/entry or even tropism. The envelope glycoproteins encoded by RL11 and 
UL119-UL118 (gp34 and gp68 respectively) are Fc receptors that bind IgG (86).  A trimer 
of gB (UL55) assists membrane fusion during entry. Another glycoprotein complex of 
gH:gL (UL75 and UL115 respectively) can modify the tropism of the virus. gH:gL functions 
to stimulate attachment and when used with gB-mediated fusion it is more efficient 
than gB alone (87). The gH:gL complex can be found in two forms, firstly as a trimer 
consisting of gH:gL:gO, which is necessary for entry into fibroblasts by binding to 
PDGFRa (88) and secondly as the pentameric complex. The pentameric complex consists 
of gH:gL and the three gene products of the UL128 locus (UL128L:UL128, UL130 and 
UL131A) giving gH:gL:pUL128:pUL130:pUL131A. This complex binds to neuropilin-2 and 
allows for the expansion of viral tropism into epithelial and endothelial cells (89-91) as 
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well as for viral interactions with other cell types including neutrophils and DCs (92). 
Attachment and endocytosis without the pentameric complex is possible in epithelial 
and endothelial cells, however the virus is unable to enter the cytosol (89, 90). 
1.3.2 Non-infectious Viral Particles 
During productive HCMV infection many non-infectious particles are generated and 
some are even released along with infectious virions. Five types of viral particle 
excluding virions have been recovered and characterised from HCMV infections (77) 
(table 1). 
A, B and C capsids 
Similarly to other herpesviruses, three stable and distinct nuclear capsids are formed: A, 
B and C (also termed Nucleocapsids) and their fate is determined by the success or 
failure of DNA packaging (93). Their lack of viral DNA and/or scaffold proteins is what 
distinguishes these similar capsid forms (77).  It is thought that the three capsid 
structures plus the additional transient procapsid are linked by their maturation 
pathway in the nucleus by a hypothetical transition B capsid (Bt-capsid) (figure 2) (2). 
The Bt capsid has the potential to mature fully into a mature C capsid packaged with viral 
DNA and lacking scaffold proteins. If the viral DNA packaging is aborted during C capsid 
formation or the scaffold protein is prematurely lost from a B capsid without subsequent 
DNA packaging an A capsid could form. B capsids still contain an inner array of scaffold 
protein with no DNA packaged inside. It is though that C capsids can still mature from B 
capsids (94). 
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Figure 2 – The Formation of A, B and C capsids with the hypothetical Bt capsid. A-
capsids represent empty capsid shells that contain neither viral DNA nor any other 
discernible internal structure. B-capsids are capsid shells containing an inner array of 
scaffolding protein. C-capsids are mature capsid shells that are packaged with viral 
DNA and do not contain the scaffolding proteins. The Bt capsid is thought to be an 
intermediate showing how the fate of each capsid’s formation is reliant on the 
successful packaging of the viral genome and the abortion of the scaffold proteins. 
Reproduced from (2). 
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Non-infectious Enveloped Particles (NIEPs) 
Structurally and biochemically similar to virions, NIEPs differ in that they lack infectious 
viral DNA and keep some scaffold proteins. It is thought that NIEPs are a result of 
matured B capsids that have progressed into the cytoplasmic assembly compartment 
(AC) (2, 82). As they contain an immature capsid lacking DNA (B capsid) they lack an 
electron dense core compared to virions making them distinguishable from one another 
in Electron microscopy. NIEPs are often found released into the culture medium of 
infected cells in great excess along with dense bodies (DBs) (95).  
Dense bodies (DBs) 
DBs have a simple structure and composition compared to virions and NIEPs. They are 
much larger with a diameter range of ~250-600 nm. They are composed of mainly pUL83 
aggregates enveloped in a lipid envelope in the same manner as virions and NIEPs. They 
lack any viral DNA or any capsid proteins (82). gB is also a major constituent of DBs (77, 
82). Similarly to NIEPs, their exact purpose during HCMV infection was unknown for 
some time. Its hypothesised that these aberrant viral particles could aid HCMV survival 
by saturating or overwhelming the hosts viral immune surveillance (95). In fact, these 
large non-infectious particles composed of antigenic determinants induced the humoral 
and the cellular immune response in the absence of infectious virus. It was therefore 
proposed that DBs could be a promising recombinant non-replicating vaccine (96).
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Table 1 - Viral particles produced in productive HCMV infection. Adapted from (7) 
 
 
Location Nucleus Assembly Compartment 
Particle  A-capsids  B-capsids  C-capsids  Dense bodies  NIEPs  Virions  
Description  Thought to be 
the result of 
failed viral 
DNA 
encapsidation 
and lacking 
both viral DNA 
and a scaffold.  
Likely to have resulted 
from failed capsid 
formation as they 
contain a scaffold but 
lack viral DNA.  
Likely 
nucleocapsids 
during 
maturation, 
containing viral 
DNA.  
Non-infectious 
particles lacking 
capsids and 
composed mainly 
of pp65.  
Non-infectious enveloped 
particles (NIEPs) resulting 
from envelopment of B-
capsids.  
The only 
infectious 
particle 
containing 
viral DNA 
resulting 
from 
envelopment 
of C-capsids.  
Particle 
appearance 
in TEM 
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1.4 Viral Lifecycle 
The main mechanisms present at each of the stages of the HCMV lytic lifecycle are 
shared between the Herpesvirus family. These are attachment, entry, uncoating, 
replication, assembly, maturation and finally egress (figure 2). Herpes viruses have 
further distinct consecutive stages during replication; immediate early (IE), early (E), and 
late (L) cascades of gene expression. 
1.4.1 Virus Entry 
First contact of cell free HCMV virions with a viable host cell is mediated by the 
glycoproteins found on the HCMV virion envelope. Viral glycoproteins such as gB, gH/gL 
and gM interact with a series of cellular receptors on the host cell membrane (87). In 
fact, through studies with mutants it has been noted that several glycoproteins are 
essential for HCMV infection. Thus, the glycoproteins gB (UL55), gL (UL115), gM (UL100), 
gH (UL75), and gN (UL73) are highly conserved (97, 98).  
The method of HCMV entry into a viable host cell depends on the cell type. HCMV 
infects many different human cell types despite the narrow tropism observed of 
laboratory strains in vitro (99). Entry into fibroblasts is pH-neutral and occurs by direct 
fusion of the plasma membrane with the viral envelope (100). However, a low-pH is 
required for receptor mediated endocytosis into epithelial and endothelial cells (101). 
Entry into DCs is via clathrin-independent endocytosis which resembles 
macropinocytosis and is pH-independent (102). 
Clinical HCMV is mostly found cell-associated (103, 104) and this equates with direct 
cell-cell transmission. The mechanism behind this has been postulated to be through 
transitory microfusion events after direct contact between the plasma membranes of 
the uninfected and infected cells expressing the viral glycoproteins involved in cell-free 
entry (105, 106). 
1.4.2 Viral DNA Replication and Gene Expression Regulation during 
Infection 
Viral transcription, genome replication and finally encapsulation of the newly 
synthesised viral genomes occur in the cell nucleus. The HCMV lytic genes are 
transcribed in a temporal cascade. This cascade consists of three kinetic classes of HCMV 
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genes; Immediate early (IE), Delayed early (DE) and Late (L) which can be further 
categorised into leaky late and true late and are sequentially expressed over the course 
of a 72 hour lytic replication cycle (1). 
After entry into the host cell, cytoplasmic microtubules assist the nucleocapsid to the 
nuclear pores (78). The viral tegument proteins found surrounding the capsid are 
thought to diffuse into the cell and facilitate entry into the nucleus pores by interacting 
with the host’s microtubule machinery. Some tegument proteins track to specific sites 
and modify cellular metabolism (107) or cellular signalling pathways (108) in order to 
promote both intrinsic and innate cellular immune evasion as well as viral replication 
(109). The tegument protein ppUL48 and a binding protein, ppUL47, initiate viral 
uncoating and release of viral DNA (110). 
Once inside the nucleus, the virus is subjected to the intrinsic antiviral defence, 
promyelocytic leukaemia nuclear bodies (PML-NBs).  The death-domain associated 
protein (Daxx) is a prominent PML-NB which localise with the viral genome by 
associating with DNA-binding transcription factors. Daxx silences IE gene expression by 
recruiting histone deacetylases (HDAC) to viral gene promoters (111, 112). IE gene 
transcription is mapped to five loci distributed across the genome: UL36 and UL37, TRS1, 
IRS1, US3, and IE1/IE2 (UL123 and UL122). Expression of the major IE gene (MIE or 
IE1/IE2) is controlled by the MIE promoter (MIEP) and the transcribed product is 
alternatively spliced into either IE1 or IE2 (113, 114). 
The temporal cascade of HCMV lytic gene expression initiates as tegument protein pp71 
(UL82) degrades Daxx, which in turn relieves the Daxx and HDAC-mediated 
transcriptional suppression on IE1 (112). The viral genome then circularises and IE genes 
can be transcribed. Further PML-NBs are disrupted by newly synthesised IE1 and 
replication is initiated (115). ppUL84 is a transcriptional transactivator which binds IE2 
and mediates the successive association of viral proteins with the viral genome in order 
to promote viral gene transcription and the formation of replication centres (116). Viral 
DNA is replicated via the rolling circle mode by which concatemers are produced. The 
enzyme complex terminase (composed of pUL56 and pUL89) feeds the head-to-tail 
linked genomes into newly synthesised scaffold-containing procapsid until a single 
genome has entered and then cleaves the DNA at precise locations (117, 118). The two 
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cis-acting DNA packaging motifs, pac1 and pac2, are found at the ends of the genomes 
and are thought to aid in cleavage of concatemeric DNA (119). pUL56 of the terminase 
complex is responsible for binding to the pac sequences and for packaging the DNA into 
the procapsids whilst pUL89 is required to cleave the DNA at the specific locations (120). 
IE2 is a potent transactivator of DE and L viral genes, cellular genes and negatively 
autoregulates its own expression (121). The cascade continues as the expression of the 
DE genes is required for expression of L genes, which encode virion components 
necessary for virion formation, maturation and release. IE gene expression is 
independent of de novo HCMV replication as it relies on host and preformed viral 
machinery whereas translation requires host cell ribosomes (1). 
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Figure 3 -The lifecycle of HCMV. (A) HCMV fuses to the plasma membrane or utilises the 
endocytic pathway to gain entry into the host cell. (B) After entry and uncoating of the 
virion, the nucleocapsid is directed to the nucleus where expression of IE genes occurs 
initiating viral DNA replication. (C) The viral DNA is packaged into capsids which gain an 
envelope as they egress from the nucleus. (D) A secondary envelope is gained prior to 
the infectious virion leaving the cell by exocytosis. Figure reproduced from (5). 
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1.4.3 Viral Particle Maturation and Egress 
The newly formed capsids mature to become virions in a two-stage envelopment and 
egress process. The new capsids are transported to the cytoplasm by a herpesvirus-
conserved nuclear egress complex (NEC). The NEC enables the capsid to migrate through 
to the cytoplasm by binding and dissolving the nuclear lamina and mediating initial 
envelopment in the peri-nuclear space shortly followed by de-envelopment of the 
capsids at the outer nuclear membrane (1, 7, 85, 122). It is thought that the NEC could 
play a part in quality control by preferentially binding and transporting the DNA-filled C 
capsids over the non-infectious A and B capsids (123). The nascent capsids actually begin 
to acquire some of their tegument proteins during this time prior to reaching the 
cytoplasm. The translocated nucleocapsids then congregate in the viral assembly 
compartment (AC), a structure unique to beta herpesvirus-infected that forms in the 
cytoplasm 72-96 hours p.i. It is composed of hijacked and relocated cellular secretory 
compartments including the Golgi body (GB), trans-Golgi network (TGN), and early 
endosomes. This structure is described as concentric circles as Golgi and TGN vesicles 
encircle the AC, ER is distributed throughout the cytoplasm but also in a ring at the AC 
periphery and early endosomes make up the AC interior (6) (see figure 4). Viral 
tegument and envelope proteins accumulate along with the nucleocapsids in the AC. 
The tegument proteins associated with and offer stability to the maturing nucleocapsids, 
and also signal for the final envelopment process to begin. The final envelopment is 
influenced by HCMV envelope glycoproteins as well as viral proteins pUL71, ppUL35 and 
pUL103 (7). pUL71 promotes envelopment (83), ppUL35 affects virion egress (124) 
whilst pUL103 coordinates virion and dense body egress (125). The tegumented 
nucleocapsids acquire their final envelope in a vesicle thought to be either a vesicle in 
transit between the TGN and endosomes or a hybrid compartment expressing markers 
for the two vesicles. The matured virions leave the AC vertically to the cell surface where 
they merge with the plasma membrane and egress by exocytosis (6, 126). 
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Figure 4 -Viral particle formation and maturation start in the nucleus and continues in 
the AC found in the cytoplasm. HCMV-infected fibroblast shown by Transmission 
electron microscopy (TEM). The many types of viral particle formed during infection can 
be seen in: (a) The whole cell showing the nucleus and the AC formed next to it, (b) the 
nucleus and (c) the AC found in the cytoplasm.  Symbols: white arrowheads, B capsids; 
black arrowheads, C capsids; white arrows, A capsids; black arrows, mature virus 
particles; black diamond heads, dense bodies. Abbreviations: Nuc, nucleus; Cyt, 
cytoplasm; AC, assembly compartment. Scale bars represented: (a) 5 mm and (b,c) 1 
mm. Reproduced from (7). 
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Figure 5 – The AC structure and virion maturation and egress pathway. 
Reproduced from (6). (A) AC structure. The AC is a large structure of concentric 
rings of the Golgi, TGN and early endosomes. The ER is found throughout the 
cytoplasm and encircles the AC. (B) Virion maturation and egress pathway. 
Nucleocapsids leave the nucleus and mature through the AC until finally 
egressing vertically to the extracellular space. 
A 
B 
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1.4.4 Latency and Reactivation 
Latency is defined by the retention of the HCMV genome without the production of 
infectious virion progeny but with the potential to reactivate (127). This feature appears 
to be shared among all herpesviruses and allows for the virus to reside within specific 
sites within the host for prolonged periods of time whilst not actively replicating or 
producing any viral progeny. Expression of the IE genes can be initiated and the virus is 
reactivated into its lytic lifecycle in response to certain stimuli (128). In immune-
competent individuals reactivation events are usually controlled by cell-mediated 
immunosurveillance and HCMV can remain in its latent state for the lifetime of the host. 
Unlike the lytic lifecycle of HCMV which is permitted in multiple cell-types, the HCMV 
latent lifecycle is only permissible in restricted cell types (129). HCMV persists in a latent 
state in bone marrow-derived CD34+ progenitor cells (precursors of monocytes, 
macrophages and dendritic cells (DCs)) and CD14+ monocytes (127-129).  
In order to enable this transcriptionally inactive state within CD34+ progenitor cells, a 
repressive chromatin structure is required. This is possible through a number of 
processes such as the recruitment of histone proteins to the MIEP which are then 
trimethylated at H3K9 and H3K27, the presence of HP1 a repressive chromatin marker 
and HDAC activity (32). Not only is the MIEP regulated by chromatin structure but many 
repressive or activating transcription factors have binding sites within the MIEP (130). To 
name a few, repressive transcriptional factors Ying Yang-1 (YY1) and Ets-2 Repressor 
Factor (ERF) bind to repeated sequences within the MIEP. HDAC1 is recruited to the 
MIEP by ERF which acts to silence gene expression (131). The chromatin organiser KAP1 
along with the SETDB1 histone methyltransferase and HP1, associates with distal sites of 
the HCMV genome to mediate repression (132).  Additionally, latency-associated viral 
factors help to the suppression of the MIEP and the viral transactivator protein pp71 
which acts to initiate the temporal cascade of HCMV lytic gene expression (see section 
1.4.2) is excluded from the nucleus and remains in the cytoplasm (133). 
Myeloid cell differentiation has been shown to initiate chromatin remodelling of the 
MIEP, acetylation of the heavily methylated histones bound to the MIEP and the 
dissociation with HP1 likely allowing for the reactivation of the HCMV lytic lifecycle by 
allowing IE gene expression (32, 134, 135).
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1.5 HCMV Infection 
HCMV infection in humans most often initiates at mucosal sites. Although infection 
typically causes no overt pathology, an acute productive viral replication phase occurs 
and lasts from a few weeks to months, during which high titres of virus are shed. Once 
an immune response has been mounted against the pathogen the viral replication and 
shedding is heavily restricted. HCMV infection will result in systemic dissemination to 
ensure transmission to future hosts and the establishment of latency (136). 
1.5.1 Intra-host Dissemination and Tropism 
CMV exhibits a strict species specificity. However, within a host the virus spreads 
throughout the majority of organ tissues. HCMV spreads to multiple organs including the 
heart, brain, lungs, kidney, liver, spleen, retina, oesophagus, colon salivary glands, and 
inner ear (137).  The broad tropism of cell types and organs is likely responsible for the 
wide variety of sequalae observed in HCMV infection. The cell range of HCMV infection 
is remarkedly broad with targets of natural infection including connective tissue cells of 
various organs, parenchyma tissues, and various hematopoietic cell types (60, 138).  
The initial stage of viral dissemination, often termed primary dissemination, is likely to 
occur in mucosal tissues of the pharynx or the genital tract (137, 139). The initial cellular 
targets of HCMV after acquisition are likely epithelial cells which are thought to not only 
be an important primary infection site but for shedding of virus as well. The virus 
undergoes its lytic replication cycle and subsequently infects other permissible cell types 
such as fibroblasts, endothelial cells, dendritic cells, and other innate immune cells 
including alveolar macrophages most likely via cell-cell transmission of virus. Infection in 
polymorphonuclear leukocytes is not productive and instead it’s thought that these cells 
take up and transport virus particles to initiate infection in other tissues (137). Once 
innate immune cells with the potential to circulate in the bloodstream are infected, it is 
thought that the second stage of viral dissemination occurs (systemic spread) (136).  
HCMV viremia tends to be cell-associated as HCMV can travel through the body via 
circulating cells as well as haematogenous spread. Vascular endothelial tissues that form 
the interface between the blood circulation and solid tissues play a critical role in the 
dissemination of HCMV. These endothelial cells when infected with HCMV, can infect 
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neighbouring cells including non-endothelial cells of the underlying submucosa (29), but 
they can also swell and enter the bloodstream by detaching from the blood vessel wall 
(140). The majority of these infected cells lyse but some initiate organ infection as they 
accumulate in capillary beds (141). Data from MCMV studies suggests the importance of 
patrolling monocytes in the dissemination of HCMV as well. It is thought that these 
CX3CR1hi monocytes but not inflammatory monocytes aid in MCMV dissemination to 
distal organs most likely due to their immune-privileged phenotype post differentiation 
(142). 
The virus establishes latency in bone marrow-derived hematopoietic cells (e.g. CD34+ 
progenitors and CD14+ monocytes) and even endothelial cells from within the arterial 
walls (127-129) (see section 1.4.3). These monocytes do not support lytic replication of 
HCMV (127, 143). 
1.5.2 Lessons from HCMV Infection in vitro 
Some nonessential genes of HCMV encode cell type-specific functions for virus-growth, 
functioning as either tropism factors or replication temperance factors. UL24 and UL64 
proved to be important in Human Dermal Microvascular Endothelial Cells (HMVEC) and 
Retinal pigment epithelium (RPE) infection respectively. UL10 and UL16 are considered 
some of HCMVs temperance factors as UL10 mutants and UL16 mutants were shown to 
propagate exceptionally well in RPE and HMVEC cells respectively (84). The discovery of 
pathogen-encoded temperance factors in a herpesvirus is relatively new (84), but 
temperance factors that supress virulence have been seen in Mycobacterium 
tuberculosis (144) and Leishmania major (145) before. Temperance factors are a 
prevalent survival strategy to allow the pathogen to suppress productive lytic replication 
in order to achieve co-existence with the host. 
Differences in the tropism of HCMV strains or variants is usually due to receptor 
recognition by virion envelope glycoprotein complexes (see section 1.4.1). Interestingly, 
the cell type the virus is produced in can also be important. The two gH/gL complexes 
(see section 1.3.1.3), the trimeric and pentameric complexes, dictate receptor 
recognition and when both are present the virus can infect a wider range of cell types. In 
vitro HCMV virions can exhibit different tropisms by manipulating the amount of 
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pentameric complex present on their viral envelope. Virions derived from fibroblasts 
produced cell-free progeny tropic for fibroblasts and endothelial cells whilst endothelial 
cells retained endothelial cell tropic virus on its cell membrane which in turn infected 
other endothelial cells in foci likely through cell-cell methods, and released fibroblast-
tropic virus (146). The role for this tropism switch in vivo has not yet been determined. 
1.5.3 The Immune Response and Immunomodulation 
HCMV infection is targeted by both the innate and adaptive responses. Engaging both 
cellular and humoral immunity, it generates a robust immune response in humans (147). 
The complex virus/host relationship begins with an acute infection that is normally 
controlled by a combination of innate defences and a specific adaptive response, but 
neither appears capable of eradicating the virus completely.  
Innate Immunity 
Briefly, the Innate immune system is a non-specific pathogen detection system that is 
always present. It is the first line of defence which responds within hours to a threat. It 
includes physical barriers (skin), immune cells such as NK cells, monocytes, macrophages 
and DCs, and processes such as phagocytosis and inflammation (148). Antigen 
presenting cells (APCs) such as DCs and macrophages bridge the gap between the innate 
and the adaptive immune system. Foreign material is processed by these APCs and the 
peptides are presented to the adaptive immune system. Foreign material degraded by 
the lysosome is presented on major histocompatibility complex (MHC) class II molecules 
to CD4+ T cells whereas peptides produced from proteasomal degradation are then 
presented on MHC class I molecules to CD8+ T cells (149). HCMV infection results in the 
reduction of MHC-I cell surface expression. The gene products of US2, US3, US6, US8, 
US10 and US11 all act to prevent MHC-I cell surface presentation allowing escape from 
CD8+ T cell lysis. The UL18 MHC-I homologue is not affected by the expression of these 
viral genes and so acts as an inhibitory ligand for NK cells (150).  
Another component of the innate immune system is Complement. Complement is an 
immunological defence consisting of > 20 distinct plasma proteins that react with each 
other upon activation in a sequential reaction which can result in the formation of the 
membrane attack complex (MAC), opsonisation of the pathogen, direct killing of the 
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pathogen and inflammatory cell recruitment. Virus and virally infected cells can be 
eliminated through antibody-activated complement-mediated virolysis and cytolysis 
respectively (reviewed in (151). Complement can be activated in three ways: the 
classical pathway, which is triggered by antigen-antibody immune complexes or even 
direct binding of one of the plasma proteins C1q to the surface of the pathogen; the 
Lectin pathway which is initiated by mannose-binding lectins that binds carbohydrate 
ligands found on many microorganisms; and the alternative pathway, which is activated 
directly on pathogen surfaces but is also constitutively active at low levels (reviewed in 
(151). The neutralising ability of human serum is enhanced 2-3 fold by complement in 
the presence of specific anti-CMV antibodies (152). HCMV infection has been shown to 
downregulate the complement receptors CR3 and CR4 affecting the complement 
cascade (153). HCMV virions have also found to incorporate the complement regulatory 
proteins CD55, CD59 and CD46 which could represent another way that HCMV evades 
the host immune response (152). 
The receptors of innate immunity are called Pattern Recognition Receptors (PRRs) which 
are germline-encoded host sensors that bind to conserved molecular signatures that are 
shared by groups of pathogens. PRRs are expressed mainly on cells of the innate 
immune system and can respond to cellular proteins or DNA as a result of damage, 
microbial or viral proteins and nucleic acids (154). These are referred to as pathogen-, 
microbe- or damage-associated molecular patterns (PAMPs/MAMPs/DAMPs). PRRs have 
several classes including nucleotide-binding oligomerization domain (NOD)-like 
receptors (NLRs), Toll-like receptors (TLRs) and RIG-I-like receptors (RLR) and once 
activated can induce downstream inflammatory signalling leading to the production of 
inflammatory cytokines and activation of the interferon pathway (148, 154). 
In both the immunocompetent and the immunocompromised, HCMV induces 
inflammatory cytokine production and the Interferon (IFN) pathway. These innate 
immune responses can be activated through the interaction of viral envelope 
glycoproteins with host cell attachment and entry receptors as well as TLRs. 
Inflammatory cytokine release can be trigged by gB or gH binding TLR2. In fact, it was 
proposed that a TLR2/TLR1 heterodimer functions as a sensor for the virus (155). This 
rapid innate immune detection of HCMV may provide the host cell a temporal 
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advantage; the induction of an immune response prior to the virus becoming 
transcriptionally active. TLR signalling leads to the production of IFN-alpha/beta by 
macrophages and DCs which in turn activate NK cells (5).  
NK cells are a critical part of the innate immune response to HCMV; individuals with 
genetic defects in their NK-cell response are exceptionally vulnerable to HCMV disease. 
NK cells are vital in host-rejection of virally infected cells. NK cells receive both activating 
and inhibitory signals from a wide array of cell surface receptors. The ratio of these 
inhibitory to stimulating signals is what directs the NK cell to kill the target cell or not 
(156). In addition to direct killing of HCMV-infected cells by NK cells, viral replication may 
be restricted due to NK cell release of IFN-gamma. NK cells also stimulate NF-κB-
dependent IFN-beta production from infected cells in vitro (157). Several HCMV genes 
function as NK-cell evasion genes: UL16, UL18, UL40, miR112, UL135, UL141, UL142, 
UL148, US18 and US20. These characterised evasion genes act by a variety of 
mechanisms that are informing us on how human NK cell function, namely: direct 
stimulation of an inhibitory receptor (the MHC class I homologue UL18), rescue 
expression of an endogenous inhibitor (UL40 donates a peptide that stabilises HLA-E), 
inhibition formation of the immunological synapse (UL135) and downregulation of 
activating ligands (e.g. UL16, miR-UL112, UL141, US18, US20) or an adhesion molecule 
(UL148) (158-160). 
Adaptive immunity 
The adaptive immune response takes longer to initiate and take effect but can provide a 
more robust response due to its pathogen-specificity and can also lead to the 
development of immunological memory that provides a faster response to subsequent 
repeat infections. The adaptive immune system comprises of T cells and B cells and can 
be divided into two broad classes of responses; cellular and humoral responses 
respectively both of which are involved in the HCMV adaptive immune response (161). 
The adaptive cellular immune response to HCMV is dominated by T cells with HCMV 
disease occurring almost exclusively, with the exception of congenital disease, in cellular 
immunodeficient individuals (5). T cells can be classified into different subsets; cytotoxic 
T cells (CD8+ T cells), T helper cells (CD4+ T cells), regulatory T cells (TRegs, a CD4+ T cell 
subset), natural killer T (NKT) cells and γδ T cells. T cells function to restrict viral 
 
 
29 
 
replication, but do not eliminate the virus nor prevent transmission. They do this by 
binding and reacting through their T cell receptor (TCR) to foreign antigens that are 
presented to them by APCs on MHC molecules, however this process is more complex as 
additional signals are needed for T cell activation (162). Activation of CD4+ T cells results 
in enhanced antibody responses and production from B cells whereas CD8+ T cells once 
activated result in the development of cell-mediated immune mechanisms such as the 
lysing of HCMV-infected cells through the use of perforin and granzyme B (161). An 
astounding 10-25 % of all peripheral CD8+ T cells can be specific for HCMV (5, 163). 
CD8+ T cells also take on a protective role against latent virus reactivation by targeting 
both immediate-early genes and early genes. However, the most commonly targeted 
antigens of these cells are pp65 as well as IE-1. Pp65, although expressed late is found in 
the viral tegument and so is presented to APCs immediately upon initial infection of the 
cell (163). 
 Around 9% of all periphery CD4+ T cells are HCMV specific and recognise at least 59% of 
HCMV ORFs. CD4+ T cells also target pp65 along with other HCMV antigens such as gB, 
pp28, and IE-2. The importance of CD4+ T cells is apparent in transplant patients. HCMV-
specific CD4+ T cell low lung transplant recipients experienced difficulty clearing 
infection and increased frequency of viral reactivation (164). CD4+ T cells are said to be 
necessary for memory T cell induction, replication, and preservation.  
B cells are fundamental to the humoral immune response. B cells express antibodies as a 
secreted form but also retain them bound to their membranes. Once differentiated, B 
cells become Plasma cells which secrete antibodies once activated. These antibodies can 
inactivate virus by obstructing their ability to bind cell surface receptors for entry, but 
also can mark them for destruction through ADCC or complement (161). Animal models 
show the importance of B cells in HCMV immunity. Neutralising antibodies are shown to 
protect mice from primary infection (165) and also restricting dissemination of 
reactivated of MCMV (166). Another study showed that adoptive transfer of memory B 
cells from immune mice to B cell and T cell immunodeficient mice was able to induce an 
IgG response, significantly reduce viral load and protect long term against the lethal 
course of infection after infection with MCMV (167). In fact, HCMV infection has been 
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shown to mobilise and induce the expansion of activated memory B cells (168). This 
shows the importance of B cells and the humoral immune response to HCMV. 
 HCMV-specific antibodies also play an important role in controlling HCMV dissemination 
and viral load. HCMV antibodies are detectable in human serum 2-4 weeks after primary 
infection. These antibodies are raised to an array of viral proteins, including tegument 
proteins pp65 and pp150, transcriptional protein IE-1 and viral glycoproteins (163, 169). 
In fact, gB, the gH-gL-gO complex, and the gM-gN complex, are all major antigens for 
neutralizing antibodies (169-171) however the majority of neutralising activity stems 
from antibodies directed against the pentamer (172). The genes RL11, RL12, RL13 and 
UL118-UL119 encode Fc binding proteins that are thought to circumvent the humoral 
immune response through protecting against antibody-dependent cellular cytotoxicity 
(ADCC) (86, 173, 174). 
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1.6 The Genetics of HCMV 
In HCMV research the terms clinical and laboratory strains are used frequently. Clinical 
HCMV is a term that is widely used to mean several different things. In this thesis Clinical 
refers to strains either found circulating within patients or isolates that have been 
passaged only minimally, whereas laboratory strains are considered to be passaged 
extensively in cell culture and usually adapted to fibroblasts. 
1.6.1 Genome Organisation and Coding Potential 
The HCMV genome is the largest (~236 kbp) of all human herpesviruses (37, 175). The 
class E HCMV genome consists of unique short (US) and unique long (UL) segments 
flanked by internal (IRL and IRS) and terminal (TRL and TRS) inverted repeating segments 
(11), and at each terminus of the linear genome are 3’-unpaired nucleotide overhangs 
(176). The inverted repeat sequences contain cis-acting signals (pac1 and pac2) which 
are essential for genome cleavage and encapsidation (119) but also promote genome 
isomerisation by sequence inversion (176). This potential for genome isomerisation 
yields four genomic isomers in equal amounts (11). 
Originally, based on the sequencing of a highly passaged laboratory strain, AD169, it was 
originally predicted  that HCMV possessed 189 protein coding open reading frames 
(ORFs) (177). However, many of these ORFs were later discounted due to the fact that 
they were unlikely to encode functional proteins and further ORFs that were missed in 
the first genome analysis were added after comparative genome analysis of the closest 
relative of HCMV, CCMV (178). Since then, the low-passage strain Merlin has been 
analysed and 165 functional protein coding genes have been mapped (175). However, a 
study using ribosome profiling and transcript analysis of Merlin infected fibroblasts 
identified 751 potentially protein-coding ORFs, 604 of which were previously 
unidentified. Many of the ORFs were very short (<20 codons) and found upstream of 
longer ORFs, and could possibly be non-functional polypeptides that are rapidly 
degraded (179). Yet, a recent study could only identify stable expression of 4 of these 
604 non-canonical ORFs (180). Current estimates of the coding potential of HCMV are 
170 canonical protein coding ORFs, 4 abundantly produced long non-coding RNAs 
(RNA2.7, RNA1.2, RNA4.9, and RNA5.0), at least 23 microRNAs of which some regulate 
32 
 
cellular gene expression and 2 oriLyt RNA (1, 181-186). The origin of lytic replication 
(oriLyt) is conserved for betaherpesviruses and is found between UL57 and UL69. The 
core genes, found in the central portion of the UL region, are also conserved between 
herpesviruses and are mostly essential for viral replication. The vast majority of the 
remaining genes are non-essential for lytic replication and instead have functions such 
as immune evasion and tropism. Many of these genes are grouped into the 15 multigene 
families found to cluster together in the extremities of the UL and US regions of the 
HCMV genome  (175, 177, 178) 
Although some genes also have names describing their function, conventionally HCMV 
gene nomenclature is determined by the position of the gene within the genome (37). 
As seen in figure 6, the genes UL148-UL133 which make up the UL/b’ sequence are 
inverted in reference to the rest of the genome. The UL/b’ sequence was first 
characterised in the strain Toledo. Due to genetic rearrangement in early passage, the 
UL/b’ sequence of Toledo is in an inverted orientation relative to other strains (187). 
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Figure 6 - The genome organisation of WT HCMV (Merlin). Reproduced from (1). The 
genome organisation can be seen as TRL-UL-IRL-IRS-US-TRS. Protein coding regions are 
depicted as arrows with the repeated regions shown as broader arrows compared to 
unique regions. The gene families are colour coded with herpesvirus core genes shown as 
red and introns as narrow white bars.  
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1.6.2 Natural Genetic Variation Between Strains 
In in vivo infections it is commonly accepted that multiple strains circulate within the 
population and so an individual can be infected with multiple strains. Whilst natural 
selection gives rise to genetic diversity, inter-strain recombination can contribute (188, 
189). Sequence comparisons of whole HCMV genomes has identified a subset of genes 
that display a high level of variability: RL6, RL12, RL13 US9, US28, UL4, UL11, UL18, UL37, 
UL55 (gB), UL73 (gN), UL75 (gN), UL74 (gO), UL139, UL144, UL146 and UL115 (gL) (175, 
190-192). The UL55 gene encodes the glycoprotein gB and was one of the first examples 
of natural sequence variation in clinical and laboratory HCMV strains (189). 
In a high-throughput analysis of clinical isolate genomes 15% of genes were found to 
have a mutated ORF in at least one clinical HCMV isolate, and only 23% of the isolate’s 
sequences had the full set of intact HCMV genes. Thus, only approximately one quarter 
of clinical isolates can be considered genetically intact (3). Sequence variability in ORFs 
creates distinct genotypes and depending on the ORF the consensus nucleotide 
sequences can vary by up to 50% or even more between genotypes (190).  
1.6.3 Mutations Associated with Adaptation to Cell Culture 
Propagation of HCMV in vitro is associated with the accumulation of mutations during 
serial passaging and adaptation to cell culture. As a result, this eliminates the broad 
tropism seen in the clinical virus but allows for efficient viral replication in fibroblasts 
and the production of high titre (reaching 107 pfu/mL) cell-free virus for experimentation 
(193). Since its discovery and isolation, many laboratory-adapted strains have been used 
in HCMV research. The most widely used and distributed laboratory adapted strains 
include Towne (61) and AD169 (19). These strains have been invaluable tools over years 
of research and served as candidate vaccines. Due to extensive and serial cell culture 
passaging of the strains, both have undergone substantial genetic alterations resulting in 
the loss of virulence (193). Large deletions in the UL/b′ region have been acquired 
resulting in a 15 kbp loss in AD169 and a 13 kbp loss in Towne  (178, 194, 195). The UL/b′ 
region (UL148-UL133) contains many genes with the potential to contribute to the 
virus’s virulence in many ways. Found within the UL/b′ region, the gene UL46 encodes a 
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viral CXCL chemokine (196), UL144 encodes a tumour necrosis factor receptor homolog 
(197), and UL142 encodes an MHC class I-like molecule that inhibits NK cell lysis (198).  
One region that is commonly affected in many laboratory strains is the UL128L which 
results in restricted tropism. The strain Toledo is considered to be low passage, however 
the gene UL128 is disrupted by a substantial sequence inversion. Many other laboratory 
strains including AD169, TB40F and Towne have acquired mutations in at least one of 
the three genes in the UL128L resulting in a virus that only expresses the trimeric 
complex (see section 1.3.1.3)(175, 178, 187, 199-202). Much research to date has been 
performed using human fibroblasts, despite the virus’s wide tropism in vivo, and so 
using these laboratory strains with restricted tropism is not problematic (138). Another 
ORF commonly affected by adaptation to cell culture is the RL13 ORF and is usually one 
of the first mutations observed when passaging clinical virus in cell culture. A mutation 
in RL13 results in more efficient in vitro viral growth in fibroblasts (193, 203). 
As well as mutations that plague laboratory adapted strains, the presence of multiple 
variants within and between stocks can also be a challenge for HCMV research. It has 
become apparent that laboratory adapted strains that are in common use worldwide 
differ markedly from one another despite originating from the same stock (194, 195, 
204). Inter-strain variation is also reported within stocks. The Towne strain (VR977) 
distributed by the American Type Culture Collection (ATCC) was shown by sequence 
analysis to contain two variants, one containing an inverted duplication of part of the 
left extremity of the genome replacing the UL/b’ region (varS), and the other containing 
an intact in UL/b’ region (varL) (194, 205).
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1.7 Current Methods in HCMV Research 
  In order for HCMV research to be relevant, it is vital we can work with a virus in vitro 
that is an accurate representation of the virus found in clinical samples. Adaptive 
mutations observed in passaging laboratory strains in vitro are mainly associated with 
the gene RL13 and the UL128L (193). Genome stability was an issue for in vitro research 
until the cloning of low-passage strains into bacterial artificial chromosomes (BAC) such 
as FIX, TR, TB40/E and TB40-BAC4 (206, 207).  These BACs however were created from 
stocks that had not been sequenced prior to their creation and therefore run the risk 
that they harbour mutations from the initial passaging, potentially affecting viral biology 
(208). For example, substitution mutations have been found in the UL128L of TB40-BAC4 
and FIX, which reduced (but did not eliminate) the efficiency of epithelial cell infection 
(208). The RL13 ORF in most HCMV BACs is mutated by deletions, substitutions or 
frameshifts resulting in the introduction of premature stop codons (175).  
Merlin was the first full length HCMV genome to be cloned into a BAC, it was developed 
to provide a genetically intact source of clinical HCMV and has been designated as the 
first World Health Organization reference sequence for HCMV. Merlin was BAC cloned 
after minimal passage (p5) in fibroblasts. Genome comparison of the BAC with the 
clinical isolate revealed mutations in the UL128L and RL13. Repair of these genes 
drastically impeded the virus’s in vitro growth properties and limited cell-free virus 
secretion (203). As a result of expression of these 2 genes, clinical HCMV is heavily cell-
associated (103, 104).  
1.7.1 Viral Propagation in vitro 
To address the issue of rapidly arising mutations, a system has been developed to work 
with Merlin in vitro that provides for conditional expression of RL13 and UL128 (203). 
Transcription of the two unstable genes, RL13 and UL128, is repressed by inserting a Tet-
operator upstream of the gene promoters. This strain Merlin variant is propagated in a 
special cell-line expressing a Tet-repressor to allow for viral growth without expression 
of RL13 or UL128, and thus without selection of mutants (203). Using this construct, it is 
now possible to study genetically intact, phenotypically wild type HCMV by simply 
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infecting cells that lack the Tet repressor. More specifically, it allows the function of 
RL13 to be investigated in the context of a productive HCMV infection.
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1.8 RL13  
RL13 encodes a highly glycosylated type 1 transmembrane protein (203) expressed in 
the late expression phase (209, 210). As gpRL13 is expressed on the virion envelope it 
therefore has the potential to modulate tropism (203). RL13 is conserved in vivo, 
suggesting that the gene is essential for the survival of HCMV in vivo even though it 
suppresses in vitro propagation (37, 193).  
1.8.1 The RL11 Family 
RL13 is a member of the RL11 gene family which all encode a characteristic domain 
termed RL11D. The RL11 gene family has 14 members located at the left terminus of the 
genome. Eleven of the members are conserved in HCMV as well as CCMV (RL11, RL12, 
RL13, UL4, UL5, UL6, UL7, UL8, UL9, UL10, and UL11), and the remaining three are 
HCMV-specific (UL1, RL5A, and RL6) which are thought to have originated in the last 6-5 
million years when the CMV species separated through gene duplication (177, 191, 211). 
The RL11 family consists of genes that are nonessential for viral growth (98) and among 
the most variable HCMV genes (175, 212). In fact, RL5A and UL9 along with RL13 are 
part of a restricted group of HCMV hypervariable genes (175). 
Many of the genes in the RL11 family are predicted to encode membrane glycoproteins 
and function in viral entry. RL13 and UL10 are termed temperance genes that repress 
viral replication on a cell type-specific basis (see section 1.5.2) (84, 203). Similarly to 
gpRL13, gpUL4 and gpUL1 were found to be incorporated into the virion envelope (203, 
213, 214).  
1.8.2 Limitations of Working with Functional RL13 
In vitro propagation of HCMV clinical isolates is consistently inefficient until mutations 
are selected, generally growing through first for RL13 and subsequently in the UL128L 
(193, 203). During creation of the Merlin BAC the mutations observed in RL13 was a 
single adenine insertion causing a frameshift at nucleotide 11363 (Accession number 
NC_006273.2). When an additional 10 BAC clones from the same series of experiment 
were sequenced, each Merlin BAC had acquired RL13 disruptive mutations predicted to 
result in a truncated protein, but not all mutations were identical (203). Research into 
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the function of RL13 now will use a natural truncated RL13 mutant Merlin BAC (ΔRL13) 
as well as the WT Merlin BAC (WT) which was repaired by the deletion of the additional 
nucleotide (Fig. 7). 
Since RL13 and the UL128 ORF are conditionally repressed, propagation of virus is 
performed utilising the Tet-repression system which allows for genetic preservation of 
the ORFs. However, in order for research to be performed the full genetic content of 
Merlin needs to be expressed and so experimentation is performed in a non-Tet-
repressing cell line allowing for the production of virions containing the wildtype HCMV 
protein content. 
1.8.3 Rh13.1 – an RL13 Homolog 
Sequence alignments of CMVs determined that the closest evolutionary relative to 
HCMV is Chimpanzee CMV (CCMV), followed by Rhesus CMV (RhCMV) and green 
monkey cytomegalovirus (GMCMV) (1) (see figure 1). 
The RL11 family is dispensable for viral growth and in fact Rat and Mouse CMVs lack the 
RL11 family (215). Although MCMV lacks the RL11 family it does possess the m138 gene 
that encodes a Fc receptor for murine IgG (216), and so it is possible that some of the 
immunological advantages of the RL11 family are replicated by genes elsewhere in the 
murine and rat CMV genomes. The lack of mouse or rat models does not make in vivo 
experimentation with this gene family easy and so the closest model available that has 
homologues to members of the RL11 gene family is with CMVs that infect nonhuman 
primate species such as rhesus CMV (RhCMV) (217). Sequences of different RhCMV 
strains have been fully sequenced and published and the strain RhCMV strain 68-1 is 
available as a BAC (218). Unlike HCMV, RhCMV has a class F genome with no identified 
terminal repeat sequences. Due to this, the RhCMV genome lacks the potential to 
isomerise (11). The prototypical wild-type RhCMV genome is slightly larger than HCMV 
and contains 135 ORFs homologous to known HCMV proteins (217). 
Similarly to HCMV, RhCMV was found to acquire and select for multiple mutations 
including in Rh13.1 during adaptation to fibroblasts. The mutation resulted in a 
premature stop codon, which resulted in a protein sequence almost a third of the WT 
sequence length. Once repaired, the RhCMV 68-1 BAC encoded a gene with striking 
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homology to HCMV RL13 in both sequence and length (218). Despite this homology, the 
RhCMV RL11 gene family has diverged substantially from HCMV (218).
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Figure 7 – Schematic representation of the WT Merlin RL13 and the truncated RL13 sequence in Merlin ΔRL13/ΔUL128 and ΔRL13. An extra 
Adenine at nucleotide position 11363 results in a frameshift mutation at aa position 58. This frameshift mutation causes a premature truncation 
of the protein (95aa long) leaving a protein roughly a third of the size of the wild type. 
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 1.9 Thesis Aims 
RL13 expression Is strongly inhibitory to viral replication in cell culture with sequence 
analysis detecting disruptive mutations in RL13 rapidly upon viral propagation in 
fibroblasts (203). Yet RL13 is clearly retained in many clinical isolates suggesting that 
RL13 is necessary for the success of the virus in the human host. 
The vast majority of laboratory based HCMV research has been performed using RL13 
mutant viruses. RL13 is not only conserved in clinical isolates but is a viral envelope 
glycoprotein that has the potential to modulate tropism and/or immune responses.  
As UL128L mutations have also been shown to restrict efficient viral growth in cell 
culture (203), this project will utilise a Merlin BAC RL13 mutant (ΔRL13), UL128 mutant 
(ΔUL128), a double mutant (ΔRL13/ ΔUL128) and the WT Merlin BAC. 
The aims of this thesis are to explore the function of RL13 by investigating its effect on 
the efficiency of viral infection at the different stages of the viral lifecycle. We will also 
attempt to identify how and why RL13 inhibits virus growth so drastically in vitro 
through genetic and growth analysis of HCMV variants alongside the Merlin BACs, and 
through analysis of the effects of RL13 on the virion and viral infection. To determine 
what advantage RL13 provides the virus we will explore the effects of RL13 expression 
on the virus, the host cell and host immune system. A minor aim of this thesis will be to 
generate novel reporter viruses to assist in this and future projects. 
Determining the function of RL13 could assist in the development of systems for the 
propagation of a virus containing the complete intact HCMV genome which could in turn 
would greatly facilitate HCMV research. 
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CHAPTER 2. MATERIALS AND 
METHODS
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2.1 Reagents 
2.1.1 Buffers and Solutions 
All solutions, buffers and media were prepared with double-distilled ultra-pure water 
(ddH2O) delivered from a Purelab Ultra water system. 
Table 2 – Buffers and solutions. 
Wash Buffer (PBS-Tween20)  Phosphate Buffered Saline (PBS), 0.05 % (v/v) Tween20 (Merck, 
9005-64-5) 
TE buffer (pH 8.0) 10 mM Tris, 1 mM EDTA in ddH2O 
6x DNA loading buffer ddH2O, 10 mM Tris-HCl, 0.03% bromophenol blue, 60% glycerol, 
60 mM EDTA 
1x TAE 50x TAE buffer (National Diagnostics, EC-872) diluted in ddH2O 
1:50 
Fluorescence activated cell 
sorting (FACS) buffer 
PBS containing 1 % (v/v) Foetal bovine serum (FBS) (Gibco, Life 
technologies, 10500) and 2 mM EDTA 
4% Paraformaldehyde (PFA) 4% (w/v) paraformaldehyde (Acros Organics) dissolved in PBS. 
NaPh buffer 0.0076 M sodium di-hydrogen phosphate, 0.0324 M disodium 
hydrogen phosphate, in ddH2O 
Gradient ‘Light’ solution NaPh buffer, 15% (w/w) sodium tartrate, 30% (w/w) glycerol 
Gradient ‘Heavy’ solution NaPh buffer, 35% (w/w) sodium tartrate 
PBST  0.1% (v/v) Tween20 (Merck, 9005-64-5) dissolved in PBS 
Immunoblotting block/stain 
buffer 
PBST with either 5% (w/v) fat-free milk proteins (dry milk 
powder) or 5% (w/v) BSA (Sigma-Aldrich, A7906) 
Transfer buffer 10% (v/v) NuPage transfer buffer (20X, Novel, life technologies, 
NP0006-1), 10% (v/v) methanol, 400ml ddH2O 
Reducing buffer 10% DTT (Sigma), 25% NU-Page buffer (Life technologies), 65% 
ddH2O 
Running buffer 50ml 20X NuPage MOPS SDS running buffer (Invitrogen, 
1936381) in 1L ddH2O 
Stripping buffer Restore stripping buffer (Thermo, 21063) 
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2.1.2 Bacterial Culture Media and Reagents 
All bacterial culture reagents and analytical grade chemicals were sourced from either 
Sigma or ThermoFisher unless otherwise stated. Autoclaving was used to sterilise all 
bacterial culture media which was allowed to cool to around 50°C prior to the addition 
of antibiotics and/or supplements.  
Table 3 - Bacterial culture media and reagents 
 
Table 4 - Bacterial culture media supplements 
Antibiotic or Chemical Stock concentration Dilution 
Chloramphenicol  12.5 mg/mL chloramphenicol (Doehringer), in 100% 
ethanol 
1:1000 
Ampicillin 
100 mg/mL Ampicillin (Duchefa Biochemie) in ddH2O, 
0.22 μm filter sterilised  
1:2000 
Kanamycin  
15mg/ml Kanamycin monosulphate (Melford) in 
ddH2O, 0.22 μm filter sterilised 
1:1000 
Streptomycin 
200 mg/ml Streptomycin sulphate (Melford) in ddH2O, 
0.22 μm filter sterilised 
1:500 
Isopropyl β-D-1-
thiogalactopyranoside 
(IPTG) stock 
100 mM IPTG (Melford), in ddH2O 
1:500 
5-bromo-4-chloro-indolyl-β-
D-galactopyranoside (X-
gal) 
40 mg/mL X-gal (Melford) in Dimethyl sulfoxide 
(DMSO) (Sigma-Aldrich, 41647) 
1:500 
 
 
 
 
 
 
 
 
Luria-Bertani (LB) 
broth 
2% (w/v) LB powder (Melford Biolaboratories Ltd, L1703) in ddH2O 
LB Agar LB broth, 15% (w/v) agar. 
LB Agar + Sucrose 
ddH2O, 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 15% (w/v) agar, 5% 
(w/v) sucrose 
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2.1.3 Tissue Culture Media and Reagents  
All tissue culture media was sourced from Gibco of Invitrogen/Life Technologies unless 
otherwise stated. 
 
Table 5 - Tissue culture media and reagents 
DMEM 10% 
Dulbecco’s Modified Eagle Medium (DMEM, Sigma, D5796), 5% (v/v) Penicillin 
and streptomycin, 10% (v/v) FBS 
DMEM 0% 
DMEM, 5% (v/v) Penicillin/Streptomycin sulphate (pen/strep, Gibco, Life 
technologies, 15070-063), 0% (v/v) FBS 
2X DMEM 
50% (v/v) ddH2O, 20% (v/v) 10X MEM (Life Technologies), 20% (v/v) FBS, 6% 
(v/v) sodium bicarbonate (Life Technologies), 1000 U.L-1 penicillin (Life 
Technologies), 1000 μg.L-1 streptomycin (Life Technologies), 4 mM L-1 
glutamine (Life Technologies) 
Freezing 
Medium  
90% (v/v) FBS and 10 % (v/v) DMSO 
RPMI 10% RPMI-1640 (Life Technologies) 10% (v/v) FBS 
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2.2 Cell Culture 
Table 6 - Cell lines used 
Name Organism Cell type Immortalised Notes 
HFFF Tert Human Fibroblast Yes 
Immortalised by constitutive 
expression of telomerase 
HFFF Tet Human Fibroblast Yes 
tetracycline repressor expressing 
HF Terts used for growing up 
viral stocks 
Primary 
HF 
Human 
Foetal Foreskin 
Fibroblasts 
No 
Obtained from Frank Graham 
(Porton Down). 
ARPE19 Human 
Adult Retinal 
pigment 
epithelials 
Yes ATCC #: CRL-2302 
CARs Human fibroblast Yes 
HFFF Tert overexpressing CAR 
receptor 
2.2.2 Cell Culture 
All tissue culture work was performed with aseptic techniques in a Class II biological 
safety cabinet. The inside of the Class II biological safety cabinet and all equipment and 
reagent bottles to go inside were sprayed with a solution of 70% (v/v) IMS before any 
work commenced. Any tissue culture reagents to be used were first warmed to 37°C in a 
water bath. 
Cell Maintenance 
All cells were incubated at standard tissue culture conditions: 37˚C at 5% CO2. Cells were 
propagated in DMEM 10% unless otherwise stated. Cells were passaged when 
confluency reached 90-100%, the monolayer was first washed with PBS. Cells were then 
dissociated from the flask by adding 0.05% Trypsin/EDTA (x1, Thermo Fisher, 25300-054) 
for 3 min in a rocking incubator at 37˚C. Monolayers could be disrupted by gentle 
tapping of the flask before the addition of DMEM 10% to neutralise residual trypsin. 
Once harvested the cells were either used for experiments or for sub-culturing by 
splitting 1:4 – 1:6 depending on cell type every 3-4 days. 
Cell Counting 
Cells were counted prior to plating using disposable counting chambers (Sigma, Z35962). 
Once cells were harvested as previously described, the cell suspension was pipetted to 
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ensure a single cell suspension, before 10 µl was loaded into a counting chamber.  At 
least four grids within the counting chamber were counted to give an average cells/ml. 
The average cells/ml could be calculated by multiplying the average cell count by a 
factor of 104. The appropriate number of cells were either plated in DMEM 10% or 
centrifuged at 1500rpm for 3 min to eliminate any FBS if to be plated in DMEM 0%. 
Long Term Storage and Recovery of Cells 
Cells were grown to confluency, washed with PBS and harvested with the addition of 
0.05% trypsin-EDTA as previously described. The cell suspension was then pelleted at 
1500rpm for 3 min, supernatant discarded and resuspended in an appropriate volume of 
freezing medium. Cells were aliquoted into 1.5 mL cryovials (ThermoFisher Scientific) 
and stored at -196°C in liquid nitrogen. Cells were initially cooled at a rate of -1°C per 
min using an isopropanol-based freezing vessel (Nalgene) to -80°C before transfer to 
liquid nitrogen. When recovering cells, vials were retrieved from liquid nitrogen and 
immediately put on dry ice. Vials were then transferred to a 37°C water bath to ensure 
rapid defrosting. After 3-5min thawing, cells were transferred to an appropriately sized 
flask in DMEM 10% and incubated for 24 hr. Cells were monitored by phase-contrast 
microscopy after 24 hr and DMEM 10% replaced if necessary. 
2.2.2 Peripheral Blood Monocyte cell culture 
Blood collection was approved by the school of medicine research ethics committee 
under the project ‘The Pathogenesis of Human Cytomegalovirus, ref 16/52’. 
Seropositivity of cell samples were determined using a CMV IgG ELISA as per 
manufacturers guideline (Sigma, SE120034). 
Isolation of PBMC from Whole Blood 
50 ml of donor blood was collected with heparin (1 µl/ml blood). Peripheral blood 
monocyte cells (PBMCs) were isolated by layering 2/3 human blood on top of 1/3 
Histopaque (Sigma) and centrifuged at 2000 rpm for 20 min without using a brake in a 
Beckman coulter centrifuge. PBMCs were extracted from the interface between the 
plasma and Histopaque, then washed with PBS three times, first by centrifugation at 
2000 rpm for 7 min and then centrifugation at 1000 rpm for 5 min twice. 
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Monocyte Differentiation 
Monocytes were isolated from PBMCs by magnetic separation with CD14 microbeads 
(Miltenyi). This was checked by staining with anti-human CD14 antibody. Monocytes 
were then differentiated into Dendritic cells (DCs) and Langerhans cells (LCs) by 
incubating in RPMI 10% in non-treated tissue culture dishes (Corning Costar, Sigma, 
CLS3738-100EA) with the appropriate cytokines (DCs: IL-4 100ng/ml and GM-CSF 
100ng/ml every 2 days.  LCs: GM-CSF 100ng/ml and TGF-β1 20ng/ml every 2 days and IL-
4 10ng/ml for the first 2 days only.) DCs and LCs, were phenotyped by Flow cytometry 
using a BD Accuri C6 cytometer to check for correct differentiation (see table 6). Correct 
differentiation was assumed when DCs presented as CD1a +ve, DC-SIGN +ve, CD14 low 
and LCs presented as CD1a +ve, DC-SIGN +ve, CD14 low, Langerin +ve. 
Table 7 – Antibodies used to check for correct differentiation 
Immunogen Company 
Catalogue 
number 
Dilution Conjugate 
CD14 (clone 61D3)  eBioscience Dx 9025-0149-120   1:50 Pe/Cy 7 
CD1a  BD Pharmingen  555806   1:50  FITC 
DC Sign  BD Pharmingen 551265    1:50  PE 
Langerin (CD207) Miltenyi Biotec 130-098-364   1:50 APC  
Non-adherent Cell Culture 
Non-adherent cells including PBMCs, DCs and LCs were cultured in upright T25s (25 cm2, 
Corning, Sigma-Aldrich, 430639) at standard tissue culture conditions. Cell culture 
medium for non-adherent cells consisted of RPMI 10% with the addition of IFNα when 
required at 1:6000.  
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2.3 Viruses and Infections 
With the exception of TB40/E kindly supplied from Jay Nelson (OHSU, Portland Oregon, 
USA), and Rhesus CMV kindly supplied from Klaus Früh (OHSU, Portland Oregon, USA), 
all viruses used were HCMV strain Merlin and were either provided by or generated 
from HCMV provided by Dr Richard Stanton (203). All Merlin virus had either mutated or 
wildtype RL13 and/or UL128L. Tet-operators were located upstream of the wildtype 
ORFs to prevent acquired mutations during viral propagation under conditional 
expression (219). GFP variants of these viruses were also used, some containing a P2A 
self-cleaving peptide upstream of an eGFP ORF to increase efficiency of GFP expression. 
Viruses used can be found in Results chapter 3. 
2.3.1 Generation of HCMV Stocks 
Viral stocks were either grown up from existing stocks or transfected from viral BAC 
DNA. When growing virus from existing stocks, ten T150s (150 cm2, Corning, Sigma-
Aldrich, 430825) of HFFF Tets were grown to 75-90% confluency and then infected at a 
multiplicity of infection (MOI) of 0.03. When transfecting, 2ug of viral BAC DNA 
(generated from section 2.4.6.7) was transfected into HFFF using the AMAXA 
nucleofector kit to the manufacturer’s guidelines (Amaxa Biosystems, Lonza). The 
transfected cells were then seeded in a T25 in DMEM 10% and once viral plaques 
appeared cells were trypsinised and reseeded to encourage viral spread. When the 
entire T25 monolayer was infected, bleeds were taken and frozen down at -80C. One 
bleed would usually be sufficient to infect ten T150s. The T150s were fed until the 
monolayer was sufficiently infected and CPE visible for 75-95% of cells. Bleeds were 
taken every two days and frozen at -80C until the monolayer was exhausted. Once 
finished, all bleeds were defrosted quickly at 37°C in a water bath before centrifugation 
at 1500rpm for 3 min to remove cells. Once pooled, the bleeds were centrifuged in a 
Beckman coulter Highspeed centrifuge at 14000rpm for 2 hr at 21°C. Once the 
supernatant was discarded the pellets were resuspended in a total volume of 6-8 ml 
10% DMEM, aspirated with a 25-gauge needle to break up aggregates, and aliquoted as 
300ul aliquots. 
 
 
51 
 
2.3.2 Quantification of HCMV Infectivity 
Infectivity or titration of viral stocks and experimental supernatants were quantified by 
either plaque assay or by IE1 titration assay (both outlined below).  Both methods were 
performed in HF Primary cells and viruses were diluted in a 10-fold dilution series. The 
dilution range was chosen per sample so that a predicted quantifiable number of 
plaques/infected cells could be easily counted per well. After plaques or infected cells 
were counted, titrations were calculated and expressed as total plaque forming units per 
mL (PFU mL-1). The following calculation was used to calculate PFU mL-1: 
Plaques/infected cells (in 100 µL) x 10 x dilution factor 
Plaque Assay 
Primary HFs were seeded into a 6 well plate in DMEM 10% 24 hrs prior to infection. The 
virus to be titred was thawed quickly in a water bath at 37°C before a serial dilution 
added to cells in duplicate. Infections were performed under the conditions described 
below and after 2hr inoculum replaced with 1:1 2x DMEM and Avicel; sodium 
carboxymethycellulose, microcrystalline cellulose mixture previously described by 
Matrosovich (220) which limits cell-free viral spread allowing for the accurate titre of 
viral stock to be calculated. After 10-21 days, depending on virus background and 
proximity of plaques, plaques were counted in the duplicate serial dilution condition 
which was most appropriate.  
Experimental Titration by IE1 Immuno-fluorescence 
Cells were seeded the day before in clear-bottomed 96-well plates, culture media was 
removed and 100 µl of appropriate serial dilutions of viral supernatant added directly to 
the wells in duplicate. After 24 hrs, viral supernatant was removed and the monolayer 
washed with PBS. Cells were fixed and permeabilised by incubation with 50 µl 
Acetone/Methanol at -20 °C for 15 mins. The Acetone/Methanol was removed and the 
monolayers washed with excess PBS three times, before incubation with IE1 primary 
antibody diluted in PBS for 1 hr at 37 °C in a rocking incubator. Primary antibody was 
removed, monolayers washed in excess PBS three times. Anti-Mouse IgG was used as a 
secondary antibody diluted in PBS and incubated with monolayers for 1 hr at 37°C in a 
rocking incubator. Secondary antibody was removed and the stained monolayers were 
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washed with PBS in excess three times. The Zeiss Fluorescent microscope was used as 
described in section 2.6.1 and Viral titre was calculated by counting fluorescently stained 
nuclei in the dilution that was most appropriate. 
2.3.3 Infection of Cells with HCMV 
Standard tissue culture conditions were used when for all infections. Unless otherwise 
stated, cells were plated in DMEM 0% 24 hr before infections. Virus was added to cells 
with enough DMEM 0% to sufficiently cover cells whilst incubating on a rocking 
platform. After 2 hrs the inoculum was removed and replaced with fresh DMEM 0%. 
Infections were monitored 24 hr after by phase-contrast microscopy for cytopathic 
effects (CPE) and media changed and replaced with DMEM 10%. 
2.3.4 Viral Timecourses 
 Viral infections were set up as previously described in section 2.3.3 in a tissue culture 
plate (Thermo Fisher). 
Harvesting Cells from a Viral Timecourse 
One well would be harvested per day by addition of Trypsin-EDTA, so sufficient replicate 
wells for the duration of the timecourse had to be infected per sample. Cells would then 
be processed for DNA extraction or lysed for western blotting. 
Harvesting Supernatant from a Viral Timecourse 
When harvesting the supernatant, the same well/flask would be used each day and 
replaced with fresh DMEM 10%. The supernatant would then either be frozen at -80 °C 
or processed immediately for DNA extraction. 
2.3.5 Isolation of DNA and Protein 
DNA Extraction 
Samples were defrosted quickly at 37˚C if necessary. Samples were first centrifuged to 
remove cellular debris. Samples were then DNAse treated by the addition of 2% DNAse 
buffer and 1% DNAse (RQ1 RNAse-free DNAse, Promega) for 1 hr at 37˚C until the 
reaction was stopped by the addition of 10% DNAse Stop buffer (RQ1 RNAse-free 
DNAse, Promega) incubated at 65˚C for 10 min. DNA was then extracted from samples 
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using a QIAamp MinElute Virus Spin Kit (Qiagen) as per manufacturers protocol and 
eluted as a volume of 100 µl Viral DNA. 
Large Scale DNA Extraction from Supernatants 
Large quantities of viral DNA from supernatants were prepared a little differently with 
the following method. Supernatant samples were defrosted quickly in a 37˚C water bath 
and centrifuged at 1500 rpm for 3 min to remove any cellular contamination. Samples 
were then centrifuged at 23,000 rpm for 1 hr at 21˚C in a Beckman coulter 
Ultracentrifuge to pellet virions. Once pelleted the supernatant was discarded and the 
pellet resuspended in 500 µl ddH2O. The resuspended virions were then incubated with 
DNAse as described previously in section 2.3.5.1. NP40 was then added to a final 
concentration of 1% to break open capsids and membranes and expose the viral DNA 
and samples were vortexed briefly. DNA was released from DNA binding proteins and 
histones by the addition of SDS to a final concentration of 0.5%. Samples were then 
incubated at 37˚C overnight with 200ug/ml proteinase K. Equal volumes of 
phenol:chloroform:isoamylalchool were then added and samples shaken gently to allow 
for the precipitation of proteins. Proteins were removed by the subsequent 
centrifugation of samples at 13,000 rpm for 5 min and the removal of the DNA layer 
found above the phenol and protein layers. This step is repeated with 
phenol:chloroform:isoamylalchool again and then a third time using just 
chloroform:isoamylalcohol ensuring samples are mixed before centrifugation. DNA was 
then precipitated by the addition of 10% sodium acetate, 1 µl glycogen, and 250% 
absolute ethanol and kept at -20˚C for 1 hr. DNA was then pelleted by centrifugation at 
13,000 rpm for 30 mins at 4˚C, washed in 70% ethanol and then centrifuged again. DNA 
pellets were left to air dry before resuspension in 10 mM Tris pH8. 
Protein Extraction 
Cell samples were first washed with PBS before incubation with reducing buffer on a 
rocking incubator for 3 mins. Once samples were fully lysed, cell scrapers (Greiner Bio-
one, 541 070) were used to ensure all sample had dissociated from the plate or flask 
before collection and storage at -20˚C. Before loading for a western blot, samples 
needed boiling at 100˚C for 10 mins to ensure complete reduction. 
54 
 
2.3.6 Purification of Virions 
Virions were purified on a Glycerol-Tartrate gradient which enabled the removal of 
NIEPs, Dense bodies and other cellular contamination.  
Sample Preparation and Concentration 
Once the timecourse was completed, samples were defrosted and all timepoints per 
sample pooled. The pooled samples were then centrifuged to remove contaminating 
cells at 1500 rpm for 3 min. Samples were concentrated by dialysis using VivaFlow50 
ultra-filtration 1MDa cartridges (Sartorius) as per manufacturers protocol. The 
ultrafiltration was driven by a peristaltic pump and any particles smaller than 1MDa 
passed through the membrane and into the waste container. The ultrafiltration was 
stopped when the final volume of concentrated virus was less than 15 mL. 5 mL PBS was 
then flushed through the cartridge to recover virions remaining in the cassette. 
Preparation of Gradients 
Continuous gradients were formed using a SG50 gradient maker (Hoefer). By loading the 
Gradient ‘Heavy’ and ‘Light’ solutions into the two linked chambers the solutions were 
allowed to gradually mix before exiting the gradient maker through one single outlet 
tube. A peristaltic pump (Pump P1, Pharmacia Fine Chemicals) was used to draw the 
mixed solution through the tubing to an Ultra-clear centrifuge tube. The tubing was 
constantly manipulated to ensure careful formation of the gradient form the bottom of 
the centrifuge tube to the top. This allowed for the lower region of the gradient to be 
mostly ‘heavy’ solution up to the ‘light’ solution in the upper regions of the gradient.  
Isolating Virions 
Around 5 mL of concentrated virus was carefully loaded onto the top of the gradient. All 
gradients were balanced by the careful addition of PBS to the top of the sample if 
necessary, before ultra-centrifugation for 45 mins at 23,000 rpm. After centrifugation, 
clear bands could be found containing purified virions, NIEPS, cellular debris and dense 
bodies. The desired purified virion band was recovered by inserting a 20 G needle and 
syringe into the ultra-clear tube just below the band, angling the needle bevel upwards 
and taking the entire virion band. Recovered purified virions were then washed by 
dilution in excess NaPH buffer to remove gradient solution, and ultra-centrifuged at 
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23,000 rpm for 1 hr to pellet the virions. The virion pellet was resuspended in PBS and 
stored at -80 °C. 
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2.4 Molecular Biology Techniques 
2.4.1 In-silico Analysis and Oligonucleotide Design 
All primer and oligonucleotide design, sequencing analysis and HCMV genome 
comparisons were performed using CLC MAIN 6 software (CLC Bio). Melting 
temperature and other parameters of primers and oligonucleotide were determined 
using Oligo Explorer 1.2 (GeneLink) and Oligo Analyser (GeneLink) software packages. 
Primers were designed as to avoid secondary structures, self-annealing regions or 
primer-dimer formation. Melting temperature of forward and reverse primers were 
between 60-65°C and similar to each other. All primers were ordered from Eurofins 
MWG as lyophilized primers, which when received were reconstituted immediately with 
ddH2O to 100 μM and stored at -20°C. For all primer sequences see appendix 1. 
2.4.2 Polymerase Chain Reaction (PCR) 
PCR reactions were set up as 50 µL reactions on ice in thin-walled RNAse and DNase-free 
tubes (ELKay). Reactions consisted of 40 µL ddH2O, 5 µL HIFI buffer 2 (Expand High 
fidelity; HIFI, 11732641001, Roche), 1.5 µL DMSO, 1 μL of deoxynucleotides (dNTPs) 
(NEB), 1 μL of template DNA, 1 μM forward and reverse primers 0.5 μL of HIFI 
polymerase (HIFI, 11732641001, Roche). All PCR reactions included a negative control 
containing 1 μL ddH2O in place of DNA template. A T3000 Thermocycler (Biometra) was 
used with the following two programs (see tables 5 and 6). Programs were only modified 
to change the extension time depending on the length of the template to be amplified 
and to change the annealing temperature depending on the primer melting 
temperatures. 
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Table 8 - LONG PCR programme 
LONG PCR program stages  Temperature 
(˚C)  
Time  Cycle  
Pre-heating  99  2 min  -  
Initial denaturation  95  2 min  1  
Denaturation  
Annealing  
Extension  
95  
55  
68  
30 s  
30 s  
4 min 30 s  
33  
Final extension  68  15 min  1  
Hold  4  ∞  -  
 
Table 9 - HIFI PCR programme 
HIFI PCR program 
stages  
Temperature (˚C)  Time  Cycle  
Pre-heating  99  2 min  -  
Initial denaturation  94  2 min  1  
Denaturation  
Annealing  
Extension  
94  
55  
72  
15 s  
30 s  
3 min  
34  
Final extension  72  7 min  1  
Hold  4  ∞  -  
 
2.4.3 DNA Gel Electrophoresis 
Agarose gels were prepared by dissolving 1% (w/v) Hi-Res Standard Agarose (AGTC 
Bioproducts) in TAE buffer (see section 2.1.1) by microwaving until the agar dissolved. 
Once cooled sufficiently, 0.5 μg/mL of ethidium bromide (Sigma) was added to the 
solution and mixed. The agarose solution was poured into gel casts and left to solidify at 
RT. Once set, 6x DNA loading buffer (see section 2.1.1) was added to DNA samples at a 
final 1x concentration, and the DNA mixture loaded into the gel wells. Every gel included 
10 μL of HighRanger Plus 100 bp DNA Ladder (Norgen biotek).  The electrophoresis was 
run at 100 Volts for 1-2 hours in TAE buffer until bands were sufficiently separated. DNA 
bands were visualized using UV illumination on a GeneSys xx6 gel doc system. 
2.4.4 DNA Gel Extraction and Purification 
The desired DNA fragments were cut from the gel whilst being visualised on a UV 
transilluminator (Spectroline TVC-312A) briefly, taking care not to extend exposure 
times unnecessarily as to prevent DNA damage. Isolated fragments were weighed in 
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clean 1.5 mL Eppendorf tubes (Fisher Scientific) and DNA purified using a Geneflow Q-
Spin gel extraction/PCR purification kit as per manufacturers protocol. Briefly, sufficient 
binding buffer was added to the gel fragments and dissolved at 60 ˚C until a 
homogenous solution formed. The DNA gel solution was then centrifuged through DNA 
binding columns to collect the DNA on the column membrane. The membrane was 
washed twice by discarding flow-through and adding supplied wash buffer, centrifuging 
the column and repeating. Residual wash buffer was removed by a final centrifugation 
after discarding flow-through. DNA was eluted by placing the column in a clean 1.5 mL 
Eppendorf tube, adding 30 μL of ddH2O and centrifuging a final time. 
2.4.5 Measuring DNA Concentration 
DNA concentration was measured using a (Nanodrop). The Nanodrop was equilibrated 
with 2 µL ddH2O before loading 2 µL of sample. The sample purity was monitored by 
checking that the 280/260 reading was ~ 1.8 or within 0.1 of this as per manufacturers 
guidelines. 
2.4.6 Recombineering 
Recombineering processes were carried out as previously described (203). 
Theory 
Desired Merlin variants were obtained through recombination mediated genetic 
engineering (Recombineering) which allows for desired sequences or genes to be 
modified, inserted or deleted from bacterial artificial chromosome (BAC) cloned HCMV 
genomes. Recombineering was performed in SW102 E.coli containing phage lambda red 
genes that are expressed from a temperature sensitive promoter. These genes mediate 
homologous recombination of short stretches of DNA (221). Manipulating the 
temperature of the bacteria allows for bacterial growth and BAC production without 
recombination at 32°C and induction of the recombination genes at 42°C. Two 
successive rounds of transformation are required to manipulate the BAC-cloned HCMV 
genome. In the first transformation round, the desired DNA region to be modified was 
replaced with the Rpsl cassette, a selectable cassette encoding both positive (Kanamycin 
resistance) and negative (streptomycin sensitivity) selectable markers (see section 
2.4.6.4). In a first round, cells that had successfully inserted the cassette were selected 
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on the basis of kanamycin resistance. In a second round the cassette was replaced with a 
desired sequence, and correct recombinants selected based on resistance to 
streptomycin. The cassette also included laczA for blue/white screening, as an additional 
marker. The region of manipulation in the BAC genome was sequenced prior to 
propagation of a single clone. 
DNA Sequence Design and Preparation 
Two sets of primers (~100bp each) were required for recombineering. One set is needed 
to amplify and insert the Rpsl cassette into the target region. These were designed with 
~80bp of homology to regions flanking the target insertion site in the BAC-cloned 
genome as well as ~20bp at the 3’ end with homology to 5’ of the Rpsl cassette itself. 
The Rpsl cassette was amplified with the primers found in appendix 1. The second set of 
primers were engineered to amplify the desired sequence and replace the Rpsl cassette. 
These were designed with both homology to the regions flanking the target sequence 
and the desired sequence. Again, the desired sequence was amplified as described in 
section 2.3.1 or smaller modifications were possible with just the two overlapping 
primers. PCR products were separated on an agarose gel, then the appropriate band cut 
out and DNA purified. 
Production of Competent SW102 E. coli and Transfection of DNA 
SW102 E. coli were cultured in LB broth overnight in a shaking incubator (200 rpm at 
32°C, thus restricting the expression of recombineering genes). All bacteria containing 
BACs were cultured with chloramphenicol (12.5 μg/mL). This culture was then used to 
inoculate (0.5 mL) 25 mL fresh LB broth and the SW102 E. coli were cultured to high 
concentration whilst remaining in log-phase of replication. Cultures were monitored by 
UV spectrophotometry (Pharmacia Ultraspec 3000) and when a culture density of 0.6 
OD units was reached, the phage-lambda red proteins were induced by shifting the 
culture to 42°C in a water bath for 15 mins with frequent mixing. All further replication 
was then arrested by cooling to 0°C. Transformation competent cells were then washed 
three times by centrifuging for 5 mins at 3345 x g at 0°C and then washing with ddH2O 
0°C. After the final wash, cells were re-suspended in ~400 µL ddH2O 0°C and distributed 
as 25 µL aliquots to pre-cooled 1.5 mL Eppendorfs ready for the addition of 4 µL of 
purified PCR product. In the first round the Rpsl cassette was inserted, in the second 
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round it was replaced to leave the resulting desired sequence (amplified desired DNA 
sequences from section 2.3.8.2). Once thoroughly mixed the aliquot is transferred to a 
Geneflow 2mm electroporation cuvette (Cell Projects) and chilled on ice for 5 mins. The 
samples are then electroporated in a Micropulser electroporation unit (BioRad) using 
program EC3 delivering a voltage of 2.5 KV. The cells are then allowed to recover in 5 mL 
LB broth in a shaking incubator for 1 hr (200 RPM at 32°C) in which time homologous 
recombination of the DNA segment and the BAC occur. Recovered cultures are then 
plated out onto either positive or negative selection LB agar plates for first or second 
round transformations respectively. The plates are incubated for 48 hr at 32°C.  
Positive and Negative Selection of Transformants 
After recovery of the first round transformation, cultures were plated onto LB agar 
plates supplemented with 12.5 µg/mL Chloramphenicol, 200 μM IPTG, 80 μg/ml X-gal 
and 25 μg/ml kanamycin for positive selection of E.coli containing BACs which have 
successfully inserted the Rpsl cassette. E.coli containing BACs with inserted Rpsl cassette 
will also contain the LacZ gene which when plated on ITPG and X-gal allows for an 
additional check in the form of blue-white screening. Blue colonies that grow on positive 
plates are selected and overnight cultures grown for small scale DNA purification (see 
section 2.4.7.5) and genome analysis in the form of a restriction digest.  
Second round transformants are plated onto LB agar plates supplemented with 12.5 
µg/mL Chloramphenicol, 200 μM IPTG, 80 μg/ml X-gal and 200 μg/ml streptomycin for 
negative selection of E.coli containing BACs which have successfully replaced the Rpsl 
cassette with the desired sequence and are therefore now streptomycin resistant and 
kanamycin sensitive. White colonies are selected from negative selection plates as the 
LacZ gene from the Rpsl cassette is now missing and the X-gal will remain colourless. 
Similarly, to the first round, overnight cultures of the selected white colonies are set up 
for small scale DNA purification and restriction digest.  
Small Scale BAC DNA Extraction and Purification 
BAC DNA isolation was performed using buffers from the QIAGEN Spin Miniprep Kit 
(27016) from a 5 mL overnight culture (200 RPM at 32°C) of the SW102 E. coli colony 
containing the desired BAC supplemented with 12.5 μg/ml chloramphenicol. Cells were 
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pelleted by centrifugation at 4,000 rpm for 5 min at 4˚C and the supernatant discarded. 
250 μL of P1 buffer with RNase A was used to resuspend cells before incubating with 250 
μL P2 buffer for 5 min at RT to lyse cells. The cell lysis solution is then neutralised with 
the addition of 250 μL N3 buffer before the resulting flocculate is separated by 
centrifugation at 13,000 rpm for 10 min. The supernatant containing BAC DNA is then 
transferred into new 1.5ml Eppendorf tubes (Fisher Scientific) and precipitated by the 
addition of 750 μL of isopropanol (Fisher) and centrifuged for 10 min at 4˚C. The DNA 
pellet was then washed by addition of 500 μL of 70% ethanol and centrifuged at 13,000 
rpm for 10 min at RT, before being left to dry at 37˚C to remove any residual ethanol. 
The DNA pellet was then re-suspended in 30 μL of ddH2O and the DNA stored at -20 °C. 
Restriction Digest 
Restriction digests were performed with the enzyme HindIII to analyse digestion 
patterns of the BAC genomes from selected transformant colonies from positive and 
negative selection plates to ensure that no gross rearrangements of the BAC had 
occurred. Reactions were set up with 8 µL of sample DNA (generated from section 
2.4.6.5), 1 µL HindIII enzyme and 1 µL NE 2.1 buffer (New England Biolabs) and 
incubated at 37˚C for 1 hour. The resulting DNA fragments were visualised by DNA gel 
electrophoresis (see section 2.4.4) and compared with a predicted pattern generated on 
CLC Main of the HCMV BAC genome to serve as a positive control of HCMV genome 
integrity. 
Sequencing BACs 
Once a successful BAC was generated sequencing was used to check the region that was 
modified for any errors. The manipulated region of the BAC was first PCR amplified and 
gel purified. A Mix2Seq kit (Eurofins Genomics) was used to set up sequencing reactions 
as per manufacturers protocol. Two μL of either forward or reverse 10 μM sequencing 
primers were mixed with 15 μL gel purified BAC DNA and sent away to be sequenced in 
Mix2Seq tubes supplied. Once the sequence of the BAC was confirmed to be correct a 
15% glycerol (v/v) stock was made of the SW102 culture containing the BAC, aliquoted 
and stored at -80 °C.   
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Large Scale BAC DNA Extraction and Purification of DNA 
Isolation of tissue culture transfection grade BAC DNA was performed by large scale 
overnight culture of the desired SW102 E. coli BAC and plasmid DNA purification using a 
NucleoBond BAC100 kit (Macherey-Nagel) to manufacturers protocol for low-copy 
number plasmid purification. In brief, 500ml overnight cultures were subjected to 
alkaline lysis resulting in the precipitation of cellular debris in a flocculate. The flocculate 
was separated out by pouring the lysate over fine filter paper supplied in the kit. The 
DNA is isolated by passing the flow-through through a BAC 100 column. The captured 
DNA in the column is then washed with supplied buffers repeatedly until finally the DNA 
was recovered with prewarmed elution buffer (supplied with kit). Isopropanol is added 
to precipitate the eluted DNA before centrifugation at 15000 x g for 30 mins at 4°C. The 
precipitated DNA is then washed with RT 70% (v/v) ethanol and a further centrifugation 
at 15000 x g for 10mins RT. The resulting DNA pellet is then air-dried and resuspended in 
TAE buffer. All purified BAC DNA is stored at 4°C for several months and used for 
transfection into HFFF Tet cells to generate viral stocks (see section 2.3.1).  
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2.5 Functional Assays 
2.5.1 Co-Cultures 
Separate co-cultures were performed with both adherent (HF-tert and Arpe19) and non-
adherent (DCs and LCs) target cells. 
Fibroblast -Fibroblast Co-Cultures 
For adherent co-cultures, HF-terts were infected with virus at a MOI of 8 and incubated 
until co-culture at around 7 days post infection. Infected HF tert cells were trypsinised, 
counted and approximately 60 infected cells were co-cultured with uninfected target 
cells (either HF-terts or ARPE19s plated out the day before), in the presence of a range 
of concentrations of Cytotect, a purified human anti-CMV IgG (Biotest (0mg/ml, 
0.5mg/ml, 0.1mg/ml and 0.02mg/ml)), which was replaced every 2 days. At multiple 
time points images were taken of plaques formed in the target cells on a Leica DMIRBE 
Microscope. Plaque size was then measured using Fiji, as pixels2. 
Fibroblast -DC/LC Co-Cultures 
For non-adherent cells, DCs and LCs were incubated either with or without IFNα (6,000 
units/ml) overnight before co-culture. Cells were then washed and counted before being 
added directly to wells 1:1 with infected HF-terts (4 days post infection, MOI of 8). If 
cells had been cultured in IFNα it was maintained throughout the co-culture. The DCs 
and LCs were pipetted off the co-culture at 48hr and incubated in fresh wells. At 72hrs 
post co-culture, cells were stained with BD Horizon Fixable viability stain 570 according 
to manufacturer’s instructions and fixed in 2% paraformaldehyde (PFA) before analysis 
on a BD Accuri C6 cytometer. 
Cell Free DC/LC Infections 
DCs and LCs were incubated with TB40/E at a MOI of 50 for 2hrs on a rocker at 37˚C and 
5% CO2. Supernatant was removed and washed from the cells by centrifugation at 1500 
rpm for 3 min. 10% FBS media was added to cells which were left 72hrs before plating 
onto a 96-well flat bottom plate coated with poly-d-lysine. Cells were fixed with acetone 
methanol and stained with a primary anti-IE1 antibody, washed with PBS and then 
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secondary Anti-Mouse IgG added (see table 6). Cells were washed and imaged on a Leica 
DMIRBE Microscope. Images were analysed with Fiji software. 
2.5.2 Flowcytometry 
Accuri C6 Flow Cytometer 
Fluorescence was measured by running samples in 4% PFA through an Accuri C6 flow 
cytometer. Gating strategies practiced were performed by differentiating different 
cellular populations based on forward scatter (FSC) relative to the cell size and side 
scatter (SSC) which is proportional to the cell’s granularity. When cells were stained, an 
unstained sample was used as a negative control to help define the gating strategy. All 
analyses were performed using Flowjo software (TreeStar Inc., USA). 
Table 10 - Stains and antibodies used for flow cytometry and surface staining 
Immunogen Company 
Catalogue 
number 
Species 
Dilution Conjugate 
IE1 Merck Millipore MAB810R Mouse 1:500  
Mouse IgG 
(H+L) 
Life 
Technologies 
A11020 
Goat 
1:500 AlexaFluor594 
Mouse IgG 
(H+L) 
Life 
Technologies 
A-21235 
Goat 
1:500 AlexaFluor647 
Human IgG 
(H+L) 
Life 
Technologies 
A-21445 Goat 1:500 Alexafluor647 
gB Virusys CA005 Mouse 1:200  
MHC I (W632) Biolegend 311414 Mouse 1:200  
CD107 Biolegend 328606 Mouse 1:333 FITC 
CD3 Biolegend 317334 Mouse 1:250 Pe/Cy7 
CD56 Beckman 
Coulter 
A07788 Mouse 1:250 PE 
 
RL13-Fc Binding Analysis 
HF CARs were seeded in T25s in DMEM10%. The following day, cells were infected at a 
MOI of 10 under conditions previously described (see section 2.3.3) except in 
DMEM10%. At 72 hr PI, cells were trypsinised and aliquoted into a 96-well V-bottomed 
plate (ThermoFisher) in duplicate between the different conditions; no stain, secondary 
only stain, 100 µL/mL, 10 µL/mL and 1 µL/mL. Cells were pelleted and washed twice by 
centrifugation at 1500 rpm for 3 min and resuspension in excess PBS. Seronegative 
Human IgG was added to the appropriate conditions at a concentration of 1-100 µL/mL 
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and incubated for 30 mins. Seronegative IgG was removed and cells washed twice as 
before. Cells were resuspended in secondary (Anti-human Alexafluor647) (see table 9) in 
PBS and incubated for a further 30 mins before pelleting and removing. Cells were 
washed a further two times as described previously and fixed in 4% PFA for 15 mins. 
Samples were run and fluorescence quantified as previously described (see section 
2.5.2.1). 
Cell Surface Glycoprotein Expression Analysis 
72hr post infection (PI) HFFF Tert cells were trypsinised and pelleted. Cells were 
resuspended in DMEM 10% and 50 µl put into a 96 well plate in triplicate. On ice, cells 
were washed twice with PBS. Human serum was then added 1/50 to block Fc-receptor 
interactions, followed by primary antibodies (in individual wells) and then secondary 
antibody all for 30 min at 4˚C with a PBS wash and resuspension in-between each step 
(for antibodies see table 9). After fixing with 4% PFA, samples were analysed on a BD 
Accuri C6. 
2.5.3 Antibody-Dependent Cellular Cytotoxicity (ADCC) Assay 
  HFFF Terts were infected as previously described at a MOI of 5. The following day 
infections were monitored and if satisfactory, PBMCs were isolated as described in 
section 2.2.3.1 and cultured with 1:6000 IFNα for 24 hrs. The next day, HFFF Terts (48 hr 
post infection) were exposed in duplicate to the prepared PBMCs, with either CMV 
positive or negative serum (1/10), and CD107 antibody for 1hr (37˚C, 5% CO2) before a 
5hr incubation with (1/1000) Golgi stop (Biolegend, 317334) at 37˚C, 5% CO2. Cells were 
then harvested and washed with PBS twice at 4˚C. On ice, cells were stained with anti-
CD3 and anti-CD56 (each 1/250 in PBS) before another PBS wash. Cells were then fixed 
in 4% PFA and run and analysed as previously described (see section 2.5.2.1) (see table 9 
for antibodies). 
2.5.4 SiRNA Knockdown of Cellular Proteins 
siRNA to cellular proteins was used for short term knockdown during viral infection. 
siRNAs came as 4 sequences per target. The siRNA sequence with the most efficient 
knockdown was chosen during optimisation. HFFF terts were seeded in 12-well plates in 
DMEM10% without any antibiotics. The following day, culture medium was replaced 
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with 1 mL Optimem (ThermoFisher) ready for siRNA transfection. Transfection of siRNA 
was performed using lipofectamine (ThermoFisher) as per manufacturers instruction for 
either a forward or reverse transfection in a 12 well plate. Lipofectamine and siRNA 
diluted in 200 µL Optimem were incubated for 20 min to allow for complexation.  The 
lipofectamine and siRNA solution was then added to the cells and left for 48 hrs. siRNA 
controls were included in every assay, a positive control siRNA to ensure the 
transfection had been successful and a negative control siRNA as well as an 
untransfected well, both to ensure no non-specific changes in protein expression had 
occurred.  
Table 11 - siRNAs used in this study 
Target Other names Qiagen Flexitube GeneSolution Catalogue 
number 
TMEM16C ANO3 GS63982 
SERCA ATP2A1 and ATP2A2 GS487 and GS488 respectively 
GRP78 HSPA5 GS3309 
DNAJB11 ERdj3 GS51726 
Calnexin CANX GS821 
ERp57 PDIA3, GRP58 GS2923 
ABI1 Positive control 55338 
AllStars Negative 
control 
Negative Control 1027281 
 
Optimisation 
Three different conditions were tested for optimisation in a forward transfection; 1 µL 
lipofectamine with 12 pmol siRNA, 2 µL lipofectamine with 24 pmol siRNA and 3 µL 
lipofectamine with 48 pmol siRNA. 48 hr post transfection with siRNA, cell lysates were 
taken as previously described 2.3.5.3 and siRNA efficiency analysed by expression of 
protein found by western blot (see section 2.5.5). The siRNA sequence with the most 
efficient knockdown per target was carried through to the knockdown assays.  
Knockdown Co-Culture Assay  
HFFF terts were seeded in 12-well plates in DMEM0% without any antibiotics the day 
before and then infected with GFP expressing virus at a MOI of 8. The following day a 
reverse transfection was performed as per ThermoFisher protocol in a 48-well plate. 6 
pmol of siRNA was diluted in 40 µL Optimem in the wells to which 0.5 µL lipofectamine 
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was added and incubated for 20 mins at RT. The infected HFFF terts were trypsinised, 
resuspended in Optimem and counted. Infected cells were seeded as 200 µL aliquots in 
the 48-well plate containing siRNA so that they would reach 50-70% confluency. The 
plate is gently rocked to ensure thorough mixing and then incubated for 48 hr. In the 
meantime, the following day, HFFF terts were seeded in 48-well plates in DMEM0% 
which will serve as the recipient cells in the co-culture. The following day the co-culture 
is performed, the recipient cells were washed with PBS and stained by addition of 100 µL 
of DDAO (7-hydroxy-9H(I,3-dichloro-9,9-dimethylacridin-2-one)) diluted in PBS 1:2500 
for 15 mins before a further wash in PBS to remove residual stain. The transfected 
infected cells, which will serve as the donor cells in the co-culture, are trypsinised and 
counted. The donor cells are added to the stained recipient cells in a series of dilutions; 
1:3, 1:5, 1:15. 72 hr post co-culture cells are trypsinised and fixed in 4% PFA and run as 
previously described (see section 2.5.2.1) on the Accuri C6 Flowcytometer analysing 
efficiency of viral transfer during knockdown. The fluorescence of recipient infected cells 
was analysed by gating for DDAO+ (FL4 channel) GFP+ cells. 
2.5.5 Western Blotting 
 Samples were prepared as described in section 2.3.5.3. Samples were loaded as 10 µl 
aliquots to a 10% pre-cast Bis-Tris SDS-Page gel with 10 µl Novex Sharp Pre-Stained 
protein standard (Invitrogen) as a reference ladder. The gel was run in 1x MOPS buffer 
for 45min at 200 V. During this time the PVDF membrane could be prepared by soaking 
in Methanol for 10 mins before soaking in transfer buffer with thick blotting paper. 
Proteins were transferred to PVDF membrane by semi-dry transfer for 2 hr at 10 V in 
transfer buffer. The membrane was then washed with ddH2O and left to air dry to allow 
for all methanol to evaporate and prevent any further binding of proteins. The PVDF 
membrane was then rewetted in PBST for 2-4 hr until sufficiently saturated. Primary 
antibody was added in immunoblotting block buffer and left overnight at 4˚C on a 
rocker. The following morning the primary antibody was removed and washed 3 times 
with PBST for 5 min. Secondary antibody could then be added in immunoblotting block 
buffer and left for 1 hr on a rocker before 3x5 min washes in PBST. If high background 
was an issue, the membrane would be left in an extended wash in PBST for 1 hr on a 
68 
 
rocker. Supersignal West Pico (Thermo Fisher scientific, 10481755) was added as per 
manufacturer’s instructions before imaging using a GeneSys GelDoc (Syngene).  
Table 12 - Antibodies used in Western Blotting 
Immunogen Company/ 
Catalogue # 
Dilution Secondar
y 
Company Dilution 
IE1 Millipore 
MAB810R 
1:2000 HRP anti-
Mouse 
 
Bio-Rad 170-
6516 
1:2000 
 
gB Abcam 
ab6499 
1:2000 
pp28 Abcam 
ab6502 
1:2000 
pp65 Virusys 
CA003-100 
1:2000 
pp44 Virusys 
P1202-2 
1:2000 
SERCA (ATP2A1, ATP2A2) Santa Cruz sc-
271669 
1:2000 
CNX (Calnexin) Millipore 1:1000 
ABI 1 (positive control) gifted 1:200 
Human beta actin Sigma A-
2066 
1:2000 HRP anti-
Rabbit 
Bio-Rad 170-
6515 
1:2000 
 
DNAJB11 (ERdj3) Santa Cruz sc-
99208 
1:2000 
ERp57 (PDIA3/GRP58) Santa Cruz sc-
28823 
1:2000 
TMEM16C (ANO3) Abcam 
ab82781 
1:2000 
HSPA5 (GRP78)  Santa Cruz sc-
1050 
1:2000 HRP anti-
Goat 
Santa Cruz 
Biotechnology 
Sc-2056 
1:2000 
 
2.5.6 Quantitative PCR (qPCR) 
Viral DNA and primers to HCMV gB were used to set up qPCR reactions against serial 10-
fold dilutions of BAC DNA (see section 2.4.6.5) and DNA extracted from HFFF Tet cells 
(see section 2.3.5.1) were used to generate standard curves. Triplicate samples were set 
up consisting of 200 nM primers, sample diluted to be within the standards range and 1× 
iQ™ SYBR® Green Supermix (BioRad). Virus genomes were quantified using primers gB F 
and gB R, while an endogenous control was generated using primers GAPDH F and 
GAPDH R (for primer sequences see Appendix 1) Reactions were run under the 
thermocycling conditions described in section 2.5.5.2 on a QuantStudio 12K Flex Real-
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Time PCR system. To ensure only the desired sequence was bound by SYBR green, the 
melt curve of each reaction was carefully analysed. 
Table 13 - qPCR Thermocycling program 
 Hold stage PCR stage (x40 cycles) Melt curve stage 
Temperature 95 ˚C 95 ˚C 60 ˚C 95 ˚C 60 ˚C 95 ˚C 
Time (min) 03:00 00:15 01:00 00:15 01:00 00:15 
Step 1 1 2 1 2 3 
Data collection   X   X 
 
2.5.7 Infectivity vs Particle Numbers 
To compare the particle numbers and infectivity between samples, supernatant 
timecourses in 12-well plates were set up as previously described (see section 2.3.4.2). 
HFFF Terts were infected at a MOI of 8. Every day, the supernatant was taken 
centrifuged at 1500 rpm for 3 min to remove any cellular contamination, and divided 
between the infectivity analysis and the particle number analysis. Samples were either 
progressed with fresh or frozen until needed. 
Infectivity Analysis 
To measure Infectivity, the half aliquot of supernatant sample was subjected to a plaque 
assay as previously described in section 2.3.2.2. 
Particle Number Analysis by qPCR 
To quantify particle numbers, the half aliquot of supernatant sample was subjected to 
DNA extraction with DNAse treatment (see section 2.3.5.1) and then qPCR (see section 
2.5.6) to quantify viral genomes. As samples were from supernatants, no cellular 
endogenous control could be used.  
Particle Number Analysis by NanoSight 
Another method to quantify viral particle numbers was using a NanoSight (NanoSight 
NS300). Samples prepared as described in section 2.3.6. and diluted to give a 
concentration of 108 particles when running. The standard measurements used were 5 x 
60 second captures under a flowrate of 50. Analysis of particles was performed on the 
NanoSight NTA 3.2 software (NanoSight). A detection threshold of 5 was used and a 
camera level of 13. Particles within the range of 100nm-350nm were considered virions. 
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2.6 Microscopy 
2.6.1 Zeiss Microscope for Immunofluorescence 
The Zeiss microscope (Axio Observer Z1) was used for immunofluorescent imaging. 
Using the Zen2 Pro (Zeiss) software, entire wells could be imaged and the images 
stitched together to make plaque size measurements and counting more reliable. 
Exposure time for fluorescent samples was determined by using the auto-exposure 
function and then ensuring that there was no risk of photobleaching of the samples.  
2.6.2 Transmission Electron Microscopy (TEM) 
HFFF Terts were plated in DMEM0% in T25s. The following day, cells were infected at a 
MOI of 5. The cells were fixed, processed and imaged 96hr PI by Dr Hobot as previously 
described (222). 
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2.7 Statistical Analysis 
GraphPad Prism 6 software (GraphPad Software, Inc., CA, USA) was used for all 
statistical analyses. Data sets with multiple samples were analysed by either one-way 
ANOVA or two-way ANOVA tests with Tukey’s post-hoc analysis. All data was plotted as 
mean ± standard error mean (SEM) unless otherwise stated. Differences were 
considered and displayed as significant in figures and tables as follows; *p < 0.05; **p < 
0.01; ***p< 0.001 and ****p<0.0001.
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CHAPTER 3. GENETIC 
MANIPULATION AND 
ANAYLSIS OF RL13 
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The RL13 ORF is dispensable for viral growth in vitro and has been shown to actively 
impede viral propagation. This unusual effect is not unique to RL13 as the UL128L is also 
detrimental for growth in fibroblasts. However, a great deal is known about the role of 
the UL128L in production of the pentameric complex and providing an expanded HCMV 
tropism (see Intro Section 1.3.1.3). Not much in known about RL13 and in order to 
investigate the function of RL13, several new viruses were constructed. New reporter 
viruses, HCMV RL13 genotypes and non-human CMV RL13 variants were created by 
recombineering (see Table 14). As the presence of an intact UL128L also restricted viral 
growth, it was important to distinguish any effects of RL13 expression from UL128 
expression. Therefore, where possible, experiments were performed with viruses lacking 
the expression of the functional proteins (ΔRL13 and/or ΔUL128) as well as viruses with 
the expression of both functional RL13 and UL128 (WT) (see table 14).  
All viruses containing wildtype sequences of RL13 and/or UL128 carried the risk that 
mutations would be selected. Therefore, a repression system was used when 
propagating these viruses. Transcription of the two genes, RL13 and UL128, is repressed 
by inserting a Tet-operator (TetO) upstream of the TATA box. The virus is then grown up 
in HFFF Tet cells which express the Tet-repressor (TetR). TetR binds to Tet, repressing 
gene expression, and therefore removing the selective advantage of genomes carrying 
mutations in either gene. This therefore allowed for the growth of viruses containing 
wildtype sequence without risk of mutants being selected for (203).  
Using the Tet-repression system as well as being vigilant in checking experiments for 
signs of RL13 mutations (such as dramatically increased plaque size or efficient viral 
growth) is vital to ensure reliable research is performed. Stocks thought to be WT in 
sequence have previously been reported to contain 50/50 mixes of WT and ΔRL13 
virions. This was not seen for other ORFs showing that strong active selection that 
favours RL13 mutants is a real concern during prolonged research and replication in 
fibroblasts (3). 
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Table 14 – Viruses used and created for this study. 
 
 
Name 1 pAL number CMV Backbone strain RL13 UL128 GFP 
ΔRL13/ΔUL128 
1111 Merlin Mutated Mutated None 
2079 Merlin Mutated Mutated Fused to IE2 
2159 Merlin Mutated Mutated IE2-P2A-GFP 
Wildtype (WT) 
1502 Merlin Tet repressed Tet repressed None 
1511 Merlin Tet repressed +V5 tag Tet repressed None 
2081 Merlin Tet repressed Tet repressed Fused to IE2 
2157 Merlin Tet repressed Tet repressed IE2-P2A-GFP 
2176 Merlin Tet repressed Tet repressed IE1-P2A-GFP 
ΔUL128 
1516 Merlin Tet repressed Mutated None 
2082 Merlin Tet repressed Mutated Fused to IE2 
2160 Merlin Tet repressed Mutated IE2-P2A-GFP 
ΔRL13 
1778 Merlin Mutated Tet repressed None 
1938 Merlin Mutated Tet repressed Fused to IE2 
2167 Merlin Mutated Tet repressed IE2-P2A-GFP 
TR RL13 
2524 Merlin From HCMV strain TR Tet repressed None 
2526 Merlin From HCMV strain TR Tet repressed IE2-P2A-GFP 
TR RL13/ΔUL128 
2525 Merlin From HCMV strain TR Mutated None 
2527 Merlin From HCMV strain TR Mutated IE2-P2A-GFP 
Rh13.1/ΔUL128 2574 Merlin Rh13.1 from RhCMV Mutated IE2-P2A-GFP 
TB40E  TB40E TB40E TB40E  
1 Often referred to as the genetic background of the virus/group of viruses. 
pAL numbers in Bold were created by recombineering for this project, others were created previously by Dr Stanton. 
Viruses highlighted in any shade of green express GFP. 
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3.1 Generation of HCMV Reporter Viruses to Aid 
Investigation into RL13 Function 
A series of HCMV reporter viruses had previously been constructed in the laboratory 
that encoded GFP fused to the IE2 ORF by a flexible linker sequence (Table 14). While 
such constructs were useful, they were not ideal. GFP was detectable in cells infected 
with these strains by 48h p.i. (data not shown) whereas ppIE1 can be detected as early 
2-6h by immunohistochemistry. Moreover, the IE2-GFP fusion virus displayed prolonged 
growth and slightly higher titres when compared to its non-GFP counterpart (Fig. 8), a 
result that implies that direct C-terminal tagging of ppIE2 impacted on its function and 
expression. A new set of reporter viruses was needed that did not display any altered 
growth properties and that ideally expressed GFP at an earlier timepoint. 
3.1.1 Generation of Novel Reporter Viruses by Recombineering 
 In order to improve on the previous reporter system, GFP was inserted downstream of 
IE1 with a P2A peptide rather than a direct fusion between the ORFs, the strategy is 
outlined in Figure 9. The first aim was to exchange the existing linker for a self-cleaving 
P2A peptide. The second was to insert the P2A-GFP after IE1, rather than IE2. This 
required two distinct steps; one to insert the P2A sequence between IE2 and GFP in a 
previously created virus and the second to clone the new p2A-GFP sequence into the 
desired BAC after IE1. This process created novel IE2-P2A-GFP viruses as an intermediate 
from the first step as well as the planned IE1-P2A-GFP viruses. The P2A peptide should 
minimise any effect on expression of IE1/IE2 due to co-translational cleavage of the 
linked proteins. The P2A peptide was favoured over an internal ribosome entry site 
(IRES) as an IRES often results in reduced translational efficiency of the gene placed after 
the IRES site, and the sequence itself is fairly large at approximately 600bp which makes 
recombineering less efficient (223, 224). 
IE1-P2A-GFP viruses could only be successfully recombineered in the WT and ΔUL128 
backgrounds despite numerous attempts. After transfection of the BAC DNA, recovery of 
virus following transfection of the BAC DNA proved unusually problematic. Although the 
IE1-P2A-GFP sequence could be inserted into the ΔUL128 background by 
recombineering, viral stocks were never produced as recovery of virus after transfection 
76 
 
of the BAC DNA never proved successful. When growing up stocks of WT, the virus 
spread through the cell monolayer incredibly slowly taking nearly 4 weeks to completely 
infect a T150, compared to the usual 7-10 days for Merlin HCMV.  The highest titre of 
virus stocks (3x105 PFU/mL) achieved with this construct was not sufficient to allow for 
experimentation. From this we concluded that manipulating the HCMV genome at the C-
terminus of the IE1 ORF inhibited virus growth.
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Figure 8 - IE2-GFP fusion virus shows altered growth properties. Infections were set up 
in HFFF-primary cells (MOI 5) and the supernatant was titred in plaque assays every 2 
days to generate this growth curve of ΔRL13 viruses. The IE2-GFP fusion virus (red) 
shows slightly prolonged growth and higher titres compared to the Non-GFP 
counterpart (blue). Graph courtesy of Dr Stanton (unpublished data). 
Non-GFP 
IE2-GFP Fusion 
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Figure 9 - Recombineering of a Novel reporter virus.  Original plan to construct IE1-P2A-
GFP reporter viruses. (A) IE2-P2A-GFP construct plan to insert the Rpsl cassette between 
the IE2 and GFP ORFs during the first round. The Rpsl cassette is then replaced with the 
P2A sequence in the second round. (B) IE1-P2A-GFP construct plan. First round to insert the 
Rpsl cassette after the IE1 ORF which is replaced in the second round with the P2A-GFP 
sequence created in (A). 
A 
B 
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3.1.2 Growth characterisation of modified virus by Plaque Assay 
Plaque assays were used to determine if the modifications from recombineering altered 
any growth kinetics of the virus when compared with an unmodified (non-GFP) virus. 
Figure 10 shows the effect of inserting a P2A-GFP sequence after the IE1 or IE2 ORFs. As 
only the WT genetic background of the IE1-P2A-GFP viruses had been successfully made, 
this was the genetic background used for the comparison. The IE2-GFP fusion viruses, 
which has already been observed to exhibit impaired growth, were included in this 
analysis to determine whether the new constructs were an improvement. The IE2-GFP 
fusion virus showed slightly reduced plaque sizes, although this did not reach statistical 
significance (Fig. 10). Consistent with the problems experienced when attempting to 
propagate the virus, the IE1-P2A-GFP virus showed significantly smaller plaque sizes 
when compared to the non-GFP control. However, the IE2-P2A-GFP virus showed plaque 
sizes similar of those from the non-GFP viruses. Therefore, due to minimal or no effect 
on growth properties, only the IE2-GFP fusion and the IE2-P2A-GFP viruses were used 
for experimentation and the recombineering of the rest of the IE1-P2A-GFP viruses were 
not pursued. 
 
3.1.3 Brighter GFP Expression Observed from IE2-P2A-GFP Virus by 
Flow Cytometry Assessment 
To determine whether the translational efficiency of the P2A peptide provided an 
advantage to the brightness of the GFP compared to the directly-fused GFP. Flow 
cytometry assessment was performed on cells infected with the newly created IE2-P2A-
GFP reporter viruses to determine at what timepoint GFP was expressed. 
GFP expression of cells infected with two of the genetic backgrounds was assessed at 
two timepoints (Fig. 11). The IE2-P2A-GFP viruses exhibited a very slight trend of 
brighter GFP expression however significance could not be calculated due to lack of 
replicates. All viruses showed brighter GFP at 72 hrs compared with 48 hrs.  
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Figure 10 - Comparison of plaque sizes of current and novel reporter viruses. Plaque 
assays showed that IE1-P2A-GFP virus displays altered growth properties as reduced 
plaque size. HFFF Primary cells were infected with 40 pfu of each virus (in a WT 
genetic background), and covered with 2x DMEM and Avicel. 3 weeks PI overlay was 
removed, cells washed, plaques were IE1-stained and imaged on the Zeiss fluorescent 
microscope. Plaques were measured using Fiji ImageJ software. Results were subject 
to a one-way ANOVA with Tukey post-hoc analysis (**=P < 0.01) Error bars display 
SEM. 
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Figure 11 – Novel reporter viruses show brighter GFP expression than IE2-GFP fusion counter 
parts. HFFF terts were infected at an MOI of 5 with ΔRL13/ΔUL128 and ΔUL128. At the two 
timepoints shown (48 and 72 hr) cells were trypsinised, fixed with 4% PFA and run on a BD 
Accuri flow cytometer. (A) The gating strategy used discriminated against dead cells and 
multiple cells. (B) Comparison of GFP expression from IE2-P2A-GFP and IE2-GFP viruses with and 
without RL13 expression. Comparisons were made at two MOI (1 and 5) and at two timepoints 
(48 hr and 72 hr). GFP expression was brightest at 72hrs compared to 48hr from both reporter 
viruses. Statistical analysis could not be performed due to lack of replicates. 
  A 
  B 
82 
 
3.2 Genetic Analysis of RL13 
3.2.1 RL13 is a Hypervariable Gene 
Passaging of HCMV in cell culture allows for the emergence and selection of mutants 
adapted for growth in an environment distinctly different to the natural setting that 
HCMV would encounter (193). Because of this, many of the HCMV strains used in 
today’s research have multiple deletions, mutations and rearrangements within their 
genomes (225). Not only are the strains used genetically different to clinical virus but 
their biological properties have become distorted between stocks confirming the 
existence of strain genetic divergence and variance which has considerable impact on 
experimental studies (195). Although inhibitory in vitro, RL13 is conserved in-vivo 
suggesting that the gene is important for the survival of HCMV (37). RL13 is also known 
to be hypervariable (175). To investigate how variable the RL13 ORF is between clinical 
isolates, the sequences of 96 clinical strains with low in vitro passaging were obtained 
from NCBI (3) and CLC Main software used to align the RL13 ORFs of these sequences. 
Analysis of RL13 ORFs 
All 96 sequences were aligned as both the nucleotide and the protein sequences. Both 
the nucleotide sequences of the RL13 ORFs and the amino acid sequences amongst the 
96 isolates displayed variation with the 3’ and N terminus displaying the highest degree 
of conservation (Fig. 12A&B). Previously, the overall selective pressure on HCMV genes 
was investigated on these 96 sequences by calculating the dN/dS ratio (3). This 
compares the number of synonymous or silent (dS) and nonsynonymous or amino acid-
changing (dN) substitution rates within a gene alignment. A ratio of 1 suggests a neutral 
amino acid substitution, whereas a ratio lower than 1 indicates purifying or stabilising 
selection. If the substitution provides a selective advantage the ratio is greater than 1 
(226) . Of all HCMV genes, 96%, including RL13, had a ratio of <0.5 (3). RL13 appeared to 
be under relatively strong evolutionary constraint despite its diversity, with a ratio of 
0.321. For comparison, they calculated the ratio of gB (UL55), a glycoprotein found in 
abundance in the virus envelope and considered to be one of the most conserved 
human herpesvirus glycoproteins, to be 0.116 (3). 
 
 
83 
 
Considering RL13 seemed to be under stabilising selection we wanted to determine 
whether the RL13 ORFs could be grouped into distinct clades. Using the RL13 ORF 
sequences obtained, a Phylogram was created (Fig. 13). The Phylogram indeed exhibited 
distinct clades of RL13 ORFs variants. Some of these clades contain many of the RL13 
ORFs suggesting that this particular variant sequence is quite frequent among clinical 
isolates. Thus, RL13 was hypervariable, however out of 96 clinical isolates, the levels of 
variation of RL13 ORF DNA sequence are relatively low as only 9 rough clades were 
generated. This may indicate that the gene is not actively evolving in current 
populations. Instead, genotypes are relatively fixed, and thus may be advantageous in 
certain patients or situations in vivo. 
Consensus protein sequences were generated for each clade to understand the level of 
variation between clades (Fig. 14). Overall the transmembrane region and YxxL motif 
showed the highest conservation between clades, whereas the cytoplasmic region 
proved to be moderately conserved between clades. The signal peptide and Ig-like 
domain, which is the domain responsible for RL13’s Fc binding capabilities, showed the 
greatest variation of the domains identified between clades.
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Figure 12 – Conservation of RL13 Nucleotide and Protein sequences with a schematic representation. Conservation of RL13 sequences 
between HCMV clinical strains with minimal passaging. Sequences obtained from (3) were aligned and processed using CLC Main software. 
(A) Conservation of nucleotide sequence. (B) Conservation of amino acid sequence. Schematic representation based on the Merlin sequence 
showing the signal peptide, Ig-like domain, transmembrane region, Cytoplasmic region and YxxL motif. 
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Figure 13 – RL13 ORFs cluster into distinct clades. Radial neighbour-joining tree 
illustrating the clustering of RL13 ORFs into 9 clades based on similarity of DNA 
sequence from clinical HCMV with minimal passaging. Sequences were obtained from 
(3) with the exception of Merlin (GenBank: GU179001.1) and TR (GenBank: 
AC146906.1) and the phylogram was created using CLC Main software. Scale bar 
shows divergence as substitutions per amino acid site. Clades are numbered 1-9 
clockwise. 
Merlin RL13 
TR RL13 
9 
8 
2 
1 
3 
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Figure 14 – Consensus sequences between clades display variation. Consensus protein sequences from each clade from figure 12 were generated using CLC 
Main software and aligned to determine whether any hotspots of variation could be determined between clades. The transmembrane region and YxxL 
motif showed the high conservation between clades, the cytoplasmic region showed moderate conservation whereas the signal peptide and Ig-like domain 
showed greatest variation. Schematic representation based on the Merlin sequence. 
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3.2.2 Insertion of TR RL13 into the Merlin BAC 
Generation of TR RL13 Merlin BAC Viruses by Recombineering 
As RL13 is a hypervariable gene, the question arises as to whether all RL13 genotypes 
exhibit the same ability to repress virus growth. A construct was therefore designed in 
which the sequence of RL13 in Merlin was replaced with RL13 from another strain. The 
strain TR was chosen as the genome is readily available and TR RL13 is interesting in that 
it does not mutate during in vitro passage of the TR virus (208). Figure 15 shows the plan 
that was followed to insert TR RL13 into the Merlin genome in the place of Merlin RL13. 
The viruses created were TR RL13/ΔUL128 and TR RL13, in both IE2-P2A-GFP reporter 
and a conventional virus (non-GFP) backgrounds. The Tet operator inserted upstream of 
Merlin RL13 was not removed, nor was it assessed to see if it still conditionally repressed 
TR RL13. As the viruses were tested directly from transfection there was no need to 
optimise the Tet operators for use with TR RL13. 
The Effect of Inserting TR RL13 into the Merlin BAC on Plaque Size 
As RL13 significantly inhibits cell-free titres of virus and slows viral spread through the 
monolayer (203), by monitoring plaque size of the various viruses the effect of the 
specific RL13 genotype can be analysed. IE2-P2A-GFP viruses were used for ease of 
measuring plaques on the fluorescent microscope. Both TR RL13 and TR RL13/ΔUL128 
genetic backgrounds were compared to their Merlin RL13 counterparts. As TR RL13 
remains intact during in vitro propagation of the TR virus, it is possible that the ORF does 
not inhibit virus growth, or is not well expressed (208). If this were the case +TR RL13 
virus should produce plaques considerably larger than +RL13 Merlin virus.  
All viruses expressing either Merlin RL13 and/or UL128 displayed smaller plaques than 
those of the ΔRL13/ΔUL128 virus (Fig. 16). The presence of TR RL13 in the virus 
produced plaques that were comparable to the size of those of the Merlin RL13 
counterparts. Viruses expressing both UL128 and either TR RL13 or Merlin RL13 
displayed the smallest plaques.  
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Figure 15 - Recombineering plan to create TR RL13 Merlin BAC.  Plan to construct TR 
RL13 in Merlin. 1st round to insert the Rpsl cassette in the place of Merlin RL13. During 
the 2nd round the Rpsl cassette is then replaced with the TR RL13 sequence. 
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Figure 16 – TR RL13 displays the same phenotype as Merlin RL13 as similar sized 
plaques. Plaque assay to analyse the effect of TR RL13 on the growth properties of 
Merlin HCMV. HFFF Primary cells were transfected with 2µg IE2-P2A-GFP BAC DNA, 
seeded and left in DMEM 10% for 24 hr to recover. The next day cells were overlaid with 
2x DMEM and Avicel. 2-3 weeks PI overlay was removed, cells washed and plaques 
imaged on the Zeiss fluorescent microscope. Plaques were measured using Fiji ImageJ 
software. Results were subjected to one-way ANOVA with Tukey post-hoc analysis 
(****= P < 0.0001.). Error bars display SEM. 
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TR RL13 Sequence Variation 
To determine whether the TR RL13 sequence, which is different to Merlin RL13, had 
mutated during in vitro passaging of the TR virus, a BLAST nucleotide search was 
performed. The search revealed 10 hits with 100% identity to TR RL13 (shown in table 
15). The 10th hit (shown in table 15 in bold italics) is the TR BAC itself (Fig. 15). The 
remaining 9 sequences are all clinical HCMV isolates and passaged minimally or not at 
all. This includes the clinical TR isolate sequenced after several passages in fibroblasts. 
Since the HCMV strain TR RL13 ORF has an identical amino sequence to that in multiple 
circulating HCMV clinical strains, it is likely that the gene has not been modified during 
cell culture passaging. 
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Table 15 – TR RL13 sequence similarity search.
Name Identity 
to TR 
RL13 
NCBI 
Accession 
number 
Origin 
Human betaherpesvirus 5 
strain PAV31, complete 
genome 
100% KY490061.1 Plasma from transplant 
patient. Sequenced directly 
from clinical material. 
Human herpesvirus 5 strain 
JER5550, complete genome 
100% KR534212.1 Amniotic fluid. Sequenced 
directly from clinical material. 
Human herpesvirus 5 strain 
NANU, complete genome 
100% KU550090.1 Neonatal urine. Sequenced 
directly from clinical material. 
Human herpesvirus 5 strain 
HAN40, complete genome 
100% KJ361958.1 Bronchoalveolar lavage. 
Passaged twice before 
sequencing. 
Human herpesvirus 5 strain 
2CEN15, complete genome 
100% KJ361948.1 Bronchoalveolar lavage. 
Passaged once on human 
fibroblasts prior to 
sequencing. 
Human herpesvirus 5 strain 
BE/22/2011, complete 
genome 
100% KP745653.1 Urine.  Passaged twice on 
human fibroblasts prior to 
sequencing. 
Human herpesvirus 5 strain 
BE/5/2012, complete 
genome 
100% KP745635.1 Urine.  Passaged twice on 
human fibroblasts prior to 
sequencing. 
Human herpesvirus 5 strain 
TR, complete genome 
100% KF021605.1 Isolated from a vitreous 
tumour from the eye of HIV-
positive male. Passaged 
several times before 
sequencing. 
Human herpesvirus 5 strain 
HAN13, complete genome 
100% GQ221973.1 Bronchoalveolar lavage. 
Passaged once on human 
fibroblasts prior to 
sequencing. 
Human Herpesvirus 5 TR-
BAC isolate, complete 
sequence 
100% AC146906.1 TR BAC derived from the TR 
clinical ocular isolate. 
Passaged in fibroblasts. 
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3.2.3 Insertion of Rhesus CMV RL13.1 into the Merlin BAC 
Recombineering 
Given that two divergent RL13 sequences had the same phenotype in the context of the 
Merlin genome, we wondered whether the ability to repress viral replication extended 
to RL13 sequences from CMV that infect different species. Therefore, the Rhesus 
Macaque CMV (RhCMV) RL13 homolog was used to replace Merlin RL13. RhCMV Rh13.1 
is the closest known homolog for HCMV RL13 within the RhCMV genome (218). Rh13.1 
exhibits significant homology in both sequence and length to HCMV RL13 (218), and 
displays a similar phenotype of inhibited viral growth when the ORF is expressed in 
RhCMV (Früh, personal communication). Figure 17 shows the plan to insert Rh13.1 in 
the place of Merlin RL13. This time, the first round BAC created in figure 15 (Rpsl in the 
place of Merlin RL13) could be used and the recombineering process was now to simply 
swap the Rpsl cassette with Rh13.1. Initially, the genetic backgrounds Rh13.1/ΔUL128 
and Rh13.1 were to be created as IE2-P2A-GFP and non-GFP viruses. However only the 
Rh13.1/ΔUL128 IE2-P2A-GFP virus was successfully created in time. Like previously with 
the TR RL13 viruses, the Merlin RL13 Tet operator inserted upstream of the newly 
inserted Rh13.1 was not removed, checked or optimised for Rh13.1 expression as the 
viruses were simply intended for plaque assays following transfection. 
Plaque Assay 
A plaque assay was set up with the Rh13.1/ΔUL128 virus created alongside the Merlin 
ΔUL128 counterpart and a ΔRL13/ΔUL128 control (both IE2-P2A-GFP viruses). Plaques 
were measured on the fluorescent microscope, and relative sizes measured using Fiji 
Software. Unfortunately, the ΔRL13/ΔUL128 control transfection failed and therefore no 
plaques were present for measurements. The mean ΔRL13/ΔUL128 plaque size, 
generated from a previous experiment (Fig. 15) is included in figure 18 for reference 
only. Plaque sizes of the ΔUL128 virus were small, as expected. The presence of Rh13.1 
in the genome showed a slight increase in plaque size however this was not statistically 
significant, suggesting that Rh13.1 is also able to inhibit spread when expressed from the 
HCMV genome. However, this must be interpreted with caution as Rh13.1/ΔUL128 
plaques also show a fairly large range of sizes and the ΔRL13/ΔUL128 transfection used 
as a positive control for large plaques was absent. 
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Figure 17 - Recombineering plan to create Rh13.1 in Merlin. Construct plan to insert 
Rh13.1 into Merlin. Only the 2nd round step was necessary as the Rpsl cassette had 
previously been inserted into the Merlin BAC genome in place of RL13. The cassette was 
replaced with the Rh13.1 sequence. 
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Figure 18 – The effect of Rh13.1 in the Merlin BAC on plaque size. Plaque assay to analyse 
the effect of Rh13.1 on the growth properties of Merlin HCMV. Although not significant, a 
trend of slightly larger plaque sizes is seen in the Rh13.1/ΔUL128 virus compared to 
ΔUL128. The expected average plaque size of the ΔRL13/ΔUL128 control is seen displayed 
as a grey line. 2µg IE2-P2A-GFP BAC DNA was transfected into HFFF Primary cells, seeded 
and left in DMEM 10% for 24 hr to recover. The following day cells were overlaid with 2x 
DMEM and Avicel. Overlay was removed 2 weeks PI, cells washed and plaques imaged on 
the Zeiss fluorescent microscope. Plaques were measured using Fiji ImageJ software. 
Results were subjected to one-way ANOVA with Tukey post-hoc analysis but no 
significance found. Error bars display SEM. 
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3.3 Chapter Summary 
Multiple viruses were generated in this project, some as novel reporter viruses and 
others to look at different variants of HCMV RL13 and their effect on the growth 
phenotype observed for Merlin RL13. The generation of reporter viruses expressing GFP 
downstream of IE1 resulting in an earlier reporter virus was not achieved in this project 
due to problems during recombineering, transfection and growth of the viruses. 
Recombineering in the four genetic backgrounds resulted in only the WT and ΔUL128 
backgrounds successfully accepting the construct despite numerous attempts. However, 
when attempting to propagate the virus in fibroblasts only the WT, albeit relatively 
poorly, produced infectious viral progeny. Although likely due to chance, this seemed 
counterintuitive as this background should be the worst to propagate virus from. 
However, improved novel reporter viruses (IE2-P2A-GFP backgrounds) that did not show 
altered growth properties were successfully created. The sequences of these new HCMV 
reporter viruses were confirmed by sequencing, and will aid future experimentation. The 
IE2-P2A-GFP viruses displayed GFP expression at 48 hr at a slight increased trend in 
intensity (although not significant) compared to the previous GFP-fusion viruses. These 
reporter viruses will be useful for investigating the function of RL13. It would be 
informative to repeat the analysis of GFP expression from the new IE2-P2A-GFP 
constructs at earlier timepoints to see whether GFP expression could be achieved at 
24hrs.  
The transfer of TR RL13 was successfully inserted into the Merlin BAC and the resulting 
viruses (TR RL13, TR RL13/ΔUL128) produced. Plaque assays with these viruses 
demonstrated that TR RL13 inhibits virus growth in the same way as Merlin RL13, when 
encoded in the Merlin genome. This transfer of phenotype occurred despite the 
considerable sequence differences between TR and Merlin and the fact TR RL13 is 
shown to remain genetically intact in vitro (208).  Therefore, it is possible that factors 
elsewhere in the TR genome are responsible for maintaining intact TR RL13. It could be 
valuable to assess whether Merlin RL13 would be tolerated in the TR BAC. Although I did 
not explicitly check that the TR RL13 ORF is expressed in the context of the Merlin 
genomes, the fact that its presence repressed plaque size indicates that it was 
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expressed. The TR RL13 ORF sequence had 100% identity in many other clinical isolates, 
indicating that the TR RL13 sequence is not a product of in vitro passage.   
An IE2-P2A-GFP virus containing Rh13.1 in the place of RL13 was also successfully 
created and used in a plaque assay to determine the phenotype of Rh13.1 in Merlin. The 
presence of Rh13.1 in the Merlin genome resulted in slightly larger plaques than those 
of the Merlin RL13 counterpart, although not statistically significant or to the extent as is 
usually observed for a virus lacking RL13. Thus, Rh13.1 may have a partial ability to 
inhibit virus spread in HCMV, although the experiment will need repeating with 
appropriate controls. 
 In this project only the RL13 ORFs from TR and RhCMV were analysed in the context of 
the Merlin genome. It would be interesting to analyse the growth phenotype of more 
RL13 HCMV variants that come from differing clades in the context of the Merlin 
genome in future experiments. 
RL13 has been designated a hypervariable gene. Genetic analysis of multiple clinical 
HCMV RL13 ORFs in this project suggests that It may be more appropriate to describe 
RL13 as having multiple conserved genotypes. When sorted into a Phylogram the RL13 
ORFs exhibited distinct clades that could represent multiple conserved genotypes. This 
could suggest an evolutionary purpose for each clade, such as immune evasion function. 
The consensus protein sequences of these 9 genotypes were aligned to assess whether 
each clade varied considerably from one another in specific regions of the protein 
sequence. Considerable variation was identified in the Ig-like domain and the signal 
peptide which could suggest that some clades don’t share the Fc binding properties of 
clades 8 and 9 that TR and Merlin are found in, or that the difference in signal peptide 
could affect the efficiency of protein trafficking or even affect the protein translocation. 
More conservation was found between clades in the transmembrane domain, YxxL motif 
and to some extent the cytoplasmic region. 
Overall the genetic analysis of RL13 improved our understanding of the variability of the 
gene and the generation of novel reporter viruses greatly helped the next steps 
investigating at which point RL13 acted upon the viral lifecycle (see Chapter 4) and 
analysing the functional effects of RL13 (see Chapter 5). 
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CHAPTER 4. THE EFFECTS OF 
RL13 ON THE VIRAL 
LIFECYCLE
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RL13 expression during in vitro Merlin infection dramatically reduces cell-free titres of 
virus and slows viral spread through the monolayer (203). To gain insights into how RL13 
expression causes this remarkable phenotype, it was important to determine whether 
RL13 acted at a particular stage of the viral life cycle.
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4.1 Replication 
4.1.1 RL13 Expression has no Effect on Viral Genome Replication 
qPCR of Viral Genomes 
It was hypothesised that RL13 may affect the growth properties of Merlin in vitro by 
inhibiting replication of the virus genome. During this study it was also reported that 
RL13 interacted with host cell nucleoside diphosphate linked moiety X (nudix)-type motif 
14 (NUDT14), a UDP-glucose pyrophosphatase, to affect viral DNA replication (227). 
Therefore, infections were set up with the four genetic backgrounds of viruses and DNA 
extracted from cells daily. qPCR was performed to measure the copy number of virus 
genomes in infected cells, and thus determine whether the expression of RL13 inhibited 
viral DNA replication over a 6-day timecourse. Amplification of UL55 (encodes gB) was 
measured relative to genomic control (GAPDH) for each sample. Over 6 days, there was 
no significant difference between any samples found (Fig. 19).  
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Figure 19 – RL13 expression does not affect viral genome replication. A qPCR was 
performed using primers to UL55 (gB gene) and endogenous control GAPDH on DNA 
produced from infected HFFF tert cells over a 6-day viral timecourse using the non-GFP 
viruses (MOI of 2). No statistically significant difference was found between samples at 
any timepoint. Data were subject to two-way ANOVA with Tukey post-hoc analysis. 
Error bars represent SEM. 
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4.1.2 RL13 Expression has no Effect on Viral Protein Expression 
Western Blot Analysis of the Temporal Protein Expression Cascade 
Since RL13 expression did not affect the efficiency of viral DNA replication, it was 
hypothesised that RL13 could be impairing the efficiency of virus-encoded protein 
expression. Infections were therefore performed with all four genetic backgrounds of 
virus at an MOI of 1 and analysed by western blotting. Immediate-early (IE1), early 
(pp44) and late (pp65 and gB) protein expression was analysed at 8, 24, 48, 72, and 96 
hours. As expected, the levels of Actin in the uninfected control increased overtime. The 
expression of functional RL13 did not result in major or consistent differences in the 
temporal cascade of viral protein expression (Fig. 20).  
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Figure 20 - Western blots showing temporal viral protein expression. Lanes: 1. Mock, 2. ΔRL13/ΔUL128, 3. WT, 4. ΔUL128, 5. ΔRL13. 
Fibroblasts were infected at an MOI of 1 with the non-GFP viruses and cell samples were taken at each timepoint in reducing buffer and 
subjected to western blotting. No obvious difference was found in the expression of immediate-early (IE1), early (pp44) or late (pp65 and gB) 
time points with regards to RL13 expression.  
pp44 
72 kDa 
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Analysis of Early Viral Protein Expression 
The expression of some viral proteins did not follow the anticipated kinetics (210). The 
expression of gB, a late protein, was unusual in that faint expression was present at 
8hrs, and not again until stronger expression present at 72 and 96 hr. pp44 is not 
expressed until 48 hrs, however there was faint expression present at 8 and 24hr. The 
late protein pp65 was expected from 72hrs onwards, yet it is seen throughout the 
timecourse.  It seemed likely that protein present at earlier times represents protein 
from the initial input virus. 
To investigate this, infections were repeated with the ΔRL13/ΔUL128 virus at an MOI of 
1 and cell extracts prepared at 8 and 24 hr (Fig. 21). Cells were incubated with the 
protein synthesis inhibitor Cycloheximide before, during and post infection to determine 
whether proteins seen at the early timepoints were de novo expressed or not. The 
major IE protein (IE1) was detectable at 8hr and 24hrs post infection only when 
cycloheximide was absent. Therefore, the IE1 protein seen is synthesised at 8hrs and 
24hrs and not due to input virus. The pp44 blot detected the protein in the 8hr samples 
with and without cycloheximide and again faintly with and without cycloheximide at 
24hrs.  pp44 expression was reduced by the presence of cycloheximide, which suggests 
that some of the protein seen at 8 and 24 is due to input virus. gB and pp65 were 
present with and without cycloheximide treatment, implying that the early bands seen 
were indeed delivered by the input virions. Infections were performed with (10%) and 
without (0%) FBS to determine whether this effected cycloheximide treatment results. 
Expression of all proteins, but especially gB, was stronger in the absence of FBS. This 
suggests that infection efficiency is increased in the absence of FBS which has been 
noticed before (Stanton, personal communication).
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Figure 21 –Early detection of viral proteins attributable to input virions. Infections were set up with ΔRL13/ΔUL128 non-GFP virus (MOI 1) and 
Mock with/without cycloheximide. Infections were performed in both DMEM 0% and DMEM 10%. Blots confirmed that IE1 expression seen 
was de novo expressed, unanticipated pp44 expression was due to input virus. gB and pp65 unexpected expression is solely due to input virus. 
pp44 
ΔRL13/ΔUL128 ΔRL13/ΔUL128 
ΔRL13/ΔUL128 ΔRL13/ΔUL128 
72 kDa 
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4.2 Maturation 
4.2.1 Particle Formation Analysis 
Transmission Electron Microscopy analysis of HCMV infected cells. 
As RL13 expression reduced cell free titres (203), we next proposed that this could be 
due to a reduction in the number of infectious viral particles generated during infection. 
We wanted to look at the various particles that are assembled and matured in the 
infected cell before viral release. Transmission electron microscopy (TEM) was 
performed to determine the relative numbers of different particle types present during 
virion formation and maturation as detailed in the Introduction (Section 1.3) and Table 
16. Infections with the four genetic backgrounds of virus were set up and 3 days post 
infection, samples were processed and multiple images taken of the nucleus (where 
capsids form), and the assembly compartment (AC) within the cytoplasm, where viral 
particles mature (7). An example of the structure of each type of virus particle quantified 
is illustrated in Figure 22 and described in Table 16. 
RL13 Expression had Minimal Effect on the Number of Viral Particles Formed 
Particles were identified and counted from 20 images from each compartment in each 
sample. The average particle ratios were calculated from the total particle counts for 
each compartment in each sample (Fig. 23). When RL13 is expressed there was an 
increase in the number of C-capsids produced, however this difference was not seen in 
the numbers of virions produced (Fig. 24), nor would the magnitude of this difference 
account for the >10-fold reduction in cell-free titres when RL13 is expressed. There was 
also no difference in average particle ratios in either compartment between the four 
viruses that reached statistical significance.  
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Table 16 - Viral Particles to analyse within the Nucleus and Assembly compartment. Adapted from (7). 
LOCATION NUCLEUS ASSEMBLY COMPARTMENT 
PARTICLE A-capsids B-capsids C-capsids Dense bodies NIEPs Virions 
DESCRIPTION Thought to be 
the result of 
failed viral DNA 
encapsidation 
and lacking both 
viral DNA and a 
scaffold. 
Likely to have 
resulted from 
failed capsid 
formation as 
they contain a 
scaffold but lack 
viral DNA. 
Likely nucleo-
capsids during 
maturation, 
containing viral 
DNA and lacking 
scaffold. 
Non-infectious 
enveloped 
particles lacking 
capsids and 
composed 
mainly of pp65. 
Non-infectious 
enveloped 
particles (NIEPs) 
resulting from 
envelopment of 
B-capsids. 
The only 
infectious 
particle 
containing viral 
DNA resulting 
from 
envelopment of 
C-capsids. 
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B 
Figure 22 - TEM images of the nucleus and the AC of cells infected with ΔRL13/ΔUL128. 
Cells were processed 96 hr post infection and sections cut and viewed by TEM by Dr 
Hobot. Both images show a scale bar of 1 µm. (A) Nucleus with A- capsid (blue), B-
capsid (yellow) and C-capsid (red) highlighted. (B) AC with Virion, NIEP and dense body 
highlighted. 
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Figure 23 – Expression of RL13 shows no significant difference in the proportions of 
developing viral particles within either the nucleus or AC. 96 hr post infection cells were 
processed by Dr Hobot and sections cut and viewed by TEM. Particles were counted and 
average particle ratios calculated. No significant difference was found when comparing 
each particle ratio between viruses in either compartment when analysed by two-way 
ANOVA with Tukey post-hoc analysis. Error bars display SEM. 
Nucleus                                                      Assembly compartment 
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Figure 24 – ΔUL128 infection produced the greatest total number of C-capsids in the 
nucleus, however this did not affect the number of virions that mature. 96 hr post 
infection cells were processed by Dr Hobot and sections cut and viewed by TEM. 
Particles were counted and total particle numbers calculated. Total C-capsid numbers 
increased when only RL13 and not UL128 is expressed. No other great difference in total 
particle numbers was found between each virus. As data is total particle numbers 
counted, statistical analysis could not be performed due to lack of replicates. 
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4.3 Virion Release 
4.3.1 Supernatant Virion Particle Numbers VS Infectivity 
The difference found between the viruses in the types or numbers of virion particles 
present in the infected cell was not great enough to explain the >10-fold reduction seen 
in infectious titres of virus expressing RL13 and/or UL128. It was therefore hypothesised 
that either the infectivity of viral particles or the number of viral particles successfully 
released from a productive infection could be altered following RL13 expression.  
Analysis by qPCR and Titration Assay 
Cells were infected with the four genetic backgrounds of viruses. Supernatants were 
collected daily for 10 days and split between a titration assay to determine the 
infectious titre of the sample, and qPCR to determine the viral genomes (and therefore 
the viral particle numbers) present. This experiment was repeated numerous times as 
results varied between repeats. Results that are in line with the majority of findings are 
represented in figure 25. 
The HCMV genome copy numbers detected in infected cell supernatants followed the 
same trend over time for all of viruses tested (Fig. 25A). The high viral genome copy 
numbers detected initially that were markedly reduced by day 3 must be due to residual 
input virus, even though the initial inoculum was washed off. Genome copy numbers 
then proceeded to increase steadily to their highest numbers at days 5-6. The increase in 
genomes then reduced gradually until the end of the timecourse. Although there was 
variation between the viruses at certain timepoints, these differences were neither large 
nor consistent, nor did they correlate with expression of RL13. 
The viral timecourse generated numerous samples needing to be titred. To reduce the 
number of HF Primary cells used, small scale IE1 immuno-fluorescence titration assays 
were set up. Biological titres were calculated as fluorescent focus units (FFU) per mL of 
each virus at each time point. Similarly, to the particle numbers, the four viral titres also 
followed a very similar trend (Fig. 25B). Again, input virus was seen initially for most 
viruses which dropped at day 2. Titres began to rise at around days 3-5 and peaked 
around day 7 before tapering off. ΔRL13/ΔUL128 had the highest titre throughout the 
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timecourse as expected. Both UL128 and RL13 independently reduced biological titres, 
although expression of UL128 led to a greater reduction than RL13. Expression of both 
led to even lower titres. 
Genome/FFU ratios were calculated for each sample at each timepoint (Fig. 25C). A low 
genome/FFU ratio would mean a virus is efficient at infecting cells. Expression of both 
intact UL128 or intact RL13 caused higher genome/FFU ratios, however the effect was 
more pronounced with UL128.  
Analysis by NanoSight and Titration Assay 
The results from the qPCR assays varied slightly between experiments. Unfortunately, 
there was no reasonable cellular DNA control to quantify genomes against for the 
supernatant samples, especially as samples were DNAse treated to remove free DNA 
prior to extracting encapsidated DNA. Therefore, the experiment was repeated using a 
NanoSight to quantify particles directly. The NanoSight uses light and Brownian motion 
to detect, measure and quantify particles on a nanoscale (228), allowing for the 
quantification of HCMV virions. Samples were collected every other day during a 10-day 
infectious timecourse, then pooled and concentrated before titration, then further 
purified on glycerol-tartrate gradients before particle quantification on the NanoSight. 
As the viral timecourse sample numbers were reduced due to pooling of samples, 
titration by plaque assay was possible. 
Mature HCMV virions range from 150-200nm (45, 74) to 200-300 nm (1) in diameter.  
Therefore, we focused on particles within a diameter range of 100-350 nm to ensure 
that all possible virions were recorded (Fig. 26). All viruses showed a similar pattern of 
particle size distribution between the sizes of 100-350 nm. The double mutant 
(ΔRL13/ΔUL128) displayed the greatest total particle numbers over 10 days (Fig. 27A). 
Viruses expressing UL128 showed only a very slight reduction in particle numbers, 
whereas viruses expressing RL13 showed approximately 10-fold lower total particle 
numbers, similar to the levels of the WT virus. This suggests that the expression of intact 
RL13 inhibits virion particle release. The total virion infectious titres over the 10-day 
infection displayed a similar pattern to the previous timecourse in that the expression of 
either RL13 or UL128 reduced total titres from the level of the double mutant (Fig. 27B), 
with an additive effect when both are expressed together. Genome/PFU ratios over the 
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10-days (Fig. 27C) were similar to those seen in the previous experiment (Fig. 24C). The 
double mutant (ΔRL13/ΔUL128) proved again to be the most efficient virus with the 
lowest genome/PFU ratio. Expression of UL128 gave a clear increase in genome/PFU 
ratio. Expression of RL13 also led to an increase in genome/PFU ratio, although this was 
not as dramatic as UL128 (Fig. 27C).  
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Figure 25 - RL13 expression does not affect genome copy numbers but does affect titre 
over a timecourse of 10 days. Cells were infected at an MOI of 8 with non-GFP viruses of 
all four genetic backgrounds. Supernatant was collected every day and split between a 
plaque assay and DNase treatment before qPCR. (A) Genome copy number quantified 
by qPCR showed no consistent significant differences between viral samples. (B) Titre of 
supernatant was measured by IE1-stained titration assay and calculated as FFU. A 
drastic reduction in titre was seen when RL13 is expressed. (C) Genome/FFU ratio of 
each virus. Data were analysed by Two-way ANOVA and all samples found to be 
significantly different to each other (p < 0.0001) at each timepoint for both genome 
copy/µL (A) and titre (B). Genome/FFU ratios (C) between viruses were analysed by 
Two-way ANOVA and found to be statistically significant (p < 0.01) from one another. 
Error bars display SEM. 
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Figure 26 – Particle size distribution of viruses between 100-350 nm. Cells were infected 
at an MOI of 8 with non-GFP viruses of all four genetic backgrounds. Supernatant was 
collected, pooled and concentrated from a 10-day timecourse and split between a 
titration assay (Figure 23B) and NanoSight analysis of particle numbers. Particles were 
quantified within a 100-350 nm range and although particle numbers differed between 
viruses the size distribution of particles between 100-350 nm displayed a similar pattern. 
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Figure 27 – RL13 expression results in a relatively low genome/PFU ratio despite 
reducing particle numbers and viral titre. Cells were infected at an MOI of 8 with non-
GFP viruses of all four genetic backgrounds. Supernatant was collected, pooled and 
concentrated from a 10-day timecourse and split between NanoSight analysis of 
particle numbers (A) and a titration assay (B). Particles were quantified within a 100-
350 nm range and results showed that expression of either RL13 and/or UL128 reduced 
particle numbers and viral titre. Genome/PFU ratios (C) were calculated and results 
showed that expression of UL128 causes a higher genome/PFU ratio. One-way ANOVAs 
were performed with Tukey post-hoc analysis (**= P < 0.01, ****= P < 0.0001.) Error 
bars display SEM. 
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4.4 Chapter Summary 
RL13 expression has been shown to dramatically reduce cell-free titres of virus and slow 
viral spread through the monolayer during in vitro Merlin infection (203). It was 
important to investigate each step of the viral lifecycle to gain more of an understanding 
of how RL13 expression could promote this phenotype. 
When assessing the first few stages of viral progeny production no significant difference 
was found in viral genome quantification and so it was concluded that RL13 expression 
did not cause reduced cell-free titres and inhibited growth in vitro by inhibiting viral 
genome replication. The expression of RL13 also had little effect on the temporal protein 
expression cascade when looking at selected viral proteins from different kinetic classes, 
over a timecourse of 96 hrs. The expression of some of these proteins however was 
unusual and further steps were taken that showed the presence of early and late phase 
viral protein at the earliest timepoints could be attributed to input virions. For example, 
pp65 was found to appear much earlier than predicted but when infections were 
performed in the presence of cycloheximide conclusions could be made that this 
unusually early expression was due to input virions. Previous work has reported pp65 
remaining in cells for hours which supports this conclusion. Pp65 has been found 
intracellularly 16hrs after infection (229) and has be found to remain on the cell surface 
up to 24hrs after infection (210). For greater insight this could be repeated with a 
greater selection of viral proteins from the kinetic classes.  
When looking at the effect of RL13 expression on particle formation and maturation the 
expression of RL13 showed to minimally effect the proportions of developing viral 
particles within infected cells. However no significant differences were found between 
the average particle ratios of the viral samples within either compartment. 
Finally, the effect of RL13 expression on viral particle release and infectivity of those 
particles was assessed. Analysis of particle numbers using the qPCR approach produced 
somewhat variable results. Despite this, there was no experiment in which expression of 
RL13 resulted in a difference in genome copy number that would account for the >10-
fold reduction seen in infectious titres. Particle infectivity was reduced by expression of 
RL13. 
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Due to variability in the qPCR assays, the experiment was repeated, but the qPCR assay 
was replaced with a NanoSight assay to determine particle numbers directly. The results 
showed that the expression of intact RL13 reduced both the infectivity of particles and 
the quantity of particles released. Interestingly it was expression of intact UL128 had a 
greater effect on genome/PFU ratios than RL13. RL13 expressing virus had the 
genome/PFU ratio most similar to that of the double mutant. However, it should be 
noted that the NanoSight experiment was only performed once and required pooling of 
timepoints as well as more significant levels of processing than the QPCR experiment, 
potentially accounting for the slightly different results. As the Genome/FFU and 
Genome/PFU ratios relied on the particle number analysis of both experiments the 
limitations of each assay extended to this data too. 
Taken together, RL13 clearly acts to reduce particle infectivity, however more work is 
needed to determine whether there is a significant and consistent effect on particles 
released. This finding led the investigation to analyse gpRL13, as it is present in the 
virion envelope and comes into contact with cells during entry. Next I investigated 
whether the gpRL13 present on the virions had any functional consequences leading to 
this reduced infectivity, or whether it provided an immunological advantage for WT 
HCMV during in vivo infection. 
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CHAPTER 5. THE FUNCTIONAL 
EFFECTS OF RL13
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 GpRL13 is not just a non-essential protein, its presence markedly inhibits virus 
replication in vitro. The incorporation of gpRL13 in to virions is a feature its shares with 
members of the UL128L. In the case of the three proteins encoded by UL128L, there is 
experimental evidence they impair virus infection of fibroblast by their effect on virion 
receptor recognition, through displacing the interaction between gO and gH/gL (Intro 
section 1.3.1.3). It is therefore important to consider the functional consequences of 
gpRL13 in the virions themselves. Values for HCMV titres could be reduced if gpRL13 
were to affect how the virions are released, transmitted between cells or interact with 
cell-surface receptors during entry. In addition, previous work has shown involvement of 
RL13 with aspects of the immune system (173). 
Therefore, the effects of RL13 on the virion, host cell and immune system were explored 
to determine whether any effects seen could be responsible for the loss in viral titre 
seen when RL13 is expressed. The published work stating RL13s role in immune evasion 
was also replicated with Merlin.  
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5.1 Effects of RL13 on the Virus 
5.1.1 Analysis of Viral Infection Spread by Co-Culture 
A consequence of RL13 and UL128L expression by clinical HCMV strains is that the virus 
is extremely cell-associated and must be transmitted primarily by direct cell-to-cell 
spread (103, 104). Interestingly, direct cell-cell infections in retroviruses has been shown 
to more readily overcome immune restriction factors as compared to cell-free infections 
(230). As RL13 forces HCMV to be transmitted directly from cell-to-cell rather than cell-
free spread (203), Co-culture experiments were used to investigate whether RL13 
enabled the virus to better overcome innate and intrinsic anti-viral host immunity. This 
was performed in multiple cell types that the virus would encounter during infection and 
also in the presence of IFN or neutralising antibodies. Understanding how HCMV spreads 
through tissues and immune cells such as fibroblasts, epithelials, DCs and LCs could 
greatly aid the design of vaccines and therapeutics to protect these cells during 
infection. 
 DC/LC Co-Culture 
DCs are antigen-presenting cells and are thought to be some of the first immune cells to 
come into contact with HCMV during infection and aid viral dissemination and even 
reactivation from latency (231).  As messengers between the innate and the adaptive 
immune systems, DCs establish themselves deep within mucosae and skin (231) whilst 
LCs are a tissue-resident DC uniquely found in the epithelium (232). In cell culture, 
immature LCs are resistant to cell-free infection with HCMV (233, 234), whilst monocyte-
derived DCs are fully permissive to HCMV infection (231). Infection of LCs with Merlin 
lacking RL13 was likewise heavily restricted by the cell-free route, however infection by 
the cell-cell route was more efficient, indicating that cell-cell spread could more readily 
overcome innate immune responses (235).  
Interferons (IFN) are a group of cytokine mediators that are released in response to a 
pathogenic threat and are a part of the innate immune response. Once bound to an IFN 
receptor an excess of Interferon stimulated genes are expressed in attempt to restrict 
and control the infection. IFN alpha (IFNα) is a type I IFN also known as viral IFNs that are 
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induced by viral infections. IFNα is synthesized by most cell types when infected with 
virus (236). 
Co-cultures between infected HF Terts and DCs/LCs were set up to investigate whether 
RL13 expression provided an advantage to the virus during infection in DCs and LCs 
enabling the virus to overcome IFN-induced antiviral factors. Experiments were 
conducted using all four genetic backgrounds of the IE2-GFP fusion viruses enabling the 
transmission of virus to be tracked by flow cytometry. HF-terts were infected and co-
cultured 1:1 with either uninfected DCs or LCs, with or without IFNα. DC/LC were 
removed from the co-culture at 48hrs and percentage infection determined at 72hrs by 
the presence of GFP using Flow cytometry. Direct cell-cell spread of HCMV to monocyte-
derived DCs and LCs was dependent on UL128 expression (Fig. 28A). The assay was 
repeated with viruses expressing functional UL128 and with or without IFNα (Fig. 28B). 
There was efficient cell-cell spread in all samples compared to ΔUL128, although the 
addition of IFNα slightly reduced infection efficiency in both LCs and DCs. The effect of 
RL13 expression on cell-cell infection efficiency was comparatively small, but a 
significant reduction in infection efficiency could be attributed to RL13 (Fig. 28A and 
28B). A cell-free control was set up with the HCMV virus TB40-BAC4, to test whether 
cell-free entry was restricted as previously reported (Fig. 28C). Both LC and DC cell-free 
infections were less efficient compared to cell-cell spread, and the addition of IFNα 
restricted infection further, as was seen previously with a virus lacking RL13 (Stanton, 
unpublished). Therefore cell-cell spread of virus in DCs and LCs proved to be more 
efficient than cell-free spread in the presence of IFNα, however this was independent of 
RL13 expression.
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Figure 28 - Cell-cell spread is dependent on UL128 expression, however RL13 
expression provides no advantage to cell-cell spread. DCs and LCs were co-cultured 
with HF terts infected with GFP expressing viruses. Non-adherent cells were removed 
and at 72hr post co-culture, percentage infection was determined by flow cytometry. 
(A) All four genetic backgrounds of virus were used with and without the treatment 
with IFNα. (B) Only viruses expressing UL128 were used for a repeat experiment. (C) 
Cell-free infections were set up as a control to ensure that restriction of cell-free 
infection occurred as previously reported. DCs and LCs with or without IFNα were 
infected with cell-free virus TB40 (ΔRL13 reduced expression) for 72hrs after which 
cells were washed, fixed and stained for IE1 and DAPI. Fluorescent microscopy was 
used to take images and % infected DCs/LCs per field of view was calculated using Fiji. 
Data were analysed by two-way ANOVA with Tukey post-hoc analysis. Error bars 
display SEM. 
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HFFF Tert Co-Culture 
Retrovirus spreading via the cell-cell route is able to avoid the humoral immune 
response, unlike cell-free infections (237).  As RL13 causes HCMV to remain highly cell-
associated (203), it was important to determine whether RL13 affected sensitivity to 
neutralising antibodies. The effect of RL13 on cell-cell spread was investigated by 
performing co-cultures in the presence of Cytotect, a purified human IgG containing high 
titre HCMV-neutralising antibody. Approximately 60 infected HF terts were plated onto 
uninfected HFFF terts (Fig. 29), plaques were then allowed to form and sizes measured 
at various timepoints.  
In HFFF tert–HFFF tert co-cultures (Fig. 29), plaque sizes of virus lacking both UL128 and 
RL13 were significantly larger compared to all other viruses. Virus expressing both RL13 
and UL128 had even smaller plaque sizes than that of the single mutant viruses, showing 
that these genes have an additive effect on plaque size. Plaque sizes of virus lacking both 
Ul128 and RL13 were inhibited by Cytotect in a dose-dependent manner. However, 
when either RL13 or UL128 were expressed, plaque sizes were unaffected by Cytotect. 
Thus, expression of either RL13 or the UL128L provided resistance to neutralising 
antibodies in HFFF. 
ARPE19 Co-Culture  
 The same co-cultures were set up with infected HFFF terts plated on ARPE19s (adult 
retinal pigmented epithelials) (Fig. 30) with a wider range of cytotect concentrations to 
determine if the same effect of RL13 expression was seen in another adherent cell type. 
Infections were set up only with virus expressing UL128, as viral entry and spread in 
epithelial cells is dependent on the pentameric complex. Plaque sizes from the virus 
containing RL13 were comparable across the different Cytotect concentrations. Virus 
expressing RL13 proved to be affected by neutralising antibody. Low levels of Cytotect 
resulted in enhanced infection as a slight increase in plaque size was observed. 
Although, these differences were only seen at the low cytotect concentrations, and were 
relatively small in magnitude. Overall, neither virus was inhibited by neutralising 
antibodies in ARPE19 cells regardless of the expression of RL13. 
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Figure 29 - Cell-cell spread of virus expressing RL13 and/or UL128 shows resistance to 
neutralising antibodies in HFFF Terts.  HFFF terts were infected with GFP expressing viruses 
of all four genetic backgrounds with a varying concentration range of Cytotect and plated 
onto HFFF terts. Fluorescent images of viral plaques were captured and then measured. 
Plaques sizes displayed were measured at 10 days post infection. One-way ANOVAs were 
performed with Tukey post-hoc analysis (*= P < 0.05, **= P < 0.01, ***= P < 0.001, ****= P 
< 0.0001.) Error bars display SEM. 
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Figure 30 - Cell-cell spread of virus expressing UL128 shows resistance to neutralising antibodies in ARPE19s.  HFFF terts were infected with 
ΔRL13 or ΔRL13 GFP expressing viruses with a varying concentration range of Cytotect and plated onto ARPE19s. As UL128 is needed for 
infection of epithelial cells its presence may mask any effect that RL13 expression has on cell-cell spread. Fluorescent images of viral 
plaques were captured and then measured. Plaques displayed were at 10 days post infection. One-way ANOVAs were performed (*= P < 
0.05, **= P < 0.01, ****= P < 0.0001. Error bars display SEM. 
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5.1.2 Analysis of RL13 Expression Effect on Virion Composition 
As RL13 affects virion infectivity (Chapter 4), it was important to determine whether 
these effects were due to its expression altering the virion proteome, and thus 
influencing virion binding and/or entry. Previously produced mass spectrometry (MS) 
data comparing WT and ΔRL13 virions and WT and ΔRL13/ΔUL128 virions were analysed 
(Data produced by Isa Murrell). The viruses were cultured in HFFF tert cells grown in 
SILAC media before concentrating the viral preparations by centrifugation as previously 
described for growing up viral stocks (see section 2.3.1). Virions were purified by 
layering the concentrated virus preparations on glycerol tartrate gradients to separate 
virions from cellular debris and other virus particles as they migrate through the 
gradient at different rates. Further steps were taken to remove salts derived from the 
gradient and the virions were pelleted and resuspended ready for quantitative SILAC-MS 
(Isa Murrell, personal communication). In this manner, the relative amounts of each 
protein could be compared between viruses. 
Analysis of Virion Composition 
For this project the MS data was used to identify statistically significant enrichment or 
loss of protein in the virions lacking or containing RL13. The relative abundance of each 
protein between the samples was normalised to the capsid protein UL86, then analysed 
by significance B, using Perseus software. First, the WT and ΔRL13 virion comparison was 
analysed. Both Human and HCMV proteins were identified in the virions (Fig. 31). 
Generally, most proteins identified were shifted towards enrichment in the WT virions, 
however this enrichment was not significant. In the WT virions, 6 proteins were 
significantly reduced (p<0.00000000001) and 9 proteins were significantly reduced but 
to a lower degree of significance (p<0.00001) (Displayed in table 17). A further 83 
proteins were reduced, and 7 proteins enriched, to an even lower degree of significance 
(p<0.05) but were too numerous to include in table 17. No viral proteins (other than 
RL13) were reduced or enriched in this comparison. The majority of the proteins that 
were identified with highly significant reduction in WT virions, were human proteins 
involved in the immune response. Many were components of Igs or potential Ig Fc 
receptors, involved in Ig internalisation or binding. This could suggest manipulation of 
the immune response and a strategy to avoid Ig detection.  
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To validate the identification of these proteins another comparison was analysed (WT 
compared to ΔRL13/ΔUL128 virions) to ensure that these hits could be identified again 
(Fig. 32). All proteins identified in the first comparison in table 17 were also found to be 
reduced in the WT virions in the second comparison and so are more likely to be true 
differences. A viral protein, UL48 the large tegument protein, was found to be 
significantly enriched (p<0.00001) in the ΔRL13/ΔUL128 virions. This was not found in 
the first comparison and so this difference is assumed to be due to UL128 and not RL13. 
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Figure 31 – RL13 expression results in significant loss of proteins within the virion. SILAC-MS comparison of WT and ΔRL13 virions, which 
identified both Human and HCMV proteins present in the virion. Data were analysed using Perseus software. 13 proteins were found to be 
highly significantly (p<0. 00000000001 or p<0.00001) reduced significantly in the virion when RL13 was expressed. 
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Figure 32 – Second virion composition comparison to verify first analysis. SILAC-MS comparison of WT and ΔRL13/ ΔUL128 virions, which 
identified both Human and HCMV proteins present in the virion. Data were analysed using Perseus software. 1 protein was found to be 
highly significantly (p<0.00001) reduced in the virion when RL13 and UL128 is expressed. 
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Table 17 – Proteins identified that were highly significantly reduced in the virion when 
RL13 was expressed. 
Protein 
Identified 
Full Protein name Protein description 
p<0.00000000001 
RRAS2 
Ras-related protein 
R-Ras2 
A GTP-binding protein with GTPase activity found in the 
plasma membrane (238). Has displayed transforming 
properties similar to those of the Ras subfamily of 
proteins (239). 
KRT1 
Keratin 1, a type II 
keratin 
Structural protein expressed in Keratinocytes in the 
epidermis (240). (Likely contamination) 
IGHA1 
Ig alpha-1 chain C 
region 
Constant domain isotype of immunoglobulin A heavy 
chain. Constant domains specify effector function, for 
example binding Fc receptors (241). 
IGKC 
Ig kappa chain C 
region 
The constant domain of immunoglobulin light κ chain. 
Constant domains specify effector function, for example 
binding Fc receptors (241).  
IGLC3;IGLL5; 
IGLC1;IGLC2;
IGLC6 
Ig lambda constant 
3; Ig lambda like 
polypeptide 5; Ig 
lambda constant 1; 
Ig lambda constant 
2; Ig lambda 
constant 6 
Various constant domains of immunoglobulin light λ 
chain. Constant domains specify effector function, for 
example binding Fc receptors (241). 
IGHA2 
Ig alpha-2 chain C 
region 
Constant domain isotype of immunoglobulin A heavy 
chain. Constant domains specify effector function, for 
example binding Fc receptors (241).  
p<0.00001 
IGJ 
 
Immunoglobulin J 
chain 
 A small polypeptide that links two monomers of IgA or 
IgM and is important in secretory immunity (242). 
MAP2K1;MAP
2K2 
Dual specificity 
mitogen-activated 
protein kinase 1 
and 2 
an essential protein kinase and component of the MAP 
kinase pathway required for cell survival and 
proliferation (243). 
S100A8 Protein S100-A8 
A member of the Myeloid-related Proteins (MRP). A small 
zinc- and calcium-binding protein highly expressed in 
neutrophils, monocytes, activated macrophages and 
some epithelial and activated endothelial cells. It is 
mainly found as calprotectin (S100A8/A9) which can 
enhance the migration of monocytes across endothelial 
cells. S100A8 is important in the immune response, the 
regulation of inflammatory processes and can induce 
adhesion and chemotaxis of neutrophils (244). 
S100A9 Protein S100-A9 
A member of the Myeloid-related Proteins (MRP). A small 
zinc- and calcium-binding protein highly expressed in 
neutrophils, monocytes, activated macrophages and 
some epithelial and activated endothelial cells. It is 
mainly found as calprotectin (S100A8/A9) which can 
enhance the migration of monocytes across endothelial 
cells. S100A9 is important in the immune response, the 
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regulation of inflammatory processes and can induce 
adhesion and chemotaxis of neutrophils (244). 
NDUFS2 
NADH 
dehydrogenase 
[ubiquinone] iron-
sulfur protein 2 
A subunit of Complex I, also known as the mitochondrial 
membrane respiratory chain NADH dehydrogenase 
(245). 
LTF Lactotransferrin 
Also known as Lactoferrin, is a multifunctional protein 
with iron-binding, antibacterial and anti-viral properties. 
It is localised in neutrophil granules and found in various 
exocrine fluids such as tears, saliva and breast milk (246).  
PIGR 
Polymeric 
immunoglobulin 
receptor 
Binds polymeric IgM and IgA on the epithelial cell 
basolateral surface. The protein complex is then taken 
into the cell, transported and secreted at the epithelial 
apical surface (247).  
F10 
Coagulation factor 
X/Activated factor 
Xa 
An important enzyme of the coagulation cascade. This 
vitamin K-dependent glycoprotein acts by cleaving 
prothrombin to create thrombin during blood clotting 
(248). 
KRT2 
Keratin, type II 
cytoskeletal 2 
epidermal 
Protein expressed in the epidermis and is associated with 
the activation and proliferation of keratinocyte and 
keratinization (240, 249). (Likely contamination) 
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5.1.3 HCMV Virion Stability 
RL13 expression causes a reduction in cell-free titres and may also reduce virion particles 
released (Chapter 4). HCMV is an enveloped virus that is known to be sensitive to low 
pH, fat solvents and even extreme physical conditions such as temperature (250). As 
gpRL13 is expressed on the virion envelope it was hypothesised that RL13 could affect 
the stability of the virions after egress from infected cells relative to the RL13 mutant 
virions resulting in the reduction in cell-free titres.  
Titration of Virus Over Time 
To investigate whether RL13 had an effect on virion stability, cells were infected with all 
four genetic backgrounds (non-GFP), then supernatants removed at 3 days post-
infection. Supernatants were incubated at room temperature in a clean upright T25, 
then aliquots removed and used to infect fresh cells at certain timepoints. These fresh 
cell infections were then titrated by IE1 staining (Fig. 33). Consistent with previous 
findings, ΔRL13/ΔUL128 showed the highest titres, however after 72 hrs storage its titre 
had declined by nearly 100-fold and were within a much closer range to the titres of 
virus containing UL128 and/or RL13. While the WT virus had the lowest starting titre, it 
remained stable over the course of 72 hrs. The viruses lacking RL13 or UL128 alone 
exhibited approximately a 10-fold loss in titre over 72 hrs. These results imply that 
rather than destabilising HCMV virions, RL13 and an intact UL128L provided some 
resistance to virion degradation, and this effect was enhanced when both were 
expressed together.  
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Figure 33 – Virus expressing RL13 and UL128 display virion degradation resistance. Viral 
supernatant from all four genetic backgrounds was left for 0-72hr and titred. Results 
showed that the presence of both RL13 and UL128 provided resistance to viral 
degradation over time when compared to the ΔRL13/ΔUL128 virus. Titres are in 
duplicate and therefore statistics could not be performed. 
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Titration of Virus at Different Temperatures Over Time 
Although the ΔRL13/ΔUL128 virus showed the greatest loss of titre in the previous 
experiment, the titre was never reduced to the titre of the viruses containing UL128 and 
RL13 at that time point. It was therefore possible that the titre reduced the most 
because it started off higher. This experiment was therefore repeated with a longer 
timecourse, from 0-144hrs. Virion stability was tested at 3 different temperatures; 37 °C 
(Fig. 34A), room temperature (RT) (Fig. 34B) and 4 °C (Fig. 34C). Titres for the 
ΔRL13/ΔUL128 incubated at 37 °C showed a similar pattern of degradation to the 
previous experiment. However, unlike the previous experiment, viruses expressing RL13 
and/or UL128 exhibited virion degradation across all temperature conditions over the 
timecourse. The 4 °C timecourse exhibited the most dramatic loss in titre for all four 
genetic backgrounds with no titre detectable after 48 hrs (Fig. 34C). HCMV Merlin 
appears to be very sensitive to storage at 4˚C, more so than at RT. Titres observed at RT 
dropped more suddenly over 8-24 hr compared to 37 °C but remained detectable for 
slightly longer. This important information could aid future experimentation using 
Merlin as the virus should clearly never be exposed to 4˚C for extended periods of time. 
Overall, RL13 and/or UL128 expression did not appear to provide an advantage to virion 
stability.
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Figure 34 – Virion degradation over 144 hrs in different temperature conditions. Viral supernatant from all four genetic backgrounds was 
left for 0-144 hr at either (A) 37 °C, (B) RT or (C) 4 °C and titred. Results varied compared to the previous experiment, with all viruses 
regardless of genetic background displaying susceptibility to virion degradation over time. The 4 °C temperature conditions caused the 
fastest and most dramatic virion degradation across all samples. Titres are in duplicate and therefore statistics could not be performed. 
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5.2 Effects of RL13 on the Host Cell 
5.2.1 Cell Surface Glycoprotein Expression 
Flow Cytometry 
Previously, cell-surface proteomics on cells infected in parallel with HCMV WT and 
ΔRL13/ΔUL128 showed there was a reduction in cell-surface expression of certain virus-
encoded glycoproteins (most notably gB) when both RL13 and the UL128L were intact 
(Stanton, unpublished). To determine whether this difference was a result of RL13 or 
UL128 expression, FACs was performed on infected cells infected with the four genetic 
backgrounds. Gating of cells discrimated against dead cells and other debris (Fig. 35A). 
The efficiency of HCMV infection was determined by monitoring cell surface MHC-I 
downregulation (data not shown). As first observed in the proteomics experiment, 
expression levels of gB were reduced in WT virus compared to ΔRL13/ΔUL128 virus. 
However analysis of the individual RL13 or UL128 mutant viruses, showed that the 
reduced expression was most likely due to the presence of intact UL128 and not RL13 
expression (Fig. 35B). 
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A 
Figure 35 - RL13 expression does not affect gB cell-surface expression on infected cells. 
HF- terts were infected at an MOI of 5 and stained for gB at 72 hr PI. Efficient infection 
was determined by MHC I staining and background fluorescence determined by IgG 
staining. Results show a reduced expression pattern of gB in WT virus and ΔRL13 virus 
when compared to the double mutant, but not in ΔUL128 virus. (A) Gating strategy used 
to discriminate against cellular debris and then select for single cells. (B) Mean 
fluorescence intensity (MFI) of each sample. Statistical analysis could not be performed 
due to lack of replicates. 
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5.2.2 Identifying Functionally Relevant RL13: Protein Interactions 
RL13: Host Cell Protein Complexes Highlighted by SILAC Immunoprecipitation 
(IP) 
An antibody specific for a V5 epitope tag fused to gpRL13 tagged immunoprecipitated a 
set of host cell proteins (see Table 18) from HCMV infected cells in a SILAC-IP 
experiment (Stanton, unpublished). These proteins were then identified by Mass 
spectrometry and a number were found to be chaperons (ERp57, CNX, DNAJB11, GRP78) 
that may be involved in the folding of gpRL13, and TREM16C and SERCA control ion 
channels. Out of these proteins, ERp57, DNAJB11, SERCA and to some extent HSPA5 co-
localised with gpRL13 to the AC in the cytoplasm (Stanton, unpublished, see figures S1 
and S2). As the majority of these proteins are found within the ER their expression in the 
cytoplasm is expected. However, their presence in the assembly compartment is less 
predictable. It was therefore important to determine whether these interactions with 
gpRL13 during productive HCMV infection were responsible for the inhibitory phenotype 
and restriction of cell-free virus released. By knocking down said host protein and testing 
for the ability of RL13 to inhibit efficient viral transfer between infected and uninfected 
cells. 
Analysis of V5-Tagged RL13 by Plaque Assay 
The SILAC-IP was performed using a WT virus in which the RL13 ORF was V5-tagged 
(+RL13 V5/+UL128). It was therefore important to determine whether the V5-tag 
affected the growth or infection properties of the virus compared to the non-V5-tagged 
counterpart. The plaque size of WT virus was not affected significantly by the V5 tag yet 
reassuringly both had significantly smaller plaques than that of the control virus, ΔRL13 
(Fig. 36). Incorporating the epitope tag on the C-terminus of gpRL13 did not alter its 
capacity to impair growth of HCMV plaques.  
Optimisation of SiRNA Co-Cultures 
Four siRNA to each of the 6 host target proteins were tested for their ability to knock 
down the relevant protein. SERCA is encoded by 3 genes (SERCA1, 2, and 3) which give 
rise to the 3 isotypes ATP2A1, ATP2A2 and ATP2A3 (251). siRNA to ATP2A1 and ATP2A2 
were available and so 4 siRNA to each were tested. Cells were transfected with siRNA 
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and western blotting used to determine whether the target protein had been sufficiently 
knocked down. Toxicity to cells was also considered when selecting siRNAs. If multiple 
siRNAs proved efficient both were selected for optimisation, for example both siRNAs 
GRP58 5 and GRP58 6 were equally efficient for ERp57 knockdown (see figure 37). All 
siRNA to TMEM16C failed to efficiently knockdown the target protein and so no further 
investigation was performed with this host cell target protein. 
Three different optimisation conditions were assessed for all siRNAs chosen; 12pmol 
siRNA with 1µl lipofectamine (Optimisation 1), 24pmol siRNA with 2µl lipofectamine 
(Optimisation 2) and 48pmol siRNA with 3µl lipofectamine (Optimisation 3). Western 
blotting was again used to asses which optimisation condition was best for each siRNA. 
Figure 87 shows the optimisation of the chosen siRNAs selected from figure 37. 
Optimisation condition 1 showed to be the most effective across the board. One siRNA 
for each target protein was selected with the exception of two siRNAs chosen for 
DNAJB11. Neither of the two siRNAs optimised for DNAJB11 proved to as efficient as the 
other protein siRNAs or was one more superior than the other and so, both siRNAs were 
chosen at the optimisation level that was most successful for the other protein targets. 
Analysis of RL13: Protein Interactions on Infection Capacity by Si-RNA Co-Culture 
Assay 
Once the most efficient siRNAs were chosen and optimised for each target protein, 
siRNA co-culture assays were performed to assess which protein: RL13 interactions were 
necessary for viral infection efficiency. HFFF were infected with IE2-GFP-fusion virus of 
either ΔUL128 or ΔRL13/ΔUL128 background. The following day cells were transfected 
with siRNA. At 72h post-infection, cells were stained with a far-red dye (DDAO), and co-
cultured with uninfected HFFF. Donor and recipient cells were distinguished by DDAO 
staining.  
RL13 expression is inhibitory to cell free viral spread. Therefore, if the host protein is 
relevant to the RL13 phenotype, knocking it down should either abrogate RL13-
mediated inhibition of virus spread in the ΔUL128 virus, or mimic the RL13 phenotype in 
the ΔRL13/ΔUL128 virus. Co-cultures were performed multiple times with multiple 
donor: recipient cell ratios and at 48hr and 72hr post-co-culture. The results illustrated 
in figure 39 are representative of multiple experiments. In line with previous data, 
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transfer of virus between donor and recipient cells was significantly more efficient in the 
virus lacking RL13, compared to the virus containing RL13. No difference in infection 
efficiency was observed with any of the siRNA when using virus ΔUL128. Cells infected 
with ΔRL13/ΔUL128 and transfected with GRP78, ERp57 or CANX siRNA showed a slight 
reduction in infection efficiency compared to scramble. This effect was more prominent 
in the 1:5 co-culture ratio. This suggested that these interactions with RL13 could have 
some importance in promoting infection and not inhibiting as hypothesised, although 
results were variable between experiments, and were relatively small. Interestingly, 
DNAJB11 knockdown tended to increase infection efficiency slightly compared to 
scramble in both viral conditions, suggesting that this proteins expression hinders 
infection regardless of the presence of gpRL13. Result trends from the 48-hr co-culture 
were replicated in the 72 hr results but with greater GFP positivity. 
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Table 18 – Host cell proteins identified in a SILAC-IP to bind RL13 during infection. 
Protein Name Full name Function 
Co-
localisation?1 
ERp57 
 
Endoplasmic 
reticulum p57 
A component of the 
calnexin/calreticulin chaperone system 
that promotes folding and quality 
control of newly synthesised 
glycoproteins in the ER (252). 
Yes 
TMEM16C 
 
Transmembrane 
protein 16C, also 
known as ANO3 
(anoctamin 3) 
May act as a potassium channel 
regulator and could inhibit pain 
signalling (253). 
Unknown 
CANX 
 
Calnexin 
ER chaperone protein involved in 
coordinating newly synthesised 
glycoprotein folding (254, 255). 
No 
DNAJB11 
DnaJ heat shock 
protein family 
(Hsp40) member 
B11 
Co-chaperone protein that is involved 
in synthesis and secretion of proteins 
by stimulating Hsp 70 chaperones 
(256). 
 
Yes 
SERCA 
 
Sarcoplasmic/ 
endoplasmic 
reticulum calcium 
ATPase 1+2 
Calcium pump found in the 
sarcoplasmic or endoplasmic 
reticulum. Catalyses hydrolysis of ATP 
to transport Ca2+ (257). 
 
Yes 
HSPA5 
 
Heat shock protein 
family A (Hsp70) 
member 5 or 78 
kDa glucose-
regulated protein 
GRP78 or BiP 
ER Chaperone protein involved in the 
transportation, folding and assembly 
of proteins. Also targets misfolded 
proteins for degradation (258). 
Yes/No 
1Stanton, unpublished. See Figures S1 and S2. 
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Figure 36 - The V5-tag does not affect RL13 expression. A plaque assay with +RL13 
V5/+UL128 and two controls, WT and ΔRL13, was set up in duplicate. 2 weeks post-
infection the relative area was measured between 20 plaques per virus at 200 pfu. The 
V5 tag does not significantly affect the growth properties of the virus and therefore does 
not affect the expression of RL13. Analysis was performed by one-way ANOVA and 
Bonferroni post-test, *** = p < 0.001. Error bars display SEM. 
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Figure 37 -Selection of siRNA to target proteins. All western blotting performed at 48 hr 
post transfection of siRNA. siRNAs for each target protein were chosen on the basis that 
they were the most efficient or least toxic to cells. The siRNAs that were selected are 
indicated by the red arrows. TMEM16C was not pursued further as neither the antibody 
staining nor the siRNA knockdown proved to be efficient.  
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Figure 38 - Optimisation of chosen siRNA to target proteins. siRNA was chosen to each of 
the 5 target proteins and ABI1 (the positive control, known to efficient knockdown its 
target). Three Optimisation condition 1 proved to be the most efficient for knockdown of 
all target proteins. When knockdown was comparable between optimisation conditions 
the decision was made based on the toxicity to cells. Chosen optimisation conditions are 
indicated by the red arrows. Samples in lanes are described in the table seen above. 
HSPA5 and ABI1 only had one chosen siRNA to optimise and therefore lanes 4-6 are 
absent. 
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Figure 39 – An example siRNA Co-culture assay at 48 hr and 72 hr. Co-cultures were 
performed at 48 hr and 72 hr at a 1:5 and a 1:15 ratio, with the greatest clarity of 
results in the 1:5 ratio 72 hr co-culture. Greatest infection efficiency was seen in cells 
infected with ΔRL13/ΔUL128. ΔUL128 samples showed little difference in infection 
efficiency between target knockdowns and scramble control. 
ΔUL128 
ΔRL13/ΔUL128 
Mock 
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5.3 Effects of RL13 on the Host Immune System 
5.3.1 RL13 is an Fc-Binding Protein 
Flow Cytometry 
During this study RL13 was described as a Fc binding protein (see Intro section 1.5.3) 
with immune evasion potential. Recombinant glycoprotein RL13 obtained from TR or 
Merlin trafficked to the cell membrane and bound and internalized exogenous IgG or IgG 
constant fragment. A tyrosine-based motif (YxxL) that functions to intracellularly target 
transmembrane proteins was identified in the C-terminal cytoplasmic domain of RL13 
(173). Genome comparisons demonstrated that the endocytic YxxL motif was 100% 
conserved among the 96 clinical isolates (3), suggesting this function is an important 
immune evasion strategy in vivo. This conservation of motif could explain why functional 
differences in Fc binding between TR and Merlin RL13 were not identified despite the 
ORF sequence differences (173). Other RL11 family members such as RL11 and RL12 was 
identified as an IgG-Fc binding glycoprotein which can manipulate the host humoral 
immune response (173, 174). 
Although it is unlikely that Fc-binding could be responsible for the growth phenotype 
displayed by virus expressing RL13, it was a potential function of RL13 that merited 
investigation. The conclusion was also not reached using systems permitting robust 
expression of RL13 in all cells (173), and so it was also important to determine if the 
results could be replicated. 
Cells were infected with replication deficient recombinant adenovirus (RAd) encoding 
RL13, RL11, UL119 or a control vector. Cells were incubated with either a purified 
seronegative serum from a single donor, or a purified pooled seronegative human IgG at 
varying concentrations from 1µg/mL - 100µg/mL 72 hr p.i, and then a fluorescent anti-
human secondary antibody. Cells were gated to discriminate against cellular debris and 
then selected for single cells (Fig. 40A). Background levels of fluorescence were 
determined with no stain samples and secondary stain only samples on the Mock 
sample of each infection and condition (Fig. 40B). RL13 did not show substantial binding 
of human IgG at lower IgG concentrations, whereas UL119 showed binding at all 
concentrations. However, at the higher IgG concentrations, RL13 bound IgG to a similar 
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extent as, and in some conditions more than, RL11 (Fig. 40C). Some cytotoxicity 
associated with RL11 resulted in lower cell counts. Not much difference was seen in the 
results between the two different human IgG sources except that RL13 bound 10ug/mL 
pooled greater than 10ug/mL D58.  
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Figure 40 – RL13 binds Fc at higher IgG concentrations. Cells were infected with Rads 
expressing either RL13, RL11, UL119, an empty control Rad (empty vector) or left as 
mock. 72 hr PI cells were incubated with Human IgG at varying concentrations and then 
a fluorescent anti-human secondary Ab. Cells were run on a Flow cytometer and 
fluorescence quantified between samples. (A) Gating strategy used to discriminate 
against cellular debris and then sort for single cells. (B) No stain and secondary only 
stain to determine background levels of fluorescence. (C) Mean fluorescence intensity 
(MFI) of each sample. Results showed that RL13 bound human IgG more than the empty 
vector and to the same extent if not more efficiently than RL11. Statistical analysis could 
not be performed due to lack of replicates. 
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5.3.2 NK Cell Degranulation 
Antibody Dependent Cellular Cytotoxicity 
Previous work (Stanton, unpublished) showed that infections with WT virus resulted in 
reduced NK cell degranulation against target cells compared to ΔRL13/ΔUL128 when 
assays were performed in the presence of anti-CMV antibody (ADCC assays). As RL13 
proved to be an Fc binding protein (173) which was replicated in this project, it is 
possible that RL13 could function as an immune evasion gene. By binding the Fc portion 
of the cell-surface bound antibody gpRL13 could protect cells from ADCC through 
antibody bipolar bridging (see Intro section 1.5.3). It could therefore be likely that the 
effect seen previously was due to RL13 and not UL128 expression. Thus, ADCC CD107 
assays were performed with the four different genetic background viruses to test this. 
Cells infected with the four genetic backgrounds of virus were used as target cells with 
PBMCs (source of seropositive NK cells) used as effector cells. CD107a expression 
measured by flow cytometry was used as a surrogate marker for the identification of NK 
cell activity on target cells. All samples were gated as shown (Figures 41A and 42A) to 
discriminate against cellular debris and then to select for CD56+, CD3- cells (NK cells). On 
this occasion, NK cell degranulation was not affected by RL13 expression (figure 41B). It 
was hypothesized that this differing result was due to the human serum used, and so the 
assay was repeated using multiple serums (Figure 42B). Different serums did show 
varying levels of degranulation, however, serum did not consistently affect the level of 
degranulation in response to viruses either lacking or containing intact RL13. 
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Figure 41 - RL13 expression does not affect NK cell degranulation against infected 
target cells. An ADCC CD107 assay was performed with Target cells infected with all 
four genetic backgrounds (MOI of 5. Mock infected target cells (Mock) and no target 
control (NTC) were used as controls. Target cells were exposed to effector cells (PBMCs) 
48 hr infection. (A) Gating strategies to discriminated against cellular debris and to sort 
CD56+, CD3- NK cells. (B) Results show no significant difference of percentage NK cell 
degranulation between viruses. (NTC: No target control). Data were analysed by two-
way ANOVA with Tukey post-hoc analysis. Error bars display SEM. 
Mock 
ΔRL13/ΔUL128 
WT 
ΔUL128 
ΔRL13 
NTC 
A 
B 
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Figure 42 - ADCC varies with different donor’s serum. Another ADCC CD107 assay was 
performed using 3 positive human serums and 1 negative human serum. Target cells 
were infected with ΔRL13/ΔUL128 and WT viruses (MOI of 5). Mock infected target cells 
(Mock) and no target control (NTC) were used as controls. (A) Gating strategies to 
discriminated against cellular debris and to sort CD56+, CD3- NK cells. (B) 48hr PI NK cell 
degranulation was measured and results show varying amounts of degranulation 
between serum samples. Data were analysed by two-way ANOVA with Tukey post-hoc 
analysis compared to the Mock of each serum (*= P < 0.05, **= P < 0.01, ***= P < 0.001, 
****= P < 0.0001.) Error bars display SEM. 
Mock 
WT 
ΔRL13/ΔUL128 
NTC 
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5.4 Chapter Summary 
It was important to consider the functional consequences of gpRL13 in the virion 
envelope and to determine whether this had any implications or advantages for HCMV 
infection. 
 As RL13 expression forces the virus to spread cell-to-cell rather than cell-free co-
cultures were set up with adherent and non-adherent cell types to determine whether 
this viral spread mechanism could prove advantageous. Cytotect, a purified polyclonal 
human anti-CMV IgG, was included in co-cultures at varying concentrations to 
determine whether viral transmission by cell-cell spread could evade neutralising 
antibodies. In adherent cell types such as fibroblasts and epithelials, the expression of 
RL13 or UL128 alone, or in combination, provided significant resistance to neutralising 
antibody in fibroblasts. Although RL13 and UL128 expression both independently 
provide resistance to neutralising antibodies, it can only be confirmed that RL13 
provides this advantage in fibroblasts as UL128 is required for entry into epithelials and 
so the effect of RL13 alone could not be measured. 
As important immune cells, DCs and LCs are likely to be among the first antigen 
presenting cells to come into contact with HCMV during the acute phase of a primary 
infection where they are thought to contribute to viral dissemination and important for 
reactivation of HCMV from latency. It was therefore important to determine whether 
RL13 affected infection of these cell types and whether using HCMV strains lacking WT 
RL13 for research would potentially affect the interpretation of results. RL13 expression 
provided no advantage to the virus to overcome anti-viral restriction in DCs and LCs, 
although again this could only be investigated in the presence of UL128. Thus, RL13 may 
have effects on virus spread, but these effects are masked when UL128 is present. More 
co-cultures in clinically relevant cell types and live cell imaging of infections with 
fluorescent virions in future work will provide valuable information regarding the 
mechanism by which HCMV spreads cell-cell.  
The expression of RL13 proved to affect the composition of the virion as 15 host proteins 
were identified as being lost from the virion when RL13 was expressed. These proteins 
were identified again in a second comparison (WT compared to ΔRL13/ΔUL128 virions), 
thus giving more confidence that these were true differences. It is not immediately 
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obvious how these proteins could affect virion infectivity to the levels that the WT 
virions do. Many of these proteins identified are Ig fragments or Fc receptors and so it is 
unclear at how they are present in the sample especially as the virions were gradient 
purified. However, these changes in composition could affect the virions in other ways. 
MAP2K1 and MAP2K2 are involved in the MAPK/ERK signalling pathway, required for not 
only the proliferation and survival of hematopoietic cells but also for the differentiation 
of monocytes in vitro (259). As myeloid cell differentiation leads to the reactivation of 
the HCMV lytic lifecycle (32, 134) (See section 1.4.3), WT virions could be more likely to 
promote a latent state as virions lack the MAP2K1 and MAP2K2 kinases that participate 
in this monocyte differentiation signalling cascade.  
Rras-2 is a GTP-binding protein found in the plasma membrane (238). Small GTP-binding 
proteins have been implicated in HIV-1 intracellular trafficking, budding and release of 
virions (260). Additionally, RhoB GTPase is required for productive infection of HCMV 
and is implicated in virion egress. Knockdown of RhoB resulted in significantly reduced 
viral titre (261). It could be possible that the GTPase Rras-2 assists HCMV virion egress 
and in doing so becomes incorporated into the ΔRL13 virion partially explaining the 
significant increase seen in NanoSight quantified extracellular virions when RL13 was 
mutated (with increased presence of Rras-2 in the virion). R-Ras2 also interacts with T 
and B cell receptors which is essential for cell survival. R-Ras2 knockout mice displayed a 
30% decrease in the number of T cells (262). T cells are valuable in the cellular immune 
response against HCMV. Although R-Ras2 expression is tightly regulated it could be 
possible that R-Ras2 present in the virion envelope binds T cell and B cell receptors. This 
data could possibly suggest that the WT RL13 virions with significantly reduced presence 
of Rras-2 results in a loss of this tonic signalling of T and B cells leading to slightly 
impaired cellular immune response. Although just speculation and much more work 
would be needed to investigate whether this would provide an advantage to the +RL13 
clinical strains.  
Lactoferrin was significantly reduced in the virion when RL13 was expressed. Lactoferrin 
prevents HCMV entry into cells (263) most likely by competing with the glycoproteins 
gB, gM and gN for heparan sulphate (264). Its incorporation into the virion seems 
unusual given its antiviral properties, especially considering that its production is mainly 
154 
 
from mucosal epithelial cells (265). Lactoferrin is found in serum and as human and 
bovine forms exhibit high homology it is possible that its presence is due to the use of 
FBS during cell culture. Lactoferrin could be incorporated into the virion during viral 
replication or it could directly interact with the WT virions extracellularly much like how 
bovine lactoferrin binds structural polypeptides of adenovirus particles (266).  
Coagulation factor X/Xa (FX/FXa) cannot be a contaminant from FBS as FBS is depleted 
of cells, fibrin and clotting factors. Although the liver is the major site of FX production, 
human primary fibroblasts have been shown to express FX (267). Interestingly, not only 
is the procoagulant phospholipid, phosphatidylserine, found in the virion envelope 
(268), but HCMV has been demonstrated to have endogenous mechanisms to activate 
FX to FXa on the envelope surface (269). Therefore, thrombogenic activity can be 
stimulated in the absence of tissue damage providing an explanation as to why HCMV 
can be associated with a vascular pathology and the acceleration of a number of 
vascular diseases. In this thesis phosphatidylserine was also identified with no significant 
difference in abundance between the virion samples. It is thought that 
phosphatidylserine is incorporated into the envelope during particle formation of AD169 
whereas FX binds extracellularly (269). FX/FXa however was significantly enriched on 
virions lacking RL13 in this thesis. Ad169 contains a frameshift mutation in RL13 (191, 
225), possibly suggesting that only expression of WT RL13 could inhibit binding of 
FX/FXa. 
Some proteins that were significantly reduced in the virion when RL13 was expressed 
did not provide an obvious advantage or disadvantage to the virus. The myeloid 
proteins, S100A8 and S100A9, and the A100A8/A9 complex, calprotectin have multiple 
extracellular functions during infection specifically related to inflammation (270). 
However, these proteins do not have a transmembrane region and so It remains unclear 
what advantage the reduction of these two proteins or complex would bring to the WT 
HCMV virions when incorporated into the tegument. The gene product of NDUFS2 is 
located in the mitochondrion inner membrane and was found to be significantly reduced 
when RL13 was present in the virion. NDFUS2 is part of the first complex of the 
mitochondrial respiratory chain, NADH-dehydrogenase (245). It is unclear why HCMV 
would possess this protein in the virion and why its incorporation is RL13-dependent. 
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Apart from gpRL13, all HCMV-encoded proteins were present in similar abundance in 
ΔRL13 and WT virions, except for the large tegument protein UL48. UL48 was reduced in 
the WT virions compared to the ΔRL13/ΔUL128 and so it’s important to bear in mind this 
difference could be UL128-dependent. The large tegument protein is likely to be 
important in viral capsid transport and stabilisation and envelopment (110). Loss of UL48 
expression leads to the failure of the AC to form (271). If the reduction of UL48 in the 
virion suggested reduced expression of UL48 leading to reduced capsid transport, 
stabilisation, envelopment and abrogated AC formation, this could contribute to the 
reduction in viral particles numbers seen from the WT virions. However, if this were the 
case, these results would have been confirmed by a difference in the TEM of particles 
forming and maturing and reduced stability from WT virions which were not. 
It was then hypothesised that the stability of virions once released from the cells could 
be affected by the change in virion composition and therefore could account for the loss 
in viral titre. Yet, the presence of RL13 did not reduce the stability of virions. In fact, 
when first analysed at 37 °C, RL13 provided a substantial advantage to maintaining 
virion titre when left for long periods of time before titration. The same effect was seen 
with the UL128L expressing virus and the WT virus. However, when repeated at various 
temperatures and for a longer timecourse all viruses showed substantial titre loss and 
no consistent advantage could be attributed to RL13. Although the ΔRL13/ΔUL128 virus 
showed the greatest reduction in titre, it was also the virus with the greatest titre to 
begin with. It is possible that agglutination in the high titre virus could be responsible for 
this, however this could only be determined if the starting titres (timepoint 0hr after 
supernatant collection) were comparable between viruses. This assay could be improved 
by quantifying virion numbers as well as titre at each timepoint and by dispersing 
potential virion aggregates by either vigorous vortexing or pipetting. 
Due to previous data (Stanton, unpublished) suggesting that WT virion infection led to a 
reduction in cell-surface viral glycoproteins such as gB when compared with 
ΔRL13/ΔUL128 infection. In this project however, RL13 was found to have no discernible 
effect on cell-surface gB expression. The reduction in gB observed previously is here 
shown to be dependent on restoring UL128 expression. gB is a highly conserved virion 
envelope glycoprotein that is recognised by the immune system in many different ways 
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including CD4+ T cells, anti-HCMV antibodies and TLR2 (see Intro 1.5.3). The results here 
could suggest that the expression of intact UL128L provides a mechanism for immune 
evasion for the virus and would therefore be an important hypothesis to follow up. 
Specific host proteins were previously shown to interact with and, some, co-localise with 
RL13. These interactions were investigated by knocking down said proteins and the 
capability of infection analysed by co-culture and flow cytometry. DNAJB11 knockdown 
resulted in slightly increased infection of recipient cells indicating its expression could 
hinder infection regardless of RL13. It is likely that knockdown of the chaperone host 
proteins could interfere with infection as result of protein interactions elsewhere within 
the viral genome. As results varied between co-culture assays, and differences were 
relatively small, it was not possible to draw convincing conclusions as to which cellular 
proteins are responsible for the RL13 phenotype. It seems likely that knockdown of 
target proteins was not efficient enough, or was not maintained throughout the 
duration of the assay. Due to the short lifespan of siRNA it was difficult to use within a 
HCMV assay without the risk of either ending the experiment too early for a quantifiable 
transfer of virus or too late and risk the efficiency of siRNA. The possibility of using 
CRISPR instead of siRNA for complete long-term knockdown of target cells could be 
investigated in the future. This alternate approach could assist in the investigation into 
TMEM16C which was unsuccessful using siRNA. The use of CRISPR would also eliminate 
the risk that transfection of siRNA can induce the IFN response which could affect viral 
replication of subsequent cells (272). Despite variation, the results that were obtained 
indicate that none of the proteins tested were required for RL13-mediated suppression 
of infection and that the critical interaction with RL13 to result in this phenotype is yet 
to be determined.  
Recently RL13 was shown to bind Fc (173). It was important to determine whether we 
too could replicate this finding with Merlin RL13. A few issues arose with the Fc binding 
assay, such as toxicity leading to low cell counts in the RL11 RAd infected samples. 
Another caveat is that the empty vector control showed an increase in fluorescence 
compared to Mock at the highest concentration of IgG, and this background could have 
masked low levels of binding by the HCMV proteins. Increased fluorescence was seen in 
the 10ug/mL pooled IgG Mock sample, which could mean that fluorescence levels in the 
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10ug/mL samples are exaggerated. This experiment was only performed with n=1 and so 
it would be beneficial to repeat it. Nevertheless, RL11 bound human IgG to a similar 
extent as RL13, indicating that RL13 can act as a Fc binding protein at higher IgG 
concentrations.  
As RL13 binds Fc it was possible that the expression of RL13 could also inhibit ADCC. 
Previous work also hinted that infections with WT HCMV resulted in reduced ADCC 
compared to ΔRL13/ΔUL128 (Stanton, unpublished). However, in this project, RL13 
expression did not consistently affect NK cell degranulation. This was performed with 
multiple donor serums and results suggested that the difference in ADCC seen 
previously was due to serum donor differences. 
Overall, the presence of gpRL13 did prove to have an effect on the virion. gpRL13 
influenced the method of viral transmission, the composition of the virion, and showed 
evidence of Fc-binding capabilities all of which furthers our understanding of the 
function of the RL13 gene in in vivo infection. 
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CHAPTER 6. DISCUSSION 
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Work in this thesis has furthered the understanding of the function of the HCMV gene 
RL13 and has provided insights into how and why its expression is so inhibitory to viral 
propagation in vitro. In my opinion this work has resulted in 3 main findings; the 
importance of working with HCMV strains that express functional RL13, RL13 has 
multiple conserved phenotypes and that the restrictive phenotype of RL13 in vitro can 
be explained in part by a reduction in virion infectivity. These findings will be discussed 
further below.  
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6.1 The Importance of RL13 
The expression of RL13 is strongly inhibitory to HCMV propagation in cell culture with 
disruptive mutations appearing in RL13 rapidly upon culture in fibroblasts (203). High-
throughput analysis of HCMV genome diversity found that only 3.9% of clinical isolates 
sequenced contained an ORF disrupting mutation in RL13. These clinical isolates were 
passaged on average 2-3 times on fibroblasts before sequencing (3), thus these 
mutations could be a result of adaptation to fibroblasts. In either case, RL13 is intact in 
the majority of clinical strains. Given this, it must be advantageous for the virus in the 
human host. If in vitro studies are to recapitulate the in vivo situation, it is therefore vital 
to work in vitro with strains that represent the full genetic potential of HCMV, and data 
in this thesis demonstrates this. 
 A large majority of HCMV research to date has been performed using RL13 mutant 
viruses, because it was not possible to grow RL13 intact viruses in vitro. The Tet-
repression system used in the Merlin BAC solved this problem, making working with 
genetically intact RL13 (WT HCMV) possible for the first time (203).  However, this 
required in vitro acquired mutations to be repaired, and Tet-repression elements to be 
added to a BAC clone of the virus. Recently an alternative method of WT HCMV 
propagation whilst keeping RL13 genetically intact has been proposed (273), suggested 
as a possible method for deriving BAC clones from clinical isolates without the risk of 
mutation. They reported that serial passage (>p20) of a clinical isolate in fibroblasts was 
achieved without mutation in RL13 or the UL128L by culturing in the presence of anti-
HCMV hyperimmunoglobulin. The clinical isolate also retained the ability to infect 
epithelial cells (273). The presence of HCMV-hyperimmunoglobulin in the cell culture 
medium was thought to force the virus to replicate by cell-cell spread much like in vivo, 
by neutralising cell-free virions. This alleviates the selective pressures that promote RL13 
and UL128L mutation which result in the release of cell-free virions (203, 273). The 
stocks propagated by this method, although enabling growth of RL13-intact genomes 
without needing to BAC clone, only reach titres of 104-105 pfu/mL which are unlikely to 
be sufficient for many aspects of HCMV research. Using the Tet-repression system, 
sufficient titres are achieved by propagating RL13+ strains whilst translationally 
repressing the ORF. This not only ensures that RL13 remains genetically intact, but also 
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relieves any inhibition that gpRL13 places on viral propagation. Therefore, the Tet-
repression system has advantages for propagating WT HCMV in vitro, and so improved 
novel reporter viruses expressing Tet-regulated RL13 were needed for this study. An 
ideal reporter gene for this project would be expressed to high levels, early in infection. 
IE1 seemed like an ideal candidate as expression levels are highest immediately after 
infection (210). Unfortunately, the proposed construct of IE1-P2A-GFP was unsuccessful. 
Despite this, a successful reporter virus expressing GFP fused to the C-terminal of IE1 has 
previously been created in AD169 (274). The MIE gene has multiple splice variants and is 
complex (see Intro section 1.4.1). Insertion of a substantial sequence such as GFP could 
potentially impact the functioning of the gene products (IE1 or IE2) required for efficient 
viral propagation, and/or the efficiency of splicing that results in expression of both gene 
products. Our constructs contained the P2A peptide that results in co-translational 
cleavage of the IE gene and GFP, and theoretically should have been less likely to have 
interfered with the IE1 gene products to the same extent as a fusion construct (as was 
used in the AD169 background) would have. It is possible that the reason the construct 
in IE1 in this thesis failed was due to strain-specific differences between Merlin and 
AD169. The IE2-P2A-GFP viruses on the other hand were recovered successfully and 
provided key tools for progressing this project. It seems likely that although the P2A 
sequence was used in both the IE1 and IE2 constructs, fusing to IE1 impacted on effects 
on splicing that were inhibitory for efficient viral replication.  IE2 levels are recognised to 
increase dramatically at 48-72h (210), which is when GFP became detectable, suggesting 
that expression levels were simply insufficient at earlier timepoints. 
 
 As the glycoprotein encoded by RL13 is expressed in the virion envelope (203) and 
traffics to the cell surface where it is exposed at least transiently (173), RL13 could 
potentially modulate the tropism of the virus as well as function to aid immune evasion 
or virulence. These potential attributes of the expression of RL13 demonstrate the 
importance of using clinically relevant HCMV strains in HCMV research. During this 
thesis RL13 was described as a Fc binding protein with immune evasion potential (173). 
Recombinant glycoprotein RL13 obtained from TR and Merlin trafficked to the cell 
membrane and bound and internalized exogenous IgG or IgG constant fragment. A 
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tyrosine-based motif (YxxL) that functions to intracellularly target transmembrane 
proteins was identified in the C-terminal cytoplasmic domain of RL13 (173). Genome 
comparisons demonstrated that the endocytic YxxL motif was 100% conserved among 
the 96 clinical isolates (3), suggesting this motif is advantageous to HCMV in vivo. Using 
flow cytometry this function of RL13 was supported in this thesis but only at the higher 
IgG levels tested. The lowest concentration of IgG that Fc-binding of RL13 was seen was 
at 10µg/mL, however this is around 700-fold lower than serum IgG levels in the healthy 
population (275), suggesting that in immunocompetent hosts with much higher serum 
IgG levels than tested, RL13 could successfully function to bind Fc. Having proven that 
RL13 was an Fc-binding protein, it was hypothesised that it may potentially inhibit ADCC 
as well along with many other HCMV encoded NK evasion genes. The IgG subtypes of 
IgG1 and IgG3 are good mediators of ADCC (276) and RL13 was shown to selectively bind 
IgG1 and IgG2 subtypes (173). However, there was no evidence that RL13 expression 
resulted in a significantly decreased NK degranulation response in the assays in this 
thesis, suggesting that it is unlikely that RL13 functions as an NK evasion gene to inhibit 
ADCC. However, these NK assays were performed in the context of HCMV meaning that 
other Fc-binding proteins such as UL119 and RL11 were present and could mask any 
effect of RL13. The Ig-like domain showed great variation in protein sequence between 
the 9 clades observed when analysing the 96 clinical RL13 ORFs. It could be possible that 
a clade with great variation compared to clades 8 and 9 (containing TR and Merlin 
respectively) has evolved the ability to inhibit ADCC. Nevertheless, it is clear that RL13 
does not enhance the ADCC-avoidance properties of UL119 and RL11, in the context of 
in vitro infection. 
 
 Anti-CMV vaccines generally aim to induce immune responses such as neutralising 
antibodies (277). Most HCMV vaccine research is performed using highly passaged 
strains lacking expression of WT RL13 and UL128, and therefore produce high titres of 
cell-free virions. Clinical HCMV contains RL13 and UL128, and is therefore mainly found 
in a cell-associated form (103), which affects sensitivity to neutralising antibodies in 
other viruses. It was therefore important to investigate the effect of neutralising 
antibodies on HCMV expressing RL13 and UL128. RL13 and UL128 both independently 
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provided viral resistance to neutralising antibody in fibroblasts. However, plaque size 
consistently remained smaller than ΔRL13/ΔUL128 virus, even under high antibody 
concentrations, suggesting that in this context, no actual growth advantage is achieved 
when these genes are expressed.  
 The UL128L encoded envelope proteins are together the major target of neutralising 
antibody response (278), thus the loss of the pentameric complex from the virion 
envelope should result in reduced sensitivity to neutralising antibody. However data 
from this thesis, which contributed to recently published work (235), showed that 
expression of UL128, and equally RL13, forces the virus to spread cell-cell; a mechanism 
that is resistant to neutralising antibodies (235). Additionally, the fact that the majority 
of WT HCMV in vivo is cell-associated (103), clinical isolates in cell culture also remain 
mostly cell-associated (200, 279) and the infrequent release of cell-free virus detected in 
blood in vivo (280), support a cell-cell spread mechanism that is utilised throughout the 
majority of infection in vivo. The cell-cell method of viral spread has been exploited by 
other viruses, such as HIV (281). Cell-cell spread of HIV virions still requires the assembly 
and maturation of fully formed enveloped virions (282). Although it is not yet 
determined whether HCMV utilises the same mechanism as HIV to spread cell-cell, It is 
probable that HCMV also needs fully formed enveloped virions for productive cell-cell 
infection as many envelope proteins are required for plaque formation, and some 
tegument proteins are involved with initiating viral replication (1). It has been reported 
that loss of UL99, which results in capsids being unable to acquire envelope, can still 
spread cell-to-cell, however this spread is much more inefficient than enveloped 
particles, indicating that it is not the dominant route of natural spread (283).  
 
 No difference in the numbers of matured virions in the assembly complex between WT 
and mutant HCMVs were detected by TEM in this thesis despite the restriction of cell-
free virion titres by RL13. Viral replication kinetics are enhanced during cell-cell spread 
of HIV (281, 284, 285) likely due to the fact that many infectious virions are transferred 
simultaneously during cell-cell spread of virus (286). It is possible that the reduction in 
cell-free virions caused by RL13 is due to multiple virions being transferred to 
neighbouring cells instead of being released into the supernatant. In addition, enhanced 
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replication kinetics were not seen when comparing genome replication, temporal 
protein cascade or particle maturation and formation of HCMV in this thesis between 
WT and HCMV RL13 mutants. 
 
 DCs and LCs have been shown to participate in primary infection of HCMV in very 
different ways. Immature DCs are fully permissive to cell-free infection whilst immature 
LCs are not (231, 233). However, only UL128 was necessary for cell-cell spread in these 
cells, with RL13 not providing an advantage in any of the conditions tested. Interestingly, 
immature LCs were readily infected when infection was by the cell-cell route 
(irrespective of RL13). Furthermore, cell-cell infection of these cells was only slightly 
inhibited in the presence of IFNα, whereas cell-free infections performed in parallel 
were strongly affected by the disruptive effects of IFNα. Thus, suggesting again that the 
survival of WT HCMV during in vivo infection is more likely ensured by cell-cell spread. 
The data in this thesis has demonstrated the advantages and importantly the differences 
of WT HCMV driven cell-cell spread compared to cell-free spread seen with laboratory 
HCMV strains. The cell-cell transmission of HCMV enabled by UL128 expression allows 
for the expansion of host cell tropism to include LCs as well as DCs. Cell-cell spread also 
provides a higher resistance to IFNα, as well as resistance to neutralising antibodies 
during infection. 
 
 The favoured model of HCMV particle assembly requires that virion envelope 
glycoproteins are first transported to and thus transiently exposed on the cell surface 
before being endocytosed to become components of the virion envelope (85). 
Glycoproteins exposed on the cell surface are potential targets for the immune system. 
It was considered that RL13 could act as an immune evasion function by downregulating 
gB cell surface expression, however, RL13 proved to have no effect on the cell-surface 
gB expression. The effect on gB cell-surface expression was in fact found to be UL128L-
dependent. gB is highly immunogenic and both binding and neutralising anti-gB 
antibodies are found in almost all seropositive individuals (1). As gB is a major target of 
the humoral immune system, reducing its cell-surface expression through this 
undetermined UL128-dependent mechanism could provide an advantage to UL128+ 
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HCMV strains. Of course, this preliminary data would need to be investigated further to 
confirm this assumption but nevertheless, this demonstrates the importance of working 
with WT HCMV strains as not only functions of RL13 will be absent, but other clinically 
relevant genes such as UL128 as well. 
 
 Other advantages of RL13-containing strains could be overlooked when designing 
therapeutics with laboratory HCMV strains. As RL13 was shown to bind Fc in isolation, 
the presence of gpRL13 in the virion envelope could potentially provide Fc-binding 
capabilities to cell-free virions providing the virus with advantageous immune evasion 
mechanisms. Furthermore, virions lacking RL13 had other alterations in composition 
compared to the WT virus, with ΔRL13 virions lacking 15 host proteins. The majority of 
these seem likely to be contamination, with several being components of 
immunoglobulins or potential Ig Fc receptors, involved in Ig internalisation or binding. It 
is surprising that the Ig fragments are present in the samples as samples were gradient 
purified and previously cultured with FBS, meaning any Ig proteins present could 
possibly be bovine and misidentified as human. Aside from these potential 
contaminants, a number of additional proteins were reduced in the virion when RL13 
was expressed (see table 17). Although none provide an obvious explanation for why 
RL13 intact virions have reduced infectivity, or why their abundance is altered following 
RL13 expression, some have the potential to alter the activity of HCMV virions and 
therefore highlight advantages of using WT HCMV in research (Discussed in section 5.4). 
As with all the proteins found to be altered between the WT and ΔRL13 virions it is 
uncertain whether their RL13-dependent virion incorporation is due to their increased 
abundance caused by downstream effects of RL13 expression or due to direct 
interaction with gpRL13 during virion particle formation. However, the SILAC-IP 
performed on cell infections previously (Stanton, unpublished) did not identify the 
proteins discussed above indicating that the RL13-dependent virion composition 
alterations are unlikely to be due to direct interaction with gpRL13. All that is certain is 
that the expression of RL13 changes the composition of the virion. Further work could 
involve CRISPR/siRNA knockdown of these proteins to determine the importance of the 
compositional changes to the virion with gpRL13 incorporated.   
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6.2 Is RL13 Hypervariable? 
RL13 has been described as part of a defined set of hypervariable genes (175). The 
majority of HCMV genes have highly conserved sequences, however, some genes have 
substantial genetic variation between strains and are designated hypervariable. Many of 
these genes encode for proteins that are either confirmed or predicted to be 
membrane-associated or secreted and therefore likely to interact with the host immune 
system.  
Other hypervariable genes in this discrete group include UL146 and UL139 (194). UL146 
encodes a chemokine designated vCXC-1 and displays variability throughout the 
sequence length (196, 287). Remarkably, the UL146 sequences of strains have been 
grouped into one of 14 defined genotypes (175, 194). The alignment of the RL13 ORFs 
obtained from 96 clinical isolates along with the RL13 ORF from Merlin, TR and AD169 in 
this thesis resulted in tightly delimited clusters encompassing 9 RL13 genotypes. 
Genotype analysis has been performed for RL13 before, identifying 8 genotypes. 
However, when identifying clusters, the pruning procedure was to identify a maximum 
of 8 genotypes in order to proceed with their statistical analysis of their dataset (288). 
This method could easily underestimate the true number of unrestricted genotypes. 
Whereas the majority of the HCMV genome undergoes a high-frequency of 
recombination, RL13 was found to be a region in high linkage disequilibrium which is 
consistent with locally reduced recombination, whereby genotypes are sufficiently 
divergent from one another to prevent recombination between them (288). 
 As genetic variation is prevalent in clinical HCMV strains, it has been hypothesised that 
HCMV strain variation could affect the outcome of infection, which poses problems for 
disease management and vaccine research (289). To date, the association of a particular 
genotype with a particular clinical disease outcome has been evaluated in many studies, 
some reporting inconclusive or contradictory results (194). Others however have found 
evidence of a relationship between genetic variant and pathogenic potential in the 
polymorphisms of several genes (mainly glycoproteins) including UL146 and UL147 (3). 
An increased risk of CNS damage was associated with the G1 UL146 genotype, whilst an 
increased risk of pneumonia was associated with the G7 genotype (290). The RL13 
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variants have diverged for a reason therefore it is likely that the different clades 
observed provide the virus with different pathogenic potential. Multiple virus genotypes 
can be found within patients (291, 292). It is possible that infection with multiple RL13 
genotypes could complement each other. It is also possible that the different RL13 
genotypes provide advantages in certain hosts, and that host genetics also play a role in 
the success of HCMV pathogenesis. Further insight into the immunological purpose of 
these RL13 genotypes could be gathered from investigating whether the amino acid 
sequence variation affects the chemical or structural properties of the protein. 
 The groupings of the RL13 ORFs was interesting. The Merlin RL13 was grouped into a 
fairly small clade. TR, which may be functionally different from Merlin RL13 as its 
sequence does not mutate in vitro (208), was found on the adjoining branch suggesting 
that compared to the other clades, TR and Merlin are more alike than first thought. Fc 
binding potential were described for Merlin RL13 and TR RL13 (173), as these strains are 
found on adjoining arms its seems logical that they possess the same or similar 
functions. Whether or not this function is specific to these closely divergent arms in the 
phylogenetic tree is yet to be determined, however it was found that the Ig-like domain 
that is responsible for the Fc binding capabilities showed considerable variation between 
the 9 clades. It would be interesting to determine whether neighbouring clades had 
evolved this function and/or were also able to inhibit ADCC. In this thesis RL13 did not 
affect NK cell degranulation significantly enough to confidently call it an NK evasion 
gene. However only RL13 from Merlin was analysed. 
It would be interesting to determine whether other isolates found within the clade TR 
was in also genetically retain their RL13 ORF during cell culture as their sequences are so 
similar. Interestingly, when TR RL13 was inserted into the Merlin genome, it inhibited 
virus growth in the same way as Merlin RL13. This indicates that factors elsewhere in the 
TR genome could be responsible for maintaining intact RL13 in the TR genome, or 
potentially that factors outside the immediate RL13 ORF, such as epigenetics, differ 
between the genotypes.  
This analysis of phenotype transfer was also performed with a RL13 homologue from 
RhCMV, Rh13.1, which (although it needs repeating) suggested that Rh13.1 expressed in 
the HCMV genome is also able to inhibit spread to some degree. The fact that this 
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phenotype of restricted viral spread is retained by RL13 despite considerable sequence 
differences indicates that it is an important biological function. 
Previous analysis of polymorphic HCMV gene protein sequences, including the 
genotypes of gB and gH, has shown that significant sequence variation is seen at the N 
terminus and limited variability shown at the C terminus (289). This is consistent with 
the amino acid sequence analysis of RL13 in this thesis as the vast majority of sequence 
variation is observed at the N terminus of the protein which encompasses the signal 
peptide and Ig-like domain. The transmembrane region of RL13 was almost completely 
conserved amongst the clinical isolates retaining the ability of RL13 to be expressed in 
the cell membrane and virion envelope. Interestingly the YxxL motif required for the 
ligand-dependent internalisation of the RL13-Fc complex is located in the C-terminal tail 
of RL13 (173). This YxxL motif is 100% conserved in clinical isolates sequenced (3) and 
therefore this internalisation function is likely to be important to the functioning to all 
RL13 genotypes. 
In summary, one question that arises from this data is whether the hypervariable tag 
often associated with RL13 is fitting or whether polymorphic is more appropriate. 
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6.3 Investigating the Restrictive Phenotype of RL13 
in in vitro HCMV infection 
An aim of this thesis was to investigate why expression of RL13 in vitro results in >10-
fold reduction of infectious titres of cell-free virus and inhibited viral spread. I 
hypothesised that RL13 could interact with or affect a particular stage of the HCMV 
lifecycle to result in this phenotype. 
 First, the viral DNA replication stage was investigated. During this study it was reported 
that RL13 interacted with host cell nucleoside diphosphate linked moiety X (nudix)-type 
motif 14 (NUDT14), a UDP-glucose pyrophosphatase, to affect viral DNA replication 
(227). Using fluorescence confocal microscopy, gpRL13 co-localised with NUDT14 in the 
cell membrane and cytoplasm. siRNA knockdown of NUDT14 resulted in an increase of 
viral DNA in infected cells (227). The qPCR data measuring viral genomic replication in 
this thesis did not corroborate this result and showed no evidence a difference in 
genome replication between strains expressing/not expressing RL13. The study by Wang 
et al (2016) was performed using an N terminal GFP tag on RL13 of HCMV strain Han. 
The N terminal GFP tag has the potential to disrupt the signal peptide of RL13 greatly 
effecting the results seen. In reverse transfection assays N-terminal tagging with GFP 
adversely affects protein localization with over 50% of N-terminal fusion proteins 
localising incorrectly likely due to masked signal peptides (293). 
Similarly to the analysis of viral genome replication, analysis of viral temporal protein 
expression and viral particle formation and maturation showed no inhibitory effect that 
could be reasonably attributed to the expression of RL13 to explain the reduced cell-free 
titres and viral replication inhibition associated with WT HCMV. Moving forward it was 
considered that expression of RL13 could reduce cell-free virus and be inhibitory to 
replication by interfering with either the release of virions from infected cells or the 
infectivity of those virions released, or even both. Although the infectivity and particle 
numbers of virions measured by NanoSight and plaque assay was only performed once, 
taken with the results from the qPCR assays these experiments indicated that RL13 and 
UL128 expression reduced viral infectivity both individually and together. Since RL13 
changes the composition of the virion, it has the potential to affect viral infectivity. 
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However, no obvious reason for the infectivity of virions to change was apparent in the 
virion composition comparisons. Equally, no apparent reason for a difference in 
infectivity was identified from the SILAC-IP of host cell proteins found to bind RL13 
during infection as the majority of proteins were chaperone proteins involved in protein 
folding.  
Unfortunately, a confident conclusion could not be reached when analysing virion 
particle numbers as the data were inconsistent between the qPCR and NanoSight assays, 
no appropriate internal controls were available, and the NanoSight experiment was only 
performed once. The qPCR assay, was performed numerous times and over multiple 
timepoints and so is the most reliable data at present. RL13 expression did not lead to a 
significant or consistent reduction in cell-free virions released into the supernatant over 
a 10-day period. In support of this qPCR data, RL13 induced restriction of cell-free virions 
does not originate at the DNA or protein stage of viral replication and there was also no 
evidence in the TEM data of different numbers of virions produced or of an 
accumulation of virions in the AC of the samples containing RL13, and so it seems 
unlikely that there would be a difference in the number of RL13-containing virions 
released. Therefore, it is possible that the reduction in RL13-containing cell-free virions 
occurs after virion egress. As HCMV is an enveloped virus it is sensitive to low pH, fat 
solvents and even extreme physical conditions such as temperature (250). Reduced 
virion stability caused by a difference in an envelope protein has been observed before 
in Hepatitis B virus. The mutation in the S envelope protein of Hepatitis B resulted in a 
reduced stability phenotype when treated with NP40 compared to the wildtype control 
(294). Therefore, it was hypothesised that virions with intact RL13 in the envelope could 
have reduced stability once leaving the cell compared to the RL13 mutant virions and 
this susceptibility to virion degradation was the cause of the drastic drop in viral titre. 
However, the expression of RL13 and/or UL128 did not appear to provide a significant 
advantage to virion stability over long periods of time. Although the ΔRL13/ΔUL128 virus 
showed the greatest reduction in titre, it was also the virus with the greatest titre to 
begin with. More so at higher temperatures, high concentrations of viral particles can 
induce aggregation (295). Aggregation of virions will result in an underestimation of the 
actual titre, as a viral aggregate will result in an individual plaque forming instead of the 
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dispersion of those virions making up that aggregate initiating multiple plaques. 
Therefore, the ΔRL13/ΔUL128 could appear to have the greatest titre drop but in fact 
the virions aggregate during the incubation times. In cell culture propagation of vaccinia 
virus, 69-90% was found to be aggregates of anywhere from 2-150 virions. When these 
viral preps were treated with sonic waves the viral titre increased and the dispersed 
virus was found to be 2-3 fold more efficient at initiating viral plaque formation (296). 
Many viruses have been found to form aggregates including adenovirus, poliovirus and 
influenza. Although viral aggregation has been found to increase survival in certain 
environments and even provide resistance to some disinfectants (295) the large size of 
aggregates could attract unwanted attention from the immune system as protein 
aggregates elicit an enhanced immune response (297). Thus, lower titres of HCMV (Such 
as those seen in RL13+ and UL128+ samples) that don’t aggregate as much would be 
beneficial during in vivo infection. Although it should be noted that aggregation of 
virions was not seen during NanoSight analysis of virion particles. Regardless of genetic 
background all viruses were most labile at 4°C, which has been reported for HCMV many 
times before (250). Remarkable stability of HCMV at RT and 37°C was seen, which is all 
the more surprising given that the lipid envelope of HCMV is known to be fragile (250). 
The WT virus retained ~100-50% of its starting titre in 48hrs at both RT and 37°C. These 
temperatures would be biologically relevant for viral transmission via body fluids such as 
urine. Although referred to as virion stability, the mechanism for the reduction in titre 
was not investigated. The loss in titre could have been due to a reduction in infectivity or 
the number of virions remaining.  
 
 Some host cell proteins were previously demonstrated in a SILAC-IP to interact with and 
some shown to co-localise or recruit RL13. In this thesis these host proteins were 
investigated further by siRNA knockdown to try to determine whether any of these 
interactions with RL13 could result in the inhibitory phenotype and restriction of cell-
free virus associated with expression of RL13. The results exhibited variation and 
whether efficient knockdown was achieved for the duration of the experiment was 
questionable. Although the data identified some proteins that could possibly be 
important during HCMV infection these affected viruses independently of RL13 
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expression. As many of the proteins were chaperone proteins involved in protein folding 
and secretion it is possible that their interaction with RL13 was during protein synthesis 
and formation. The fact that several of the proteins (SERCA, DNAJB11, ERp57) were 
shown to be recruited with RL13 to the AC (Stanton, unpublished) suggests that this 
could be an important interaction. One protein, ERp57, forms part of the peptide 
loading complex involved in antigen presentation by MHC (298). This could suggest that 
RL13, like other HCMV proteins, is in some way involved in the inhibition of Tcell 
recognition and Tcell mediated killing. Although this proposed theory would be unlikely 
to result in reduced cell-free titres of virus and inhibited viral propagation, further work 
exploring the possibility of inhibited Tcell recognition of HCMV infected cells could help 
determine whether RL13 provides an advantage to the virus in vivo through this 
interaction. Therefore, the results in this thesis suggest that the critical interaction with 
RL13 is still yet to be defined with further work.  
 
 During this thesis it was discovered that deletion of UL74 (gO) results in a very similar 
phenotype to that of the one RL13 expression promotes (299). In fibroblasts UL74 
promotes increased plaque sizes and neutralising antibody-sensitive cell-free spread, but 
only in the absence of UL128 expression. When RL13 expression was downregulated in 
this context the viral spread capacity was significantly enhanced (299). It is tempting to 
speculate that there may be a link between UL74 and RL13/UL128L induced viral spread 
mechanisms. We know from data in this thesis that expression of the UL74 gene product 
gO on the virion was not manipulated by RL13 expression and that RL13 did not 
immunoprecipitate with UL74 during infection in fibroblasts. UL74 is more likely to be 
affected by UL128L expression as the gene products of UL128L and UL74 compete for 
gH/gL when forming the pentamer and trimer respectively (88) (see Intro section 
1.3.1.3). 
Co-cultures performed in this thesis and published work (235) demonstrate that RL13 
and UL128 can both independently induce cell-cell spread of virus in fibroblasts. The co-
cultures in epithelials however showed that cell-cell spread was driven by UL128 
regardless of RL13 expression. It seems redundant for two genes to give rise to the same 
phenotype, however as only UL128L forced the virus to move cell-cell in epithelials, DCs 
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and LCs, two genes with the same function but relevant in different cell types seems 
more purposeful. Release of HCMV virions with different compositions and tropisms has 
been reported to be cell-type induced (146) (see Intro section 1.5.2). The MCMV 
homolog of UL74, m74, was necessary for establishing infection in vivo of diverse tissues 
but found to be nonessential during intra-host cell-cell dissemination of virus within the 
organ tissues (300). In humans, cell-free HCMV is detected in breast milk and urine (38) 
and yet once isolated and propagated in vitro the clinical virus is cell-associated (200). 
Epithelial cells, which can be found in the breast tissue and kidneys, are prime 
candidates for shedding of cell-free infectious virions enabling interhost transmission. 
Whereas efficient viral proliferation is associated with the infection of ubiquitous cell 
types such as fibroblasts (138). It is tempting to speculate on the role of RL13 during 
natural infection given this information: Cell-free spread promoted by the trimer 
(gH/gL/gO) is required for host-host transmission of the virus in bodily fluids, whereas 
during intra-host dissemination of virus via the immunologically covert cell-associated 
mechanism of viral spread is promoted by not one but two genes, RL13 and UL128, 
independently of each other but dependent on cell type. UL128 is known to be involved 
in tropism, whereas RL13 has the potential to modulate tropism but as of yet, this 
tropism is unknown. Whether these genes (UL74, UL128L, RL13) do 
interact/compete/mediate one another to result in this viral spread switch which seems 
beneficial to the different stages of HCMV pathogenesis is unknown.  
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6.4 Future Directions and Concluding Remarks 
 This thesis aimed to investigate the function of the HCMV gene RL13 and to determine 
how and why its expression is so inhibitory to viral propagation in vitro. Although the in 
vivo purpose and mechanism by which RL13 acts was not determined, data described in 
this thesis provides significant insight into this elusive HCMV gene that is so problematic 
to work with in cell culture. Work described here should help advance the field of HCMV 
research and will aid in future investigations into the role of RL13 in HCMV 
pathogenesis. 
 RL13 was proposed (173) and confirmed in this thesis to bind Fc in isolation. It would be 
useful to see if this interaction remains true in the context of HCMV infection, however 
the presence of other recognised efficient HCMV Fc-binding proteins (UL119 and RL11) 
make it hard to see how RL13 could add to their effects. The Fc-binding property of RL13 
does not explain the ability of RL13 to inhibit replication and suggests that there is 
another distinct interaction/effect by which gpRL13 impacts the HCMV life cycle. The 
retention of this effect in multiple genotypes and even across species, suggests that it 
may be the bonafide function of RL13. Further work investigating the proteins identified 
to bind and co-localise with RL13 with CRISPR could help identify any important 
interactions. 
 Alternatively, the restrictive phenotype and subsequent selection of RL13 mutants in 
cell culture may be an artefact of cell culture. However, with the data demonstrating the 
cell-cell spread method forced by RL13 and/or UL128L in fibroblasts in this thesis and 
the fact that clinical HCMV is often cell-associated, it seems possible that this restrictive 
phenotype is beneficial to the survival of the virus in in vivo infections. The fact that two 
genes in the HCMV genome result in this phenotype may seem redundant, although 
each protein may function under different circumstances, or by different methods. 
Further co-culture assays in more clinically relevant cell types could help investigate the 
potential role of RL13 in tropism. In addition, the presence of RL13 in the virion envelope 
has the potential to interact with additional cell surface receptors during entry. This 
aspect of RL13 function was not investigated during this thesis, but the production of 
soluble RL13 would be an interesting way to probe it. 
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Although I can only comment for the 96 clinical strains, Merlin and TR, only 9 clades 
were identified for RL13. To my knowledge, this is the first evidence of genotypes for 
RL13 using an unrestricted pruning approach. Although more clinical strains would need 
to be sequenced to add confidence to this proposal, maybe the term hypervariable is 
misleading and RL13 is in fact a polymorphic HCMV gene with multiple conserved 
genotypes. Current efforts in HCMV vaccine development should therefore consider not 
only the genetic differences between laboratory strains and clinical isolates but also the 
different genetic variants between clinical isolates. This adds further implications for 
achieving therapeutics and vaccines active against all variants of HCMV and maybe 
implies that although variation between clinical isolates should be considered during 
design, that highly conserved genes would be a more likely choice for providing broad-
spectrum immunity to HCMV. 
Overall, this data demonstrates the importance of not only working with HCMV strains 
that contain and express the RL13 ORF fully intact, but also the consideration of other 
commonly mutated ORFs such as UL128, which effects not only the tropism of the virus 
but impacts how the virus spreads especially in the presence of neutralising antibodies 
and the expression of cell-surface glycoproteins which are major targets for the humoral 
immune system. RL13 expression reduced the expression of many host proteins within 
the virion which could potentially result in advantages for the +RL13 HCMV strains. RL13 
also forced the virus to spread cell-cell in fibroblasts in the presence of neutralising 
antibodies, reduced infectivity of released viral particles and could potentially provide 
immune evasion through antibody-bipolar bridging as gpRL13 binds Fc. All these effects 
of RL13 expression could be valuable to bear in mind during vaccine design and would 
be missed when working with highly passaged, mutated lab strains of HCMV.
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CHAPTER 7. APPENDIX 
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Supplementary Table 1 – Primer sequences used in this project   
Project 
Primer 
Name 
Sequence 
qPCR 
 
 
 
gB 
 
F CTGCGTGATATGAACGTGAAGG 
R ACTGCACGTACGAGCTGTTGG 
GAPDH 
 
F CCTCTGACTTCAACAGCGACAC 
R TGTCATACCAGGAAATGAGCTTGA 
IE1/2-
P2A-
GFP 
 
 
 
 
 
 
 
 
 
Rpsl R 
into 
Link 
R 
TGTGGCCGTTTACGTCGCCGTCCAGCTCGACCAGGATGGGCACCACCCCGGTGAACAGCTCCTCGCCCTTGCTCACCATCTGAGGTTCTTATG
GCTCTTG 
Rpsl F 
into 
Link 
F 
GAGACCCCTCCCGAAGACCTGGACACCCTGAGCCTGGCCATCGAGGCAGCCATCCAGGACCTGAGGAACAAATCTCAGCCTGTGACGGAAGA
TCACTTCG 
Insert 
P2A-R 
R 
ACCAGGATGGGCACCACCCCGGTGAACAGCTCCTCGCCCTTGCTCACCATGGGGCCTGGATTCTCTTCGACATCCCCGGCCTGCTTCAGCAGA
GAGAAGT 
Insert 
P2A-F 
F 
TGAGCCTGGCCATCGAGGCAGCCATCCAGGACCTGAGGAACAAATCTCAGAGCGGCTCCGGTGCCACCAACTTCTCTCTGCTGAAGCAGGCC
GGGGATGT 
Rpsl R 
after 
IE1 
R 
GAGTATAACATAGAGTATAATATAGAGTATACAATAGTGACGTGGGATCCATAACAGTAACTGATATATATACAATAGTCTGAGGTTCTTATG
GCTCTTG 
Rpsl F 
after 
IE1 
F 
GATGGTGCTGAGGAACCCACCGCCTCTGGAGGCAAGAGCACCCACCCTATGGTGACTAGAAGCAAGGCTGACCAGTAACCTGTGACGGAAG
ATCACTTCG 
P2AGFP 
after 
IE1 F 
 
AGGAAGAGGAGGATGGTGCTGAGGAACCCACCGCCTCTGGAGGCAAGAGCACCCACCCTATGGTGACTAGAAGCAAGGCTGACCAGAGCG
GCTCCGGTGC 
P2AGFP 
after 
IE1 R 
 
GTATAACATAGAGTATAATATAGAGTATACAATAGTGACGTGGGATCCATAACAGTAACTGATATATATACAATAGTTTACTTGTACAGCTCGT
CCATGC 
Seq R R GAACAGTGATCAGGAAGAAAGTGAA 
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F – Forward primer, R – Reverse primer   
 
Seq F F ATTGACAGCCTGGGCGA 
TR/Rhes
us into 
Merlin 
 
 
 
Rpsl 
into 
RL13 R 
R 
CGACTTATAAGTGATTAACTCAGAATAAACACACCCAAACATTAATGACTAAAGATAAAAAATTTTATTGATGTGCATACTGAGGTTCTTATGG
CTCTTG 
Rpsl 
into 
RL13 F 
F 
ACACATGAAATTAAGTAACATATCTACCATGAAATACAGCAAAGATATACTAATGTCTATCCATCCAATAGCGGTACCCCTGTGACGGAAGATC
ACTTCG 
TRRL13 
in Rpsl 
F 
F 
ACGCAACACATGAAATTAAGTAACATATCTACCATGAAATACAGCAAAGATATACTAATGTCTATCCATCCAATAGCGGTACCATGCACTGGCA
TCTTGC 
TRRL13 
in Rpsl 
R 
R 
GACTTATAAGTGATTAACTCAGAATAAACACACCCAAACATTAATGACTAAAGATAAAAAATTTTATTGATGTGCATATCAGGTTTTAGTCCAA
AACTCA 
RhRL13 
into 
Rpsl 
FOR 
F 
ATGAAATTAAGTAACATATCTACCATGAAATACAGCAAAGATATACTAATGTCTATCCATCCAATAGCGGTACCATGACTAAGTATACGTGCTT
CAGATC 
RhRL13 
into 
Rpsl 
REV 
R 
TTATAAGTGATTAACTCAGAATAAACACACCCAAACATTAATGACTAAAGATAAAAAATTTTATTGATGTGCATACTAGGAAAACATTGACTTC
ACAGCG 
Seq R GTT CGC AGT TAT TGT GAT TCC A 
Seq F CAA ACG CCA ACG TAT CAA CA     
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